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Abbreviations 
 
General: 
 
3D         three-dimensional 
˚C                   degree Celsius 
AChBP                 acetylcholine binding protein  
Å                   Angstrom 
AcOEt                  ethyl acetate 
Boc                      tert-butoxycarbonyl 
CAM                    ceric ammonium molybdate solution 
conc.                   concentrated 
CyHex                  cyclohexane 
DCM                   dichloromethane 
DIPEA                  N,N-diisopropylamine 
DMF                   dimethylformamide 
DMSO        dimethylsulfoxide 
e.e.                   enantiomeric excess 
eq.                   equivalents 
LBD                      ligand binding domain 
M+                   molecular ion 
MeOH                  methanol 
mRNA        messenger ribonucleic acid 
m.p.                   melting point 
m/z                   mass/charge 
MHz                   megaHertz 
NaHMDS        sodium bis(trimethylsilyl)amide 
PMA                     phosphomolybdic acid solution 
TBAC                   tetrabutylammonium chloride 
TBAF                   tetrabutylammonium fluoride 
TEA                           triethylamine 
TFA                   trifluoroacetic acid 
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THF                   tetrahydrofuran 
TLC                   thin layer chromatography 
TBSCl                tert-butyl-dimethylsilyl chloride 
 
 
Spectroscopic: 
 
J                   NMR coupling constant 
                   chemical shift (ppm) 
ppm                   parts per million 
s                   singlet 
bs                         broad singlet 
d                   doublet 
dd                         doublet of doublets 
t                   triplet 
m                   multiplet 
sex                       sextplet 
Hz                   Hertz 
i                   iso 
o                   ortho 
m                   meta 
p                   para 
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1. Introduction 
 
 
1.1. The cholinergic neurotransmission 
 
The neurotransmitter acetylcholine (ACh) exerts its regulatory effects on 
the central nervous system (CNS) and peripheral nervous system (PNS) 
through two distinct families of receptors: the muscarinic and nicotinic ACh 
receptors.  
Nicotine, a natural alkaloid synthesized by several plants from the 
Solenaceae family (principally Nicotiana tabacum), has been assumed for 
centuries by the natives in South and North America and, later on, by the 
Europeans, as a major component of tobacco plants manufactured in the 
cigarettes making process. In 1857, the French physiologist Claude Bernard 
identified the chemical nature of transmission at the neuromuscular junction 
by exposing muscles to the plant toxin nicotine. Subsequently, it was shown 
that ACh is released in the neuromuscular junction cleft and that it diffuses 
into a very small extracellular space, where it acts on postsynaptic receptors 
and thereby mediates neurotransmission. These effects were inhibited by an 
induced paralysis through the action of the natural nicotinic blocking agent 
curare, while the muscle could still be directly stimulated by an electrical 
current. 
Studies on plant extracts, such as nicotine, curare and the natural alkaloid 
muscarine, the latter isolated from the mushroom Amanita muscaria, have 
facilitated the distinction between nicotinic and muscarinic cholinergic 
neurotransmission, as a function of differential sensitivity either to nicotine or 
muscarine. The dual action of ACh through individual cholinergic pathways 
was further supported by the discovery of distinct endogenous target proteins: 
the muscarinic receptors (M1 – M5), which are metabotropic or G-protein 
coupled receptors, and the nicotinic receptors, that belong to the family of 
ionotropic or ligand-gated channels. 
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1.2. Neuronal nicotinic acetylcholine receptors  
 
Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-
gated ion channels widely distributed in both the nervous system and non-
neuronal tissues. In the CNS they are principally found at presynaptic or 
preterminal sites where are associated with the modulation of 
neurotransmitters release. On the other hand, nAChRs located on cell bodies 
or dendrites are known to mediate postsynaptic effects if stimulated to a 
threshold level.[1] 
The nAChRs mediate fast synaptic transmission in ganglionic neurons, 
whereas in the mammalian CNS they exert mainly a modulatory influence, 
being involved in a wide range of physiological and pathophysiological 
processes related to cognitive functions, learning and memory, arousal, 
reward, motor control, and analgesia.[2] In addition to rapid changes in 
membrane potential, activation of these ligand-gated ion channels can 
generate longer-lasting effects in the receptive neurons, which contribute to 
the elaboration of complex intracellular signals that mediate medium- to long-
term events.[3] It is primarily because of their modulatory input to 
neurotransmitter systems other than ACh that neuronal nAChRs have been 
proposed as potential therapeutic targets for the treatment of pain, nicotine 
and other drugs addiction, epilepsy, and a wide range of neurodegenerative 
and psychiatric disorders such as Alzheimer’s disease, Parkinson’s disease, 
Tourette’s syndrome, schizophrenia, anxiety, and depression. 
The nAChRs are formed by five subunits arranged around a central pore 
that is permeable to cations. To date, 12 mammalian neuronal nicotinic 
subunits (2 – 10 and 2 – 4) have been identified and cloned, resulting in 
a huge diversity of possible combinations (Figure 1), though only a small 
subset of stoichiometries gives rise to functionally and physiologically relevant 
channels.[2] These subunits can form homomeric pentamers (consisting of 
only one type of subunit, as in the case of 7 nAChRs) or heteromeric 
pentamers (consisting of combinations of various  and  subunits).[4] 
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Conversely, the muscle nAChRs, localized within the neuromuscular plate, 
are shaped by the arrangement of five different subunits: 1, 1, ,  and . 
Each nAChR subunit is encoded by a single gene, generating a cluster of 16 
genes widely distributed in the 23 human chromosomes.[5,6] It is assumed that 
these genes have progressively diverged from a common ancestor by gene 
duplications and mutations, leading to the gene structures observed at 
present in humans. In this respect, it is worth mentioning that closely related 
nAChRs have been conserved throughout evolution in the simplest forms of 
life, such as molluscs, worms, echinoderms.[7] Moreover, several lines of 
evidence suggest that the ionotropic ion channels found in bacteria, which 
share a high degree of structural homology with the human nAChRs, can be 
used as prototypes in the elucidation of the 3D structure of the nAChRs.[8,9] 
 
 
Figure 1. Examples of homomeric and heteromeric nACh receptors. 
 
Each subunit of the neuronal nAChRs consists of a number of distinct 
functional domains (Figure 2):[10]   
 a long N-terminal extracellular domain (consisting of about 210 
amino acids), which is involved in binding to endogenous 
neurotransmitter ACh or exogenous ligands and holds a 
conserved disulfide bridge between two cysteine residues 
separated by 15 amino acids (known as the Cys-loop). 
 four highly hydrophobic -helical transmembrane domains, 
about 20 residues long, called M1, M2, M3 and M4.[11]  The M2 
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segments shape the lumen of the pore in the ion channel and 
determine ion’s conductance and selectivity. 
 a long cytoplasmic loop between M3 and M4 containing several 
phosphorylation sites, which are important in the functional 
modulation, and other shorter loops connecting the domains. 
 a short extracellular C-terminal domain. 
 
 
Figure 2. Structure of a neuronal nicotinic acetylcholine receptor. (a) 
Functional domain of the receptor through the membrane: the amino 
terminal hydrophilic portion, four transmembrane domains and the small 
hydrophilic C-terminal domain. (b) Schematic representation of the 
receptor, the location of the two acetylcholine (ACh) binding sites 
between an  and -subunit (or – subunit) and the central ion 
conducting channel. 
 
The orthosteric binding sites (i.e., the binding sites for ACh)  are located at 
the interface between two adjacent subunits, that are an  and a  subunit in 
the case of heteropentameric receptors, or two  subunits in the case of 
homopentamers. The  subunit constitutes the principal component of the 
binding site (the major subunit), whereas the adjacent subunit provides the 
complementary site (the minor subunit). The major subunit shapes an 
aromatic region of the orthosteric binding site known as the aromatic box, and 
is characterized by a disulfide bridge between two adjacent cysteine residues 
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known as the C-loop. -Homopentamers can host and bind five molecules of 
ACh or exogenous orthosteric ligands, while / heteromeric receptors are 
bound by a variable number of ligands depending on the ratio of  and  
subunits. Like all cell-surface ligand-gated ion channels, nAChRs modulate 
the flow of ions across the cell membrane and are under the control of an 
extracellular signalling molecule. A net influx of cations (usually Na+, Ca2+ and 
K+ cross nicotinic channels) through the associated channel pore depolarizes 
the cell membrane and increases neuronal excitability, thereby causing an 
excitatory postsynaptic potential (EPSP).  
 
 
1.3. Functional states of nAChRs 
 
ACh, the natural endogenous ligand for nAChRs, is released from 
presynaptic cholinergic axon terminals and binds to the extracellular ligand 
binding domain (LBD) of the receptor that, in turn, influences the rate 
constants between three distinct functional states of the receptor itself (Figure 
3): the resting (R), the open or active (A) and the desensitized (D and I) 
state.[2,12,13]  
 
 
Figure 3. Functional states of nAChRs according to the Monod-Wyman-
Changeux (MWC) model. Allosteric transitions between the resting (R, 
white complex), active (A, dark-gray complex), and fast-onset (I) and 
slow-onset (D) desensitized states (black complexes) of the nAChR.
[2]
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The equilibrium between two states is determined by the differences in the 
free energy of the states and the rate for the transition from one state to 
another is controlled by the energy barrier between the two states. The 
activation process is rapid and transient (microsecond-to-millisecond range), 
while the desensitization is slower (millisecond-to-second range). The rate 
constants between the functional states are highly dependent on the specific 
combination of subunits and the chemical nature of the ligand that is bound at 
the LBD. Therefore, different rates of the activation and desensitization 
processes were observed among different nAChR subtypes and this could 
account for the pharmacological diversity within this receptor family. The 
transition rates can also be affected by endogenous or exogenous allosteric 
modulators (i.e., compounds binding to protein recognition sites different from 
the orthosteric site) of the channel function via an effect on the equilibrium 
between the resting and the active receptor states or on the desensitization 
kinetics. 
Binding of an agonist to the orthosteric sites of the nAChR stabilizes the 
active state of the channel, while a competitive antagonist favours the resting 
states.  Agonists are characterized by higher affinity for the active than for the 
resting state whereas antagonists have higher affinity for resting/inactive 
receptor states. In addition, nAChRs show spontaneous constitutive activity in 
the absence of agonist, however binding of an agonist to the orthosteric sites 
dramatically increases the probability of channel opening. 
The synchronized release of neurotransmitter at a synapse leads to a 
sharp rise in ligand concentration at the postsynaptic membrane such that 
many receptors become occupied and then open within a few milliseconds. 
Neurotransmitter levels fall quickly due to active reuptake into presynaptic 
sites or metabolic breakdown and diffusion away from the synapse. The low 
affinity of fast ligand-gated channels for the endogenous agonist allows for 
very fast dissociation from the binding site and thus a rapid termination of 
postsynaptic signalling. These specific biophysical properties of nAChRs are 
critical for fast synaptic transmission at excitatory autonomic ganglia and at 
the neuromuscular junction. However, in the mammalian brain, nAChRs are 
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primarily located on presynaptic, perisynaptic and extrasynaptic sites, and 
neuronal nAChRs thus exert a preferred functional role in modulating the 
release of various neurotransmitters (e.g., glutamate, GABA, dopamine, 
norepinephrine) via presynaptic sites of action (Figure 4). 
 
 
Figure 4. Neurotransmission mediated by nAChRs in the mammalian 
brain. Nicotinic receptors reside primarily outside of the synaptic cleft and 
influence cell excitability on postsynaptic cells and neurotransmitter 
release at presynaptic sites. In contrast, nicotinic receptors at the 
neuromuscular junction and the autonomic ganglia mediate fast synaptic 
transmission. 
 
 
1.4. Receptor activation, deactivation and desensitization 
 
An agonist is defined as a small molecule that binds to a receptor and 
activates it. As previously described, when the natural neurotransmitter ACh 
binds to the extracellular domain of nAChRs, the resulting change of 
conformation opens the channel triggering ion gating and propagation of 
electrical signals.[14]  
Partial agonists, discovered in the 1950s, are defined as agonists that 
could produce only a sub-maximal response (less than a full agonist) even in 
case of saturation of the binding sites.[15] The model proposed for ion channel 
receptors consisted in an equilibrium between a shut and an open 
conformation, with the binding of the agonist being able to shift such an 
equilibrium towards the open state, due to the higher affinity of the agonist for 
the open than the shut state. Recent reports[14,16] on the nature of partial 
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agonism in the nicotinic receptor superfamily have proposed the existence, in 
the presence of the ligand, of an intermediate pre-open state called flip-state 
and have hypothesized that the partial agonism is not a property associated to 
the open-shut transition, but arising in the earlier conformation change from 
the resting state to this flipped state (Figure 5). 
 
 
Figure 5. The three states of the fully saturated receptor.
[11]
 
 
Crystals of the ACh binding proteins (AChBPs) LBD from Lymnea stagnalis 
and Aplysia californica have enabled atomic resolution of the structure of the 
N-terminal domain and its association with agonists and antagonists.[17-20] 
Crystal structures comparing apo conformations to ligand-bound 
conformations reveal large movements of the C-loop of the principal 
component, which adapts its configuration to the structural characteristics of 
the ligand entering the binding pocket, swinging as much as 11 Å between the 
two most extreme positions. The available data suggest that the C-loop, which 
harbours two adjacent cysteins, has a certain degree of mobility and that 
agonists are compounds that stabilize it in a contracted form in close 
apposition with the adjacent subunit, whereas antagonists stabilize it in an 
extended form.[21,22] The changes in the conformation of the C-loop might 
control the opening/closure of the channel. After all, it has been also proposed 
that the channel conductivity is modulated by the reciprocal interaction of 
three specific amino acids, and therefore ligands can act perturbing their 
contacts leading to the activation the channel.[23] 
From the agonist-bound open conformation, nAChR channels will transit to 
a non-conducting state, either by dissociation of the agonist from the receptor, 
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known as deactivation, or by an agonist-bound conformational change to a 
high affinity, non-conducting state, called desensitization. Deactivation is the 
transition from the open state to the resting state associated with dissociation 
of the agonist from the LBD. The rate of deactivation plays a critical role in 
determining the fraction of channels in the open state, which is the faster the 
rate of deactivation is, the greater will be the drive from the open state back to 
the resting state. Deactivation is particularly important in controlling steady-
state macroscopic currents in response to sustained exposure to low agonist 
concentrations. Some positive allosteric modulators have been demonstrated 
to enhance steady-state current by slowing deactivation rate. Receptor 
desensitization is a conformational transition to a relatively stable and non-
conducting agonist-bound state that has high ligand affinity. This inactivating 
effect emerges mostly at high agonist concentration or at prolonged agonist 
exposure. Parameters that characterize receptor desensitization include the 
rate of desensitization, the degree of inhibition caused by sustained agonist 
exposure and the rate of recovery from desensitization upon removal of the 
agonist. It is worth mentioning that  and  subunits contribute differentially to 
the desensitization properties of heteromeric receptors.[24] Moreover, the 
desensitization of a receptor can further be influenced by kinases and 
phosphatases activity, suggesting the possibility of dynamic modulation of 
receptor functions.[24] 
 
 
1.5. Receptor upregulation 
 
It is generally accepted that sustained exposure of ligands to various cell 
surface receptors causes, at first, receptor activation and downstream cellular 
responses, followed by consequent receptor internalization and therefore 
downregulation of the receptor at the cell surface. Surprisingly, several data 
have reported an increase in surface nAChRs levels following repeated 
exposure to nicotine in both laboratory animals and in vitro studies.[25,26] This 
upregulation process, which causes also an increase in functional response 
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as measured by agonist-evoked whole cell current of Ca2+ influx, appears to 
be intrinsic to the receptor and can be explained by some post-translational 
conformational involvements, since nAChR subunit mRNA levels are not 
changed. Upregulation has been reported for different receptor subtypes 
including 42, 7, or 3- and 6-containing receptors, but the time course, 
the amplitude of the changes, as well as the sensitivity to nicotine vary 
depending on the subunit combinations.[27] Interestingly, incorporation of the 
accessory subunit 5 into 42 receptors prevents nicotine-induced 
upregulation in vivo.[28] This process has been identified as fully reversible 
upon removal the nAChR ligand, which can be either nicotine or other non-
natural nAChR agonists. As a matter of fact, 42 or 7 agonists/partial 
agonists upregulate nAChRs in vitro or in vivo, typically about 1.5 to 5 fold, 
suggesting that some of these compounds are more potent at upregulating 
that at activating nAChRs. Nicotinic antagonists, albeit with lower potency, 
can also upregulate nAChRs, whereas they may be 2-3 orders of magnitude 
less potent at upregulating than at antagonizing ACh-induced receptor 
activation. Several mechanisms have been proposed to underlie functional 
receptor upregulation, such as: 
 decreased receptor turnover. 
 increased conformational transition of cell surface receptors from 
low to high sensitivity state. 
 increased synthesis of new proteins. 
 increased receptor assembly with increased receptor trafficking 
to the cell surface. 
 nicotine or other nAChRs ligands acting as a chemical 
chaperone. 
 changes in the subunit stoichiometry of receptors. 
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1.6. The generation of Ca2+ signals 
 
Intracellular Ca2+ signals play an important role in the survival of developing 
neurons, the modulation of their activity and their demise.[3,29] It is thought that 
nAChRs are involved in the increase of intracellular Ca2+. This process occurs 
both by direct permeation of the nAChR channel and by recruiting Ca2+ from 
several sources, including voltage-operated Ca2+ channels (VOCCs), which 
might be activated as a consequence of membrane depolarization following 
nAChRs activation. This amplification of the intracellular Ca2+ responses by 
activating VOCCs seems to be controlled by nAChR subtypes that do not 
contain 7-subunits. In turn, 7 nAChRs are highly permeable to Ca2+ and  
appear to be coupled functionally to direct activation of ryanodine (RY) 
receptor-dependent internal stores and the inositol (1,4,5)-triphosphate (IP3) 
second-messenger system, generating Ca2+-induced Ca2+ release inside the 
cytoplasm (Figure 6).[3] 
 
 
Figure 6. Generation of nAChR-dependent Ca
2+
 signals. 
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1.7. nAChR genes and subtypes 
 
As mentioned previously, nAChR pentamers are formed by the association 
of different subunits that confer distinct structural and functional properties to 
the resultant nAChR subtypes, in terms of agonist affinity potential, kinetics of 
activation, closure, desensitization, resensitization and internalization.[4]  
Homopentamers are the simplest form of nAChRs as exemplified by 7 
receptors. These receptor complexes are widely distributed in both the CNS 
and PNS and have been proposed to contribute to multiple physiological 
functions.[5] Heteropentameric nicotinic channels are composed of two or 
more subunit types and display a broad spectrum of physiological and 
pharmacological properties and functions. When considering heteromeric 
receptors, it is essential to examine the ratio of  to  subunits, which has 
been shown to influence receptor function. Of the many different subtype 
combinations, the most abundant are 42, 7 and 34. The 34 subtype 
is found mainly in the PNS, whereas approximately 90% of nAChRs in the 
CNS are believed to be the 42 subtype and the majority of the rest to be 
the 7 subtype.[2,30,31] 
Genes encoding for the 1-10 subunits are termed CHRNA (1-10) and 
genes encoding for the 14 subunits are referred to as CHRNB (1-4). The 
additional muscle subunits , and are encoded by CHRNG, CHRND and 
CHRNE genes. The chromosomal localization of the different genes encoding 
for the muscle and the neuronal nAChR subunits are presented in Figure 7. 
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Figure 7. Typical human karyotype with the representation of the location 
of the genes encoding for the nAChR subunits. 
 
The CHRNA2 gene 
The CHRNA2 gene encodes for the 2 subunit and it is highly expressed in 
the frontal cortex. Receptors containing the 2 subunit seem to be involved in 
the regulation of cognitive functions and a point mutation in the CHRNA2 
gene is associated with a form of nocturnal epilepsy.[32,33] However, the 
knowledge about the distribution and function of the 2 subunit is still limited. 
 
The CHRNA3, CHRNB4 and CHRNA5 gene cluster 
Chromosome 15 in humans groups together the CHRNA3, CHRNB4 and 
CHRNA5 genes, which show a close expression interaction, even between 
their regulatory elements, as supported by the association of certain 
phenotypes, such as nicotine-dependence, with this gene cluster.[34] The 
34* channel (the asterisk indicates that other subunits may be present in 
the pentameric receptor architecture) is essentially expressed in ganglia, but 
recent studies demonstrate high levels of this receptor in other tissues and in 
the CNS, mainly in the interpeduncular nucleus (IPN), the medial habenula 
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(MHb) and the fasciculus retroflexus, a bundle of axons connecting the two 
structures.[35] 
The exact nature of the receptor stoichiometry is still somewhat elusive. It 
has been proposed that at least two distinct 34* subtypes co-exist with 
different ratios of the 3 and the 4 subunits, since two forms of the -
conotoxin AuIB inhibit native ganglionic 34* nAChRs in a different manner, 
revealing a high and a low affinity site for these toxins.[36] The 34* complex 
nature is made even more complicated by the accessory 5 subunit, which is 
encoded by the third gene of the chromosome 15 cluster and co-precipitates 
with 3 and 4 subunits in a single pentamer.[37] The presence of the 5 
subunit in the receptor complex changes the functional properties of the 
channel, particularly for the 34* receptors expressed in ganglia, as shown 
by significant discrepancies with recombinant expressed 34 nAChRs. While 
these results indicate a limited influence of the 5 protein within the CNS, 
more recent studies have elucidated how 5 knock–out mice display lower 
nicotine-evoked dopamine release and nicotine intake. The effect was 
completely eliminated by the re-expression of the 5 subunit in the MHb, 
suggesting that the 5 containing receptors are active within the IPN-MHb 
34* system as well.[38] 
Compelling evidences support the connection of the IPN-MHb pathway and 
nicotine-reinforcement, dependence and withdrawal by influencing the 
mesolimbic dopamine system.[39] The habenular blockade of 34* nAChRs 
modulates the mesolimbic dopamine response to acute nicotine, whereas an 
inhibitory action at the IPN level causes an increase of nicotine self-
administration in animal models. This could be explained by the anatomical 
linkage of the MHb and the lateral habenula (LHb), a distinct compartment 
connected to the mesolimbic structure which controls the negative reward 
process. Nicotine acts in the MHb to inhibit the lateral habenular glutamatergic 
neurons, and the blockade of 34* nAChRs in the MHb removes this 
inhibition. However, the potential positive effects of 34* antagonism on 
chronic nicotine exposure are still uncertain.  
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The CHRNA4 and CHRNB2 genes 
The CHRNA4 gene on chromosome 20 and the CHRNB2 on chromosome 
4 encode for the 4 and 2 subunits, whose assembly leads to the major 
central heteromeric 42 nAChR. This channel protein is characterized by a 
high affinity for nicotine and a wide distribution in the CNS, making the 42 
receptor the most implicated in neurotransmission processes and 
neurotransmitters release control among all the other nicotinic subtypes; 
therefore its involvement in physiological functions and pathological conditions 
is extensive. 
It is generally accepted that the 42 receptor is an assembly of two 4 
and three 2 subunits. However, several data have suggested the presence 
of two distinct 42 pentamers that exhibit different ACh concentration-
activation curves. A high and a low sensitivity 42 nAChR correspond to 
different 4/2 ratios present in the receptor complex, with diverse functional 
properties (e.g. agonist sensitivity and ion permeability) as well.[40] 
 
The CHRNA6 gene 
Located on chromosome 8, the CHRNA6 gene encodes for the 6 subunit, 
predominantly expressed in the ventral tegmental area (VTA) and the 
mesolimbic system. Its specific localization in the CNS has proposed the 
involvement of the 6 subunit in the striatal dopamine release and its 
behavioural consequences, giving much attention to this receptor subtype for 
the modulation of nicotine-elicited locomotion and acute or chronic nicotine 
self-administration. Indeed, the reduction of 6 containing cholinergic neurons 
has been correlated with progression of the Parkinson’s disease.[41] Moreover, 
removal of the 6 subunit in 6 knock-out mice significantly alters their 
behaviour in comparison with wild type mice. The 6 protein is able to form 
functional heteromeric complexes such as the 62* receptors, which display 
high affinity to epibatidine, a ligand specific for heteromeric nAChRs, and  
overall pharmacological properties different from those of 42 channels, 
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such as enhanced ACh sensitivity, slower desensitization and markedly 
distinct desensitization rate and potency with nicotine.[42] 
 
The CHRNA7 gene 
The CHRNA7 gene is thought to be the closest ancestor to that evolved 
millions of years ago and seems to have preserved specific functionalities, as 
its encoded protein, the 7 subunit, is able to form functional homomeric 
receptors widely distributed in the CNS, PNS and other extra-neuronal tissues 
and cells (e.g., lungs, macrophages), with high calcium permeability, fast 
desensitization and specific sensitivity to certain toxins (e.g. bungarotoxin). 
Intensively used as a tool to examine nAChRs structure-function relationships, 
the 7 channel is with no doubt involved in several pathological conditions, 
from central cognitive disorders, such as schizophrenia and Alzheimer’s 
disease, to peripheral processes, like inflammation and mutagenesis. 
CHRNA7 is located on chromosome 15 and has a unique structural 
organization with a different number of introns and splicing sites than other 
nicotinic genes. Moreover, exons 6-10 of CHRNA7 are duplicated nearby in a 
gene copy termed CHRFAM7A. This duplicated gene is expressed in certain 
cells and the corresponding protein product is thought to somehow interact 
with the 7 receptor. The activity of CHRFAM7A might downregulate the 
functionality of the 7 pentamer, which could serve as an additional 
mechanism to fine-tune functional expression of nAChRs.[43] Recently it has 
been reported that the 7 subunit may potentially co-assemble with other 
nAChR monomers. Particularly, receptors co-expressing 7 and 2 are 
inhibited by amyloid A, thus correlating this novel and interesting nAChR 
complex with the cognitive impairments observed in Alzheimer’s patients.[44] 
 
The CHRNA8, CHRNA9 and CHRNA10 genes 
Few studies have focused their attention towards the 8 subunit, encoded 
by the CHRNA8 gene. This protein is quite similar to the 7 subunit, but the 
corresponding homomeric channel is poorly distributed and therefore less 
studied. 
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Conversely, the homopentamer 9, built up of five CHRNA9 gene proteins, 
is still sparsely found in the CNS, but with a distinctive expression in the outer 
hair cells of the inner ear, giving the 9 nAChRs a potentially meaningful 
pharmacology. Furthermore, new studies have pointed out the presence of 
this protein complex in other tissues other than the inner ear, i.e. it could play 
a role also in the pain perception pathway.[45] 
The CHRNA10 gene encodes for the 10 subunit, which has displayed the 
attitude to co-assemble with the 9 protein. High level of 910 nAChRs have 
been found in the sensory neurons of the sacculus in the vestibular organ. 
 
The CHRNB3 gene 
The CHRNB3 gene is probably the less studied nicotinic gene. Encoding 
for a subunit lacking the two adjacent cysteines which form the C-loop, and 
therefore for a  subunit, this gene might be related to some pathological 
conditions, since variants and mutations of CHRNB3 have been associated 
with certain smoking behaviours, as well as alcohol consumption and bipolar 
disorders. The 3 protein may behave as an accessory and modulatory 
subunit, since it is expressed in a few peculiar nicotinic channels, such as the 
6435 subtype. 
 
 
1.8 Therapeutic potential of nicotinic drugs 
 
The correlation of neuronal nAChRs with neurotransmission and 
physiological processes raised a lot of interest in the nicotinic system as 
potential target for a number of psychiatric, neurological and peripheral 
disorders. However, only one nAChR ligand has been approved and 
introduced into the market in the last 50 years: the 42 partial agonist 
varenicline for smoking cessation. The main reasons for the lack of effective 
nicotinic therapies reside mainly in the unsatisfactory clinical efficacy and in a 
relatively high incidence of adverse events. In the case of nicotinic drugs, the 
most common side effects appear to be gastrointestinal and CNS 
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consequences, while the less common cardiovascular events have to be 
monitored given the nicotine effects on both heart rate and blood pressure. 
It is well accepted that the lack of efficacy showed by nicotinic drugs could 
be explained as a result of several factors: 
 the nicotinic target may not be directly involved in the pathology 
of the disease. 
 at clinical doses the compound may not achieve efficacious 
unbound concentrations at the target receptor. 
 the compound may have insufficient potency and/or selectivity 
for the target subtype. 
Pharmacological, biological and genetic evaluations are required to better 
understand the physiopathology of a certain disease or disorder, and drug 
delivery systems represent the technological response to specifically increase 
the drug levels at the target compartment. On the other side, medicinal 
chemistry, through both structure-activity relationships (SAR) and molecular 
modelling studies, is the science called to improve the interaction between 
drugs and the biological counterparts at a molecular level. That means to 
increase potency (in terms of either binding affinity or functional activity) and 
selectivity (i.e., the ratio of affinities at the target to other proteins/target 
subtypes) of a candidate drug. For example, a compound with moderate 
potency and suboptimal pharmacokinetics will require high doses for a 
therapeutic effect, but its selectivity may be insufficient to prevent a high 
incidence of side effects. Thus, although a high binding selectivity for a 
nAChR target vs. other nicotinic subtypes is typically reached at a nM/M ratio 
level, when considering functional activation/inactivation potencies, which 
usually require concentrations (EC50 or IC50) in a relatively narrow M range, 
a compound can display high binding selectivity and be functionally non-
selective at all. As previously described, aiming at nAChR subtypes selectivity 
can reduce the overall count of side effects and also lead to the modulation of 
the specific nicotinic ion channel involved in the signal pathway that 
exacerbates the targeted pathological condition or symptoms. 
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Alzheimer’s Disease 
Alzheimer’s Disease (AD) is a neurological degenerative disorder in which 
the cholinergic pathways are severely affected and it is characterized by a 
progressive deterioration of higher cognitive functions. AD is the most 
common form of dementia and an involvement of nAChRs in AD is supported 
by the consistent reduction of these receptors observed in post-mortem brain 
tissues from patients, significantly associated with cognitive impairments. 
Extracellular neuritic senile plaques and intracellular neurofibriallary lesions 
are considered typical marks of the disease; moreover, it has been shown 
that, in patients with AD, choline acetyltransferase activity is decreased. 
Recent efforts have focused on the high affinity interactions between 
nAChRs, mainly 7 and 42 subtypes, and A, a constitutive peptide which 
under normal physiological conditions has several roles in enzymes activation 
and hormone levels regulation, and it is, on the other hand, the main 
component of neuritic amyloid plaques found in brains of patients with AD. 
The specific interaction between 7 nAChR and A is very effective under 
normal physiological conditions (binding affinity in the low pM range) and it 
may play an important role in the regulation of synaptic plasticity and, 
consequently, neuronal degeneration.[46] From a functional standpoint, binding 
of A to both 7 and 42 nAChRs has been reported either to inhibit or to 
activate the receptors. 
AD patients treated with both 7 or 42 nicotinic partial/full agonists have 
shown interesting improvements in concentration and some verbal and non-
verbal skills, suggesting that AD could benefit from the development of more 
selective nicotinic drugs, notably targeting the 7 channel. Besides, 
enhancing the cholinergic transmission via ACh-esterase inhibitors is still the 
best protocol today for the treatment of AD patients. 
 
Parkinson’s Disease 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder 
involving the dopaminergic neurons of the substantia nigra. Similarly to AD, a 
marked reduction in nAChRs activity, resulting in impaired cognitive functions, 
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has been observed. The disease is characterized by muscle rigidity, tremor, a 
slowing of physical movements and, in extreme cases, a loss of physical 
movements. Secondary symptoms may include cognitive dysfunctions and 
subtle language problems. PD is both chronic and progressive and it has 
been shown by epidemiological studies that a negative correlation exists 
between smoking and the incidence of PD, suggesting that nicotine in tobacco 
contributes to the biological protection against neurodegeneration of 
dopaminergic neurons. The two nAChR populations largely responsible for 
the nicotine-evoked dopamine release in striatum are the 42 and 62* 
subtypes, the latter displaying a higher connection to nigrostriatal damage 
induced in animal models. Thus, targeting specific nAChR populations 
represents a promising strategy for long-term neuroprotection against further 
striatal damage and for a symptomatic relief by enhancing dopamine outflow. 
The use of full/partial 62* or 42 agonists should evoke dopamine 
release by activating nicotinic ion channels that are still present in patients 
affected by PD. Nevertheless, a second possible mechanism, which seems to 
be less dependant on the presence of functional 62* and 42 nAChRs, is 
the selective pharmacological chaperoning of nAChR number and 
stoichiometry, by which nicotine or other nAChR ligands could restore to 
some extent the receptor deficit in the substantia nigra. In this case, both 
nAChR agonists and antagonists could have a therapeutic effect by acting as 
chaperones and increasing the number of functional 62* or 42 
receptors.[47] 
 
Tourette’s Syndrome 
Tourette’s Syndrome (TS) is an inherited hyperkinetic neuropsychiatric 
movement disorder related to excess dopamine transmission in the striatum, 
with symptoms of persistent, sudden, rapid and brief, stereotyped motor 
movements or verbal tics. Onset of symptoms typically occurs in childhood 
and the exact mechanism of the pathology is not fully understood but it is 
believed that nAChRs are involved. In fact it has been shown that transdermal 
~ 24 ~ 
 
nicotine can reduce some of the symptoms, probably desensitizing the 
nicotinic receptors that control dopamine release (42 and 62* subtypes). 
 
Schizophrenia 
Schizophrenia is a psychiatric diagnosis that describes a mental disorder 
characterized by abnormalities in the perception or expression of reality. It 
most commonly manifests as auditory hallucinations, paranoid or bizarre 
delusions or disorganized speech and thinking in the context of significant 
social or occupational dysfunction. The constellation of symptoms can be 
subdivided into positive (e.g., hallucinations and delusions), negative (e.g., flat 
affect and social withdrawal) symptoms and impaired cognition. Typically, the 
antipsychotic drugs used in the schizophrenia treatment are efficacious at the 
positive and to some degree negative symptoms, while there’s a great need 
for the treatment of the cognitive impairments associated with this disorder, 
which could represent the core of the disease. 
Various studies have demonstrated that the use of tobacco transiently 
restores the schizophrenic patient's cognitive and sensory deficits.[48] The 
number of 7 nAChRs is reduced in post-mortem schizophrenic patients and 
the association of 7 receptor subunit gene with an auditory deficit was 
found,[49] suggesting the development of novel 7 selective agonists for the 
treatment of this pathology.[48,50] There are less biological data linking the 
42 nAChR to schizophrenia, but substantial preclinical evidence has shown 
that agents that selectively interact with 42 nAChRs could enhance 
cognitive performance in schizophrenic patients. 
 
Pain 
The effects of nicotinic ligands in antinociception and analgesia are well 
established[51,52] and the activation of nAChRs produces antinociception in a 
variety of acute or chronic animal pain models.[53] Control of pain is one of the 
most promising therapeutic applications of nicotinic drugs and the 42 
nicotinic subtype receptor has been identified as being involved in the 
antinociceptive activity, but other subtypes could also contribute.[52,54] Gao 
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and co-workers have individuated the superficial dorsal horn of the spinal cord 
as the site where several nAChR subunits (mainly 3, 4, 5, 7, 2 and 4) 
increase inhibitory GABAergic and glycinergic transmissions, which have a 
prominent role in pain suppression.[55] The authors have found that an 
agonist-induced activation of 42 nAChRs is necessary, but not sufficient, 
for analgesic activity. Indeed, activation of 3 might play an additional role, 
while the 7 proteins seem to be less relevant. Several 7 agonists tested in 
animal models producing analgesic effects have failed to potentiate inhibitory 
synaptic transmission in the spinal cord at selected doses. As a matter of fact, 
the analgesia observed for these compounds required high doses, resulting in 
a narrow therapeutic range. 
 
Smoking cessation 
Tobacco smoking is one of the leading causes of preventable mortality in 
industrialized countries and nicotine-dependence is probably mediated 
through the activation of multiple nAChRs, in particular the 42  subtype.[56] 
Partial agonists of 42 nAChRs could enhance the activity of these receptors 
sufficiently to blunt craving and withdrawal without associated abuse 
potential;[57] these considerations led to the development of the partial agonist 
varenicline[56] (by Pfizer) as a novel protocol to treat smoking cessation. It is 
uncertain whether higher agonist activity would improve clinical efficacy or 
negatively impact the side effect profile, in particular abuse liability. However, 
it seems that minimal agonist activity is necessary, since 42 antagonists 
are not very effective in smoking cessation treatments. 
More recently, two novel nAChR subtypes emerged as potential targets for 
the treatment of nicotine addiction. The 62* nAChRs are activated by 
nicotine at the concentrations in the smokers’ brain, with slower 
desensitization rate, leading to substantial striatal dopamine release.[42] Many 
42 nicotinic drugs for smoking cessation, varenicline as well, display also 
an 642 partial agonist profile. At last, as described previously, the MHb 
34* nAChRs inhibit the LHb glutamatergic system, which interacts with the 
neurons of the VTA, implicated in the reward circuit by mediating dopamine 
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release at the mesolimbic level.[39] So, 34* blocking agents might be 
considered as innovative and alternative molecules for the treatment of 
nicotine abuse and dependence. 
 
Alcohol use disorder and other drugs dependence 
The high comorbidity of nicotine and alcohol dependence can be in part 
explained by common underlying cholinergic mechanisms. Ethanol,  but also 
several other drugs of abuse (e.g., cocaine, opioids, stimulants like 
amphetamine), can influence many receptor systems and activate the brain’s 
reward system through nAChRs. As mentioned above, the 34* receptors 
localized in the MHb and IPN modulate the sense of reward by suppressing 
the LHb-mesolimbic pathway. Thus, numerous 34* partial agonists, as well 
as 42 selective compounds like varenicline, have been monitored for the 
treatment of alcohol use disorder. 
On the other hand, updated experiments describe the ineffectiveness of  
habenular 34* receptor blockade on accumbal dopamine release 
enhancement stimulated by acute injection of addictive drugs.[39] As a matter 
of fact, the 34* negative allosteric modulator 18-methoxycoronaridine (18-
MC) more potently restrains craving and withdrawal induced by nicotine than 
the same effects induced by other drugs of abuse. This difference may occur 
because an acute nicotine injection directly stimulates nicotinic receptors in 
both the MHb-IPN and the mesolimbic dopamine pathway. The linkage of 
nicotinic receptors and accumbal dopamine release enhancement induced by 
other drugs, such as opioids or stimulants, may only occur as a result of 
modulation of the mesolimbic pathway by the MHb-IPN system and after 
chronic or sensitizing regimen of drug administration. This is evidenced by the 
decrease of chronic self-administration of methaamphetamine and morphine 
in animal models treated with 34* blocking agents such as 18-MC or -
conotoxin AuIB. 
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Depression 
The Janovski’s cholinergic-adrenergic hypothesis of depression postulates 
that hyperactivity of the cholinergic system contributes to depression, a state 
of low mood and aversion to activity that can have a negative effect on a 
person's thoughts, behaviour, feelings, world view and physical well-being. 
Since ACh esterase inhibitors can elicit or exacerbate depression symptoms, 
it is thought that nAChR antagonists or partial agonists may have positive 
effects, as shown by the natural nicotinic antagonist mecamylamine. The 
reduction of activity of 42, 7 or 34* nAChRs seems to be the key to 
decrease the cholinergic transmission and to relief depression mood. 
 
 
1.9. Pharmacophore models   
 
A pharmocophore is generally considered to be an ensemble of the 
minimal structural features common to active molecules that are recognised 
by an individual receptor.[56] Early nicotinic 42 pharmacophore models were 
based on distances between common elements in the classical agonists, 
typically (i) a basic nitrogen (N+) (which is protonated under physiological 
conditions) and (ii) a hydrogen bond acceptor (HBA) and/or a -electron rich 
moiety () with a relative separation of cationic and HBA/ groups ranging 
from 4.4 to 6 Å (Figure 8).  
          
N
NH
C
HBA/
a
b
             
Figure 8. Pharmacophore elements and (S)-nicotine. 
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Recent studies[57-59] have indicated a more complex mode of action, and 
variations between the proposed pharmacophore models could derive from 
the individuation of additional elements: a ring centroid (C)  or an atom in the 
ligand defining the direction of the ligand-receptor hydrogen bond, a planar 
area on the receptor recognizing the -electron rich moiety of the ligand, one 
or two points (a and b) on the receptor, with which N+ and HBA interact, and 
the angle between two distance vectors chosen out of those joining the 
various pharmacophore elements. Experimental applications of this new 
pharmacophore model put in evidence that the N+-HBA and the N+-b 
distances are not related to the binding affinity, which has been found to be 
more correlated with certain molecular space limits: the distances from points 
a, b and c and the bâc angle. High nAChRs binding affinity has been 
correlated with specific values of a-b (7.3-8.0 Å) and a-c (6.5-7.4 Å) distances 
as well as values of the bâc (30.4-35.8°) angle. 
This simplistic, but detailed, model containing the required pharmacophoric 
elements able to drive affinity at the nAChRs does not depict the diversity that 
must exist among the nAChR subtypes to account for ligands selectivity. In 
addition, it is conceivable that subtly different pharmacophores exist not only 
for different nAChR subtypes but also for different states of a particular 
subtype, with different molecular features preferentially favouring the 
stabilization of one state over the others.[57] 
The 3D crystal structures of several AChBPs co-crystallized with nicotinic 
agonists, partial agonists or antagonists have led to human nicotinic receptor 
homology models engineering. Triangulating binding affinity data and docking 
analysis data from human nAChR models, a true target-based drug design 
approach became possible to obtain novel selective nicotinic ligands and 
raise the overall potential of the nicotinic drugs arsenal. 
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1.10. Octahydropyrrolo[3,4,c]pyrrole derivatives 
 
A recent paper by William Bunnelle and co-workers, from the Abbott 
company, has underlined the importance of subtype selectivity, performing an 
exhaustive SAR study of a family of octahydropyrrolo[3,4,c]pyrrole derivatives, 
a group of compounds characterized by a diazabicyclic moiety in which one 
nitrogen is linked to a heteroaromatic ring (Figure 9a).[60] The investigated 
basic scaffold contains two stereogenic centers, but only two possible 
stereoisomers: in Figure 9a the active configuration of the series is shown. 
The introduction of a basic bicyclic core into the skeleton of nicotinic drugs 
represents a strategy that has been frequently followed to build more rigid 
ligands that might facilitate nAChRs selective recognition. In this case, a 
second nitrogen atom is present into the basic core to prevent any additional 
chiral carbons and therefore any further stereochemical issues. The lead 
compound Bun6 1 (Figure 9b), presenting a secondary amine and bearing a 
3-pyridyl ring, is a full agonist at both 42 and 7 nAChRs, with some 
preference for the heteromeric subtype.  
 
Bun6 1
a)
N
N
R1
X
N R3
R2
H
H
HN
N
N
H
H
b)
 
Figure 9. Structures of model compounds. 
 
The selectivity profile of analogues of Bun6 1 was described to be strictly 
dependent on the substitution pattern on the heteroaromatic nucleus (R2 and 
R3 groups). Particularly, the complementary recognition by 42 receptors 
allows only small substituents in para position, like halogens, while in contrast 
more hindered R2 groups, either aromatic or linear/ramified aliphatic chains, 
promote an increased binding affinity. Compounds bearing an ethoxy or n-
propoxy substituent in meta position (Bun13 2 and Bun14 3, Figure 10) lead 
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to a massive 42 vs. 7 selectivity ratio (41000 and >240000, respectively). 
The ligand Bun14 3 exhibits high potency towards the 42 receptor subtype 
(EC50 = 0.37 M) with a full agonist functional profile (118 ± 10% ACh 
maximum response). 
On the contrary, high 7 affinity and selectivity profiles are compatible with 
the presence of bulkier R3 aromatic or heteroaromatic rings, while even small 
meta functionalizations lead to a loss of 7 affinity. Compound Bun46 4 
(Figure 10), with an indolyl substituent on a pyridazine nucleus, shows an 7 
vs. 42 selectivity ratio higher than 400000 and an almost full agonist profile 
at the 7 receptor (87 ± 11% ACh maximum response) coupled with high 
potency (EC50 = 0.32 M). The 7-selective octahydropyrrolo[3,4,c]pyrrole 
termed A-582841 5 (Figure 10), presenting a phenyl ring in position 6 of the 
pyridazine nucleus, was studied in phase I clinical trials as a novel enhancer 
of cognitive properties. This 7 ligand, which shows an 7 binding value in 
the low nanomolar range (Ki = 17 nM) and a better pharmacokinetic profile 
than 4, has unfortunately failed phase I tests due to some adverse reactions 
(mainly tremors and weight loss) in an early 10-days repeated dose study.[61] 
The 42 nAChR binding is also influenced by the nature of the aromatic 
ring (see group X in Figure 9): a pyridine connected to the basic core in 
position 3 is essential for the interaction with the heteromeric receptor 
complex. The 7 receptor subtype seems to be, instead, more flexible, as it 
tolerates various aromatic rings, i.e. pyridine, pyridazine and biphenyl. 
Further interesting observations have been made upon the degree of 
substitution of the basic nitrogen (R1 group). Among the 42-preferring 
ligands, secondary amines possess the correct electronic properties for a 
complementary and selective binding to the orthosteric site, whereas an 
increased substitution, moving from tertiary amines to quaternary salts, 
produces a significant loss of affinity. Considering the 7-selective ligands, in 
this case the methylation of secondary amines has a positive effect on both 
affinity and selectivity and, in addition, some quaternary salts do not display 
any drop of affinity. 
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Figure 10. Structures of model compounds. 
 
 
1.11. Quinuclidine-containing nicotinic ligands 
 
The quinuclidine (1-azabicyclo[2.2.2]octane) ring system is a first choice 
scaffold for several 7 nAChR selective ligands. Incorporation of the basic 
nitrogen into this bicyclic structure has been proposed to constrain the 
orientation of the protonated nitrogen in a manner that facilitates both 7 
nAChR binding and receptor activation. The search for novel 7 selective 
agonists based on the quinuclidine molecular skeleton has been and is still 
today an attractive goal due to the synthetic accessibility of such ligands. 
In 2000, G. Mullen and coworkers[62] from Astra-Zeneca discovered AR-
R17779 6 (Figure 11), a conformationally restricted analogue of the 
cholinergic agonist carbachol. Compound 6 was the first reported full agonist 
at the rat 7 nAChR subtype, showing a meaningful 7 vs. the 42 
selectivity of the affinity profile. 
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Figure 11. Structure of model compound AR-R17779. 
 
This spirooxazolidinone derivative 6 is a potent full agonist (efficacy = 96%) 
for the 7 nicotinic receptor, twice as potent as (–)-nicotine, which however is 
a partial 7 nicotinic receptor agonist (efficacy = 59%). Whereas nicotine is 
poorly selective for the 42 nicotinic receptor, AR-R17779 6 is selective for 
the 7 receptor (approximately 35000-fold more selective than (–)-nicotine). 
Despite a less than desirable pharmacokinetic profile, compound 6 served as 
an invaluable tool for in vivo assessment of 7 nAChR function, validating a 
link between its activation and a variety of biological effects.[62] A clear 
stereochemical preference has been observed for the (S)-(–) versus the (R)-
(+) enantiomer of 6. In addition to the poor affinity for the 7 receptor, (+)-6 
also possesses weak intrinsic activity. These results suggest that the location 
of the carbonyl functionality in AR-R17779 6 is crucial to mimic ACh for 
molecular recognition by the 7 receptor. AR-R17779 6 has displayed varying 
degrees of effects in cognition models but the shortcomings of this derivative 
in vivo have been attributed, as underlined above, to its poor pharmacokinetic 
characteristics.[62] 
The Abbott laboratories have intensively focused their effort on quinuclidine 
nicotinic ligands as well. In the recent years they reported ABT-107 7 as a 
novel 7 selective full agonist for the treatment of Alzheimer’s disease and 
other cognitive disorders (Figure 12).[63] ABT-107 7 has two distinct molecular 
features that are able to drive selectivity towards the 7 channel: a 
quinuclidine core and a pyridazine nucleus bearing an indolyl ring in para 
position. Prepared as pure exo epimer, this compound reveals a quite similar 
molecular skeleton to that of 4 (a pyridazine bearing an indolyl ring), with 
oxygen that in this case links the basic core to the heteroaromatic moiety. 
Since the linking atom has been shifted by one position compared to 4 (the 
oxygen atom is not part of the bicyclic structure), the protonated nitrogen has 
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been moved too to fulfil the pharmacophoric distances. ABT-107 7 shows high 
potency in activating the 7 nAChR (EC50 = 50-90 nM) and in evoking human 
7 receptor current (about 80% of the normalized value to ACh). In spite of its 
quite promising  potential, ABT-107 7 failed phase I clinical trials due to 
severe adverse reactions (headache, sleepiness, tremors).[64] 
 
ABT-107 7
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Figure 12. Structure of model compound ABT-107. 
 
In 2009, after a joint venture between Targacept and Astra-Zeneca, T. A. 
Hauser and coworkers described TC-5619 8 (Figure 13a) as an innovative 
and potent quinuclidine 7 selective anti-schizophrenia agent.[65] In the 
molecular structure of TC-5619 8, the quinuclidine core has been coupled with 
an aromatic amide function, which can be correlated to some extent to the 
ester group of ACh. A similar bioisosteric substitution was present in the 
structure of AR-R17779 6, but in the case of 8 the H-bonding chain is not 
constrained in a spirocyclic system, resulting in some degree of freedom. In 
addition, TC-5619 8 presents an additional 3-pyridinyl-methyl substituent in 
position 2 of the basic scaffold. The parent series of TC-5619 8 can be 
identified in a group of quinuclidine aromatic amides patented by the Bayer 
AG company (Figure 13b).[66] These nicotinic ligands were initially described 
as 7-preferring molecules, even though their affinity and pharmacological 
properties at other receptor systems were not discussed. The incorporation of 
the aromatic side pendant accomplished by the Targacept researchers 
apparently improved both the 7 affinity and selectivity profiles of TC-5619, 
which was found efficacious in the treatment of cognitive impairments in 
schizophrenic mouse models. Among several aromatic side chains, the 3-
pyridinyl-methyl substituent evidenced better binding values and improved 
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functional properties. Furthermore, the authors have evaluated the required 
stereochemistry, indentifying the cis configuration as the most favourable for 
binding at the 7 channel.[67] TC-5619 8 has been characterized as a potent 
full agonist at the 7 nAChRs (Ki = 1 nM, EC50 = 33 nM, 100% ACh current 
response), with a good selectivity towards the heteromeric 42 subtype (Ki = 
2.3 M). In animal models of schizophrenia, this nicotinic ligand exhibited 
promising control of both positive and negative symptoms. However, when 
tested in humans, TC-5619 8 failed phase II clinical trials due to inadequate 
pharmacokinetic results. 
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Figure 13. Structure of model compound TC-5619 and its parent series. 
 
 
1.12. AChBP and model natural compounds 
 
AChBPs are ligand-gated ion channels isolated from the glial cells of 
several molluscs and used as tools to characterize and study nAChRs and to 
develop novel nicotinic drug candidates. The 3D structures of different 
AChBPs co-crystallized with both natural and synthetic nicotinic ligands have 
been resolved, permitting the comprehension of the overall molecular 
interactions between the channel and its respective nicotinic modulators. 
Moreover, homology models of human nAChR subtypes have been 
engineered. 
Analysis within the LBD of the AChBPs isolated from Lymnea stagnalis (L-
AChBP) and Aplysia californica (A-AChBP) co-crystallized with the three 
natural nicotinic model ligands (S)-(–)-nicotine 9[68], epibatidine 10[69] and 
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anabaseine 11[70] (Figure 14) allowed identification of the key residues 
responsible for the receptor recognition. Among them, a group of aromatic or 
hydrophobic residues from the major subunit (using the L-AChBP numeration: 
Tyr89, Trp143, Trp145, Tyr185, Tyr192 and Cys187-188 linked together as 
the C-loop) is highly conserved both in diverse AChBPs and in mammalian 
nAChR subtypes. In contrast, residues from the minor subunit (Trp53, Gln55, 
Leu102, Arg104, Met114 and Val116 in L-AChBP) are less conserved and are 
generally characterized by a more pronounced hydrophilic nature. 
The whole LDB can be described as a hydrophobic cavity with an aromatic 
portion on the major subunit (known as the aromatic box), which allocates the 
rigid and hydrophobic cyclic scaffold of the natural model compounds. The 
cation- interaction, one of the strongest interactions known in chemistry, 
between the protonated nitrogen of the ligands and the centre of the Trp145 
aromatic side chain is the driving force that directs the binding of a nicotinic 
ligand. The positive charge of the ligands is further stabilized by additional 
interactions with some carbonyl groups located in the backbone structure of 
the aromatic box. The pyridine nitrogen of the three alkaloids, recalling the 
ester function of ACh, is bound to the LBD through an H-bond involving 
certain residues, which can be either on the minor subunit (Leu102 and 
Met114 in L-AChBP) or on the major one (Trp147 and Ile118 in A-AChBP). 
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NCH3
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Figure 14. Structure of natural model compounds. 
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Further comments should be done for anabaseine 11. Isolated from the 
skin of the sea worm Paranemertes peregrina, this molecule is chemically 
correlated to anabasine 12 (Figure 14), a minor component of Nicotiana 
tabacum and a higher ring-size homologue of (–)-nicotine 9. Adding an 
unsaturation to the piperidine ring of 11 abolishes the stereogenic centre of 12 
and changes the nature of the basic nitrogen from a secondary amine to a 
cyclic imine. The imine ring of anabaseine 11 undergoes an imine-enamine 
tautomerism: an equilibrium between the non-protonated imine ring, the 
cationic closed immonium core and the charged open ammonium-ketone is 
possible under physiological pH conditions. Several studies established that 
the charged immonium ring is the active species of anabaseine 11.[71] In 
addition, the unsaturation of the cyclic imine core is partly delocalized by the 
pyridine electron orbitals, hence allowing a modest coplanarity between the 
two ring systems. Conversely, (–)-nicotine 9 and epibatidine 10 show a 
perpendicular orientation of the basic scaffold with respect to the pyridine ring. 
Recently, it has been proposed that water molecules might have a relevant 
role in the ligand-receptor interaction. The 3D structures of two AChBPs co-
crystallized with (–)-nicotine 9[68] and anabaseine 11[70] put in evidence the 
presence of a water molecule in the LBD that is able to positively contribute to 
the stabilization of the receptor-ligand complex (Figure 15). Indeed, a water 
bridge connects the pyridine nitrogen to some protein residues (Leu102 and 
Met114 in L-AChBP and Ile106 and Ile118 in A-AChBP). However, it is 
unclear whether the water molecule contributes by directly creating a H-bond 
with the ligand or by enhancing the electronic and hydrophilic properties of the 
LBD. The water molecule might have a primary action by bridging some key 
residues from the LBD to the ligand, but it might also play a role in 
predisposing an accessible environment within the LBD. As reported, the 
nicotinic orthosteric cavity is predominantly hydrophobic in nature, which 
should prevent the interaction with charged compounds. The LBD solvation 
mediated by water molecules might contribute to creating a less hydrophobic 
environment which facilitates the hosting of the ligand. 
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Figure 15. LBD of L-AChBP co-crystallized with anabaseine 11 (left) and A-AChBP 
co-crystallized with (S)-nicotine 9 (right). The water molecules are depicted as red 
spheres. 
 
Our research team elaborated and validated the models for the human 
42,34 and 7 nAChRs,[72,73] and preliminary molecular docking and 
dynamics were performed to evaluate also the putative role of water 
molecules in the binding mode of the reference alkaloid epibatidine 10 into the 
active site of the 42homology model. Epibatidine 10 was docked within the 
42LBD and a water molecule bridging the backbones of 2-Leu119 and 
2-Asn107 to the pyridine nitrogen of the ligand was included, thus 
reproducing the spatial arrangement found in the crystal structure of (–)-
nicotine 9 within L-AChBP.[68] As highlighted in Figure 16, after 10 ns of 
molecular dynamics simulations, the water molecule was still bound to the 
carbonyl groups of 2-Leu119 and 2-Asn107, whereas the distance between 
the pyridine nitrogen of epibatidine 10 and the oxygen atom belonging to the 
water molecule was slightly higher than that typical of an optimal hydrogen 
bond.  
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Figure 16. Epibatidine 10 (cyan) docked within the 42 LBD. 
 
The same analysis was applied to the complex deschloroepibatidine/42. 
Deschloroepibatidine 13 (Figure 17) is an analogue of epibatidine, in which 
the chlorine atom is missing, which shares the same affinity of the parent 
derivative at the 42 receptors. Once again, molecular dynamics simulations 
indicated that the water molecule was firmly bridged to the pyridine nitrogen of 
the ligand and to the backbone chains of 2-Leu119 and 2-Asn107. As 
illustrated in Figure 17, the average distances between the atoms belonging 
to the water molecule and the 2-backbone carbonyl groups and the pyridine 
nitrogen are less than 3 Å. At variance with what observed with epibatidine, 
the absence of the halogen atom in the structure of deschloroepibatidine 13 
could promote a better interaction of the ligand with the solvated receptor 
binding site. 
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N
N
Deschloroepibatidine 13          
 
Figure 17. Structure of model compound deschloroepibatidine 13 and the 
distance fluctuations between the water oxygen atom and the backbone 
of Leu119, Asn107 and the pyridine nitrogen of the ligand during the 
molecular dynamics simulation performed on the 13/42 complex. 
 
The role of solvent molecules in the nAChRs/ligand interaction has been 
debated in the literature: several experimental results, and even our data, 
suggest that water molecules, lying into the active cavity of nAChRs as well 
as in AChBPs, contribute to decrease the overall hydrophobicity of the binding 
site, giving rise to an optimal environment to accept the lone pair belonging to 
the pyridine nitrogen of naturally occurring nicotinic derivatives. Moreover, 
Hansen and coworkers have already stated that, even though the crystal 
structure of A-AChBP co-crystallized with epibatidine 10 doesn’t enclose any 
solvent residues, the pyridine nitrogen of the nicotinic ligand may be bridged 
to the backbone of A-AChBP-Ile108 by a water molecule.[69] 
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2. Aims and Objectives 
 
The aim of the current research project was to design, synthesize and 
pharmacologically evaluate novel ligands targeting neuronal nicotinic 
acetylcholine receptor subtypes. To identify novel agonists/partial 
agonists/antagonists towards the 42, 7 and 34 subtypes, this 
experimental research focused on three different classes of nicotinic 
compounds. Firstly, the substitution strategy applied by Bunnelle et al. was 
taken as model protocol to design novel 2,5-diazabicycle[2.2.2]octane 
derivatives. Secondly, a group of molecular hybrids was synthesized in the 
search for novel selective 7 agonists/partial agonists containing the 
quinuclidine core (the basic structure present in the model compounds AR-
R17779 6 and ABT-107 7) and the 3-pyridinyl-methyl substituent in position 2 
(the side pendant found in the model compound TC-5619 8). Finally, the 
structures of the model alkaloids (–)-nicotine 9 and anabaseine 11 and the 
synthetic nicotinic ligand deschloroepibatidine 13 were modified to generate a 
set of unprecedented analogues to investigate the putative role of the water 
molecule in the ligand-receptor interaction. 
  
 
2.1. 2,5-Diazabicycle[2.2.2]octane derivatives 
 
In the search for novel selective nicotinic ligands, the 2,5-
diazabicycle[2.2.2]octane derivatives 14-23 (Figure 18) were designed and 
synthesized, applying the previously discussed substitution approach of 
Bunnelle and coworkers.[60] Compound Bun6 1 was built choosing an 
octahydropyrrolo[3,4,c]pyrrole system as the basic core, which has two 
stereogenic centres and two stereoisomers. On the contrary, the 2,5-
diazabicycle[2.2.2]octane nucleus is a symmetric and more rigid scaffold, in 
which the degree of freedom of the protonatable system is reduced. 
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14  R1 = H           R2 = H
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N
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N
N
N
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N
H
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Figure 18. Structures of target compounds based on the diazabicycle-octane core. 
 
Bunnelle and his research team, describing a large number of nicotinic 
ligands endowed with different molecular skeletons, reported the 42 binding 
data of the target compound 14, characterized by a low Ki value in the sub-
nanomolar range, thus displaying  a 10-fold higher affinity than the model 
compound Bun6 1.[74] By the way, the 7 binding affinity of 14 was not 
reported. The basic bicycle found into the molecular structure of 14 exhibits 
some new interesting chemical features, compared to the model scaffold:  
 a reduced degree of freedom and therefore a more constrained 
orientation of the protonated nitrogen within the LBD of nAChRs. 
 the absence of stereoisomers and thus, in theory, an easier 
synthetic approach. 
 a quinuclidine-like structure, which is more generally accepted 
by nAChRs (particular the  7 subtype). 
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Preliminary molecular docking analysis, performed within the 42 human 
homology model elaborated by our research group, had already put in 
evidence that a similar binding mode and a significant overlapping exist 
between Bun6 1 and its 2,5-diazabicycle[2.2.2]octane analogue 14 (Figure 
19).[75] 
On the other hand, by means of our 7 human homology model, we tested 
in silico the reference ligand Bun46 4 and its virtual 2,5-
diazabicycle[2.2.2]octane analogue 23 within the human 7 LBD.[75] Again, a 
similar binding interaction between the two ligands was observed (Figure 20). 
 
 
Figure 19. Model compound Bun6 1 (green) and target compound 14 
(cyan) docked within the human 42 LBD. 
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Figure 20. Model compound Bun46 4 (green) and target compound 23 
(cyan) docked within the human 7 LBD. 
 
These results encouraged the design and synthesis of a series of target 
compounds characterized by the 2,5-diazabcicle[2.2.2]octane scaffold as the 
basic moiety, in which one nitrogen is linked to a pyridine or pyridazine 
heteroaromatic ring. An appropriate substitution pattern should direct 
selectivity towards the 42 or 7 nAChR subtypes. To this end, pyridine 
derivatives bearing alkoxy groups in meta position were designed, to 
selectively bind the heteromeric 42 channel. Then, para substituted 
pyridazine derivatives, aiming to enhance affinity for the 7 subtype. In order 
to investigate the adequate electronic properties of the charged nitrogen, 
some tertiary amines and quaternary salts have been prepared too. 
This novel set of nicotinic ligands will aim at the validation of both the SAR 
study of the Abbot scientists and the computational study elaborated by our 
research team.[60,75] Moreover, albeit the somewhat exceptional affinity and 
selectivity values at the 42 or the 7 nicotinic channels, the Abbott model 
compounds were unsuccessful in the clinical trials, as shown by compound A-
582841 5.[61] The use of a more rigid basic scaffold might improve the overall 
pharmacological profile of the new derivatives. 
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2.2. Quinuclidine-containing derivatives  
 
The set of novel quinuclidine-containing compounds  24-31 (Figure 21) was 
designed and synthesized.  
 
24 25  R1 = H           R2 = Cl
26  R1 = H           R2 = Ph
27  R1 = CH3       R2 = Ph
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N
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N
N
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N
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N
N
N
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N
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AR-R-17779 6 ABT-107 7
 
Figure 21. Structures of target compounds based on the quinuclidine core. 
 
As previously discussed, the quinuclidine (1-azabicyclo[2.2.2]octane) ring 
system is a frequent scaffold for nicotinic ligands selective for the 7 subtype. 
As a matter of fact, incorporation of the basic nitrogen into this bicyclic 
structure has been proposed to constrain the orientation of the protonation of 
the nitrogen in a manner that facilitates the 7 nAChR binding and activation. 
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However, the LBD of our 7 homology model was unable to allocate TC-5619 
8 (Figure 21), due to the presence of the bulky aromatic side pendant in 
position 2. The ligand induced-fit might remodel the receptor binding site 
creating an additional hydrophobic cleft. 
Therefore, we designed a group of novel derivatives retaining both the 
quinuclidine ring and the 3-pyridinyl-methyl pendant in position 2, as found in 
the structure of TC-5619 8, and replacing  the amide function of 8 with an 
ether group (25-28) or a spirooxazolidinone ring (29-31), taken from the model 
compounds ABT-107 7 and AR-R-17779 6, respectively (Figure 21). With 
these target compounds we aimed at investigating if and to what extent the 3-
pyridinyl-methyl substituent of reference TC-5619, now inserted in other 
quinuclidine-containing derivatives, should affect the affinity and functional 
profile at 7 nAChRs. Since the cis configuration of TC-5619 8 was found to 
be the most favourable arrangement for binding to the 7 subtype, the same 
stereochemistry has been retained in the new ligands.[67] 
 
 
2.3. Structural analogues of model alkaloids 
 
As discussed in section 1.9, the isolation and the structural resolution of 
several AChBPs co-crystallized with natural nicotinic ligands, such as (–)-
nicotine 9, epibatidine 10 and anabaseine 11, allowed a better 
characterization of the nicotinic receptor architecture, the identification of the 
protein residues involved in the binding process and the development of 
homology models for nAChRs.[68-70] The driving force of the ligand-receptor 
interaction process has been identified in the cation- interaction between the 
protonated nitrogen of the ligands and a tryptophan residue located within the 
aromatic box region of the LBD. The basic nitrogen is further stabilized by the 
backbone chain of aromatic box amino acids. A supplementary H-bond 
connects some key residues belonging to both the major and the minor 
subunits of the LBD to an HBA region of the ligand (ester function in ACh, 
pyridine nitrogen in alkaloids). Albeit a full characterization of this contact is 
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far from being completely understood, it is well accepted that the participation 
of less conserved residues from the minor subunit could be crucial in affecting 
the selectivity profile of nicotinic ligands. 
As already pointed out, the presence of water molecules in the LBD has 
been identified in at least two different AChBPs co-crystallized with (–)-
nicotine 9 and anabaseine 11, adding further elements to the debate on the 
nicotinic orthosteric binding site. A molecule of water might improve the 
hydrophilic properties of the LBD environment or, on the other hand, it might 
directly participate in the ligand-interaction process by bridging the pyridine 
nitrogen to some protein residues. To explore the putative role of the water 
molecule, we planned some new potential nicotinic ligands by modifying the 
structures of three natural model compounds (Figures 22 and 23). 
 
37  R1 = OH           R2 = H
38  R1 = CH2OH    R2 = H
39  R1 = CH2OH    R2 = F
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Figure 22. Structures of target compounds bearing a hydroxyl group. 
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40  R1 = H           R2 = H
41  R1 = CH3       R2 = H
42  R1 = F           R2 = H
43  R1 = F           R2 = Br
N
R2
R1
 
 
Figure 23. Structures of target compounds bearing hydrophobic 
substituents. 
 
The structures of (–)-nicotine 9, deschloroepibatidine 13 and anabaseine 
11 were modified designing new analogues which contain a hydroxyl or a 
hydroxymethyl group (target compounds 32-39) to mimic and eventually 
dislocate the water molecule in the receptor-ligand interaction. In this way, a 
potentially similar interaction will be given by the ligand. The proposed 
substitution pattern on the ligand skeleton aiming to increase its binding 
affinity is an approach which has precedents in the literature for a series of 
HIV-1 protease inhibitors.[76] 
The size of the basic core of anabaseine 11 was also reduced designing 
the lower homologue 34. On the other hand, a few analogues potentially able 
to disrupt the water-ligand interaction were prepared by considering only the 
anabaseine basic scaffold and replacing the pyridine nitrogen with 
hydrophobic groups (target compounds 40-43). In this way, the interaction 
with the water molecule would be excluded, maybe favouring a different 
binding mode and giving rise to a variation of the ligand functional profile.  
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3. Results and Discussion 
 
 
3.1. Synthesis of the 2,5-diazabicycle[2.2.2]octane derivatives 
 
The synthetic strategy adopted to accomplish the designed novel 2,5-
diazabicycle[2.2.2]octane derivatives 14-23 required the preparation of the 
2,5-diazabicycle[2.2.2]octane core, which has been the subject of various 
literature reports;[77-79] among them the most convenient approach is 
illustrated in Scheme 1. 
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N
H
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c
HN
NH
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N
N
O
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N
N
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f
HN
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2HCl
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Scheme 1. Reagents and conditions: (a) NaN3, EtOH, reflux, 6h; (b) i) PPh3, THF, 0° to 
r.t., 3h; ii) H2O, r.t., 16h; (c) Na, MeOH, reflux, 5h; (d) 60% NaH, BnCl, DMF, 0°C to r.t., 
24h; (e) LiAlH4, THF, 0° to reflux, 5h; (f) H2, Pd/C 10%, HCl 37%, MeOH, r.t., 16h. 
 
Following the Newman protocol[77], the linear starting material diethyl-meso-
2,5-dibromoadipate 44 was used as the carbon source for the diazabicyclic 
system. The nitrogen atoms were inserted by a nucleophilic substitution using 
sodium azide. Several reduction procedures are already described to convert 
diazide 45 into the corresponding diamine. As shown in Scheme 2, a high 
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pressure hydrogenation with the Adam’s catalyst is the strategy reported by 
Newman et al. to isolate diamine 51.[77] However, the low yield (due mostly to 
the high reactivity and instability of the free diamine function, which requires to 
be converted into the corresponding dihydrochloride to be stabilized) and the 
expensive platinum dioxide catalyst, suggested the search for an alternative 
approach. A milder Staudinger reaction reduced efficiently the azide functions, 
providing the monocyclic derivative 46 in almost quantitative yield.[80] The 
mono-cyclization step takes place due to the basic aqueous media of the 
Staudinger reduction environment (the basicity is given by the secondary 
product triphenylphosphine oxide, Scheme 3). The subsequent sodium 
methoxide-assisted hydrolysis and cyclization allowed a smooth conversion of 
both diamine 51 and monocyclic amine 46 to the desired intermediate 47.  
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46 100% yield
b
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NH2
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c
HN
NH
O
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Scheme 2. Reduction and conversion of 44 to 46. Reagents and conditions: (a) H2, 
Pt2O, EtOH, r.t., 4 bar, 5h; (b) i) PPh3, THF, 0° to r.t., 3h; ii) H2O, r.t., 16h; (c) Na, 
MeOH, reflux, 5h. 
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Scheme 3. Staudinger reduction mechanism. 
 
~ 50 ~ 
 
Dilactame 47 was almost insoluble in standard organic solvents and 
therefore it was impossible to reduce the carbonyl groups using any hydrides 
in dry conditions. Protection of the amide nitrogens with benzyl groups  
(derivative 48, Scheme 1) improved the solubility profile and the subsequent 
reduction with lithium aluminium hydride provided the protected 2,5-
diazabicycle[2.2.2]octane ring 49.[79] The instability of the free amine functions 
after removal of the benzyl protecting groups under standard catalytic 
hydrogenation conditions was overcome by adding concentrated hydrochloric 
acid to the reaction flask (Scheme 1), leading to the key basic core 50 as the 
related dihydrochloride.[81] 
Next, derivative 50 was mono-Boc protected using di-tert-butyl dicarbonate 
in a sub-stoichiometric amount (0.5 eq.) to avoid protection of the second 
nitrogen,[81] then intermediate 51 was coupled with properly substituted 
pyridine bromides (Scheme 4). This functionalization was achieved through a 
palladium catalyzed cross-coupling protocol, due to the low electrophilic 
character of the m-pyridine bromides (intermediates 52-54).[60,75] 
 
a
50
HN
NH
2HCl
BocN
NH
51
b
BocN
N N
R
52 R = H
53 R = OCH2CH3
54 R = OCH2CH2CH3
c
R1N
N N
R2
14 R1 = H            R2 = H
15 R1 = (CH3)2    R2 = H
16 R1 = H            R2 = OCH2CH3
17 R1 = H            R2 = OCH2CH2CH3
d
 
Scheme 4. Synthesis of pyridine derivatives 13-16. Reagents and conditions: (a) 
Boc2O, NaOH, H2O/iPrOH, 0°C, 2h; (b) 55 or 56, Pd2(dba)3, (±)-BINAP, tBuOK, THF, 
reflux, 5h; (c) HCl 2.0 N in Et2O, MeOH/Et2O, 0°C to r.t., 3h; (d) i) CH2O, NaBH4, 
MeOH, 0°C to r.t., 1h; ii) CH3I, Et2O, r.t., 3h. 
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The 5-alkoxylpyridine bromides 55 and 56 were prepared by reacting 3,5-
dibromopyridine with the proper sodium alkoxide (Scheme 5). Deprotection in 
acidic media afforded the desired final compounds 14, 16 and 17; with a 
standard procedure, the secondary base 14 gave the N-Me tertiary amine, 
which was converted into the corresponding dimethylammonium salt 15 
(Scheme 4). 
 
a
55 R = CH2CH3
56 R = CH2CH2CH3
N
Br Br
N
Br OR
 
Scheme 5. Synthesis of 3-bromo-5-alkoxy-pyridines. Reagents and 
conditions: (a) NaOR, DMF, 70°C, 3h. 
 
To obtain the desired pyridazine target compounds 18-23, the mono-Boc 
derivative 51 was coupled with both 3,6-dichloro-pyridazine and 3-chloro-6-
phenylpyridazine in the presence of DIPEA under standard thermal conditions 
(Scheme 6). Both intermediates 57 and 58 were deprotected to the desired 
secondary amines 19 and 18. The first one underwent a standard reductive 
amination and the corresponding tertiary methylamine 20 was then treated 
with methyl iodide to provide the quaternary ammonium salt 21. On the other 
hand, compound 58 was coupled with 5-indolyl boronic acid by means of a 
microwave-assisted Suzuki reaction to provide intermediate 59. Deprotection 
with 2.0 N hydrochloric acid in diethyl ether provided the secondary amine 22, 
which was converted into methylamine 23. 
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Scheme 6. Synthesis of pyridazine derivatives 17–22. Reagents and conditions: (a) 3-
chloro-6-phenyl-pyridazine, DIPEA, DMSO, 105°C, 48h; (b) HCl 2.0 N in Et2O, MeOH/ 
Et2O, 0°C to r.t., 3h; (c) CH2O, NaBH4, MeOH, 0°C to r.t., 1 h; (d) CH3I, Et2O, r.t., 3h; (e) 
3,6-dichloro-pyridazine, DIPEA, DMSO, 105°C, 48h; (f) 5-indolyl-boronic acid, (PPh3)2PdCl, 
PPh3, Na2CO3 1M, 1,4-1,4-dioxane/EtOH, MW irradiation, 150°C, 30 min. 
 
 
3.2. Pharmacological evaluation of compounds 14–23 
 
As shown in Table 1, derivatives 14-23 underwent binding experiments to 
evaluate their affinity at 42, 7 and 34 nicotinic receptor subtypes 
present in rat cortex membranes, using [3H]epibatidine (42 and 34 
subtypes) and [125I]-bungarotoxin (7 subtype) as reference radioligands. 
These pharmacological assays were performed at the Dipartimento di 
Farmacologia, Chemioterapia e Tossicologia Medica, University of Milan, in 
the research group coordinated by Dr. Cecilia Gotti. 
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Compound 
42 
[3H]Epi 
(Ki, nM) 
7 
[125I]-BgTx 
(Ki, nM) 
34* 
[3H]Epi 
(Ki, nM) 
Selectivity ratio 
42/7 
14 0.131 (17) 24 (18) 31 (19 183 
15 3.7 (13) 12 (25) 69 (11) 3.3 
16 0.368 (16) 13000 (25) 153 (22) 35000 
17 0.234 (16) 21000 (26) 50 (23) 90000 
18 2 (10) 118 (20) 4.1 (13) 59 
19 125 (12) 132 (17) 630 (34) 1 
20 2240 (22) 15.9 (40) 281 (22) 0.007 
21 1000 (14) 2300 (14) 163 (20) 2.3 
22 580 (15) 22 (18) 2000 (12) 0.04 
23 2780 (20) 2.25 (40) 191 (19) 0.0008 
 
Table 1. Binding data on the indicated compounds towards the 42, 7 and 
34 nAChR subtypes. 
 
The unsubstituted compound 14, as already shown by Bunnelle and co-
workers,[75] displayed high binding affinity at the 42 subtype with a Ki value 
of 131 pM (literature: Ki = 20 pM). Nevertheless, 14 showed a good affinity (Ki 
= 24 nM) even at the homopentameric 7 channel too, about 200-fold lower 
than that observed at the 42 receptor. The 42 vs. 7 selectivity ratio was 
massively increased when alkoxy groups were inserted in position 5. Indeed, 
compounds 16 and 17 reached 42 Ki values in the picomolar range, with 
barely no affinity at the 7 channel, thus displaying selectivity ratios of 35000 
and 90000, respectively, the same order of magnitude compared with the 
42-selective model ligands.[60] The presence of a hindered aliphatic chain in 
position 5 on the pyridine ring seems relevant to the 42 subtype binding 
selectivity, suggesting the existence of a cleft or tunnel within the 42 LBD, 
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perpendicular to the pharmacophore ground level where the protonated 
scaffold and the HBA ring lay. 
The quaternary salt 15 showed a 100-fold decreased 42 affinity, while it 
maintained, as expected, the same affinity profile at the 7 receptor complex. 
This result is in agreement with the observations made by Bunnelle et al. on 
the properties of the basic nitrogen able to promote a selective binding at the 
42 subtype.[60] Derivative 18, characterized by a pyridazine ring bearing a 
chlorine atom in position 6, has a similar behaviour towards both tested 
nAChR subtypes, with some preference for the heteromeric channel. The lack 
of selectivity, mainly due to a 200-fold reduction of 42 affinity considering 
the parent compound 14, confirmed that a pyridine moiety is a rather strict 
structural requirement for the complementary ligand-receptor recognition at 
this subtype. Conversely, in accordance with the results on the model 
compounds, the binding at the 7 channel is less affected by the nature of the 
heteroaromatic ring.[60] 
When a bulky aromatic substituent was introduced in para position on the 
pyridazine ring, the selectivity profile partly shifted towards the homomeric 7 
receptor. The 6-phenylpyridazine derivative 19 showed similar binding 
affinities at the tested receptor subtypes, whereas the indolyl-containing 
compound 22 exhibited a negligible 10-fold 7 selectivity. These results are 
scarcely in agreement with the model substitution pattern and this could be 
explained by the more rigid scaffold of the target compounds which might not 
be able to properly fit the whole 7 LBD. The existence of a larger 7 
orthosteric binding site compared to the 42 active cavity is a well 
established feature of the homopentameric nicotinic channel, which can 
allocate ligands with more sterically demanding skeletons. Indeed, the binding 
data of tertiary amines 20 and 23 denoted a high 7 affinity in the low 
nanomolar range (Ki = 15.9 and 2.25 nM, respectively) coupled with good 
selectivity ratios (140 and 1300, respectively). As described in section 1.7, the 
7 affinity is clearly affected by the degree of substitution of the basic nitrogen 
and tertiary amines generally possess the required electronic properties to 
fruitfully bind the homomeric 7 channel. A different behaviour was 
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associated to the permanently charged dimethylammonium salt 21, which is a 
low affinity ligand at both investigated nAChR subtypes. 
In conclusion, our test set has validated the substitution pattern proposed 
by Bunnelle and coworkers as well as our in silico investigation, which outline 
the SAR able to affect affinity and subtype selectivity towards the two most 
abundant and pharmacologically relevant nAChRs. 
Nevertheless, the target compounds underwent binding experiments also 
at the 34* nAChR subtype, the third most expressed neuronal nicotinic 
channel (Table 1). Even though these compounds have been rationally 
designed to selectively bind the 42 or 7 nicotinic receptors, we believed it 
was interesting to explore their affinity profile also at the 34* receptor 
complex. With the exception of compound 22, all the tested ligands showed a 
meaningful binding affinity towards the 34* subtype. The best affinity values 
were measured for compounds 14, 15 and in particular 18. The introduction of 
more hindered substituents in para or meta position led to a reduction of 
34* affinity, whereas the nature of the heteroaromatic ring did not affect the 
binding at the heteromeric channel, since pyridine and pyridazine compounds 
exhibited quite similar affinity values. In general, the relevant affinity at the 
34* nAChR subtype compromises the selectivity profile of the most 
promising compounds (15, 16 and 23), even though the 34* channel is by 
far less abundant within the CNS compared to the other tested receptors. 
Worth noting, the original report by Bunnelle et al. didn’t mention at all the 
affinity profile towards the 34* receptor for the model series, and we are 
convinced that the octahydropyrrolo[3.4.c]pyrrole derivatives are characterize 
by some, if not relevant, 34* affinity as well.  
 
 
3.3. Synthesis of quinuclidine-containing derivatives  
 
The synthetic sequence applied to afford the designed novel functionalized 
quinuclidines 24-31 started with insertion of the 3-pyridinyl-methyl pendant, 
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found in the model compound TC-5619 8, into the quinuclidine scaffold 
(Scheme 7).[67] 
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Scheme 7. Synthesis of key intermediate 62 and target compound 24. 
Reagents and conditions: (a) 3-pyridinecarboxaldehyde, KOH, MeOH, 
r.t., 48h; (b)  H2, Pd/C 10%, HCl 6N, MeOH, rt, 16h; (c) NH2NH2*H2O, 
KOH, DEG, 180°C, 6h. 
 
Commercially available 3-quinuclidinone hydrochloride 60 was condensed 
with 3-pyridinecarboxaldehyde in a basic medium to afford the unsaturated 
adduct 61. Subsequent hydrogenation in the presence of hydrochloric acid 
provided the corresponding intermediate 62. To investigate the role of the 
heteroaromatic side pendant, we prepared compound 24, which lacks any 
further substitution. To this end, the Wolff-Kishner reduction conditions were 
applied to 62 using hydrazine monohydrate and potassium hydroxide in 
diehtyleneglycol at 180°C, which provided 24 as a racemate.[82]  
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Scheme 8. Synthesis of pyridazine derivatives 25–28. Reagents and conditions: (a) 
Al(OiPr)3, iPrOH, 70°C, 6h; (b) 3,6-dichloropyridazine, NaHDMS, THF, 0°C to r.t., 5h; (c) 
fumaric acid, MeOH, r.t., 5h; (d) 5-indolyl-boronic acid, (PPh3)2PdCl, PPh3, Na2CO3 1M, 1,4-
1,4-dioxane/EtOH, MW irradiation, 150°C, 30 min; (e) 3-chloro-6-phenyl-pyridazine, 
NaHDMS, THF, 0°C to r.t., 5h; (f) CH3I, MeOH, r.t., 6h. 
 
The carbonyl function of 62 underwent two different reductive approaches. 
First, it was reduced to the corresponding secondary alcohol, applying the 
Meerwein-Pondorf-Verley (MPV) protocol, which was then reacted with a few 
substituted pyridazine chlorides (Scheme 8). The use of aluminium iso-
propoxide as reductive agent allowed to obtain the desired alcohol 63 as the 
cis predominant isomer (cis/trans ratio: 87:13, evidenced by 1H-NMR 
analysis).[67] As illustrated in Scheme 9, the MPV reaction consists of the 
aluminium-catalyzed hydride shift from the -carbon of an alcohol component 
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to the carbonyl carbon of a second component, through a six-membered 
transition state, referred to as the Meerwein-Ponndorf-Verley reduction or the 
Oppenauer oxidation, depending on which is the desired reaction product.[83] 
The major cis isomer is obtained due to the steric hindrance of the 3-pyridinyl-
methyl substituent, which forces the hydride attack from the opposite side. 
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Scheme 9. MPV reduction mechanism. 
 
Alcohol 63 was then coupled with substituted pyridazine chlorides, using 
the strong base sodium bis(trimethylsilyl)amide, which promoted the 
nucleophilic attack of the corresponding alkoxide. The chromatographic 
purification of the adducts allowed complete separation of the cis isomer from 
the trans minor component. Intermediate 64, bearing a chlorine atom in 
position 6 of the pyridazine ring, was treated first with fumaric acid to isolate 
the crystalline target compound 25, then with 5-indolyl-boronic acid in a 
microwave-assisted Suzuki coupling, to introduce the indole ring. Salification 
with fumaric acid provided the desired compound 28. Coupling with 3-chloro-
6-phenylpyridazine led directly to the desired phenyl-substituted derivative 26, 
which was then reacted with methyl iodide. Unfortunately, we weren’t able to 
selectively methylate the tertiary nitrogen without affecting the pyridine ring: 
the bis-quaternary salt 27 was thus isolated and characterized. 
A second reductive approach performed on ketone 62 is illustrated in 
Scheme 10. The introduced spirocyclic epoxide was hence transformed into 
the corresponding spirooxazolidinone derivatives 29-31. 
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Scheme 10. Synthesis of spirooxazolidinone derivatives 29-31. Reagents and 
conditions: (a) TMSOI, 60% NaH, DMSO, r.t., 24h; (b) i) CH3NH2, MeOH, r.t., 24h; ii) 
DCI, THF, reflux, 3h; (c) NaN3, NH4Cl, MeOH/H2O, r.t., 24h; (d) LiAlH4, THF, 0°C to r.t., 
3h; (e) CbzCl, DIPEA, DCM, 0°C to r.t., 3h; (f) 60% NaH, THF, 0°C to r.t., 3h; (g) 
Benzyl chloride, 60% NaH, DMF, 70°C, 12h; (h) fumaric acid, MeOH, r.t., 5h. 
 
Ketone 62 was converted into spirocyclic epoxide 65 applying the Johnson-
Corey-Chaykovsky reaction conditions.[84] As illustrated in Scheme 11, 
trimethylsulfoxonium iodide (TMSOI), treated with sodium hydride, generated 
the active species dimethyloxosulfonium methylide, whose negatively charged 
carbon attacked the carbonyl carbon of 62. Again, the bulky 3-pyridinyl-methyl 
substituent directed the diastereoselectivity of the carbon coupling, leading to 
the racemic cis isomer 65, and no sign of trans isomer formation, based on 
1H-NMR analysis.[85] The ring-closure is facilitated by the presence of the 
sulfonium cation which is a good leaving group. 
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Scheme 11. Johnson-Corey-Chaykovsky reaction mechanism. 
 
At this stage, the high reactivity of the tensioned three-membered 
spirocyclic ring was exploited to generate the spirooxazolidinone function.[86] 
Ring-opening with gaseous methylamine (with no isolation of the 
intermediate) and subsequent cyclization in the presence of N-N’-
diisopropylcarbodiimide (DCI) as the carbonyl source afforded the target 
compound 30. At the same time, several unsuccessful attempts were made to 
perform ring-opening of the epoxide 65 with aqueous ammonia. Therefore, 
intermediate 65 was treated with sodium azide and the corresponding -azido 
alcohol was reduced with lithium aluminium hydride at room temperature to 
the primary amine 67 (Scheme 10). The amine function of -amino alcohol 67 
was protected with benzyl chloroformate (intermediate 68). Treatment with 
sodium hydride allowed the nucleophilic ring-closure affording compound 29. 
At variance with the other compounds of this set, the target derivative 29 
precipitated as a colourless crystalline derivative, which was slightly soluble in 
polar standard organic solvents such as DMSO or MeOH. Its amino acid-like 
behaviour precluded any further derivations. Indeed, we tried to functionalize 
the carbamate nitrogen with several aromatic moieties (e.g., pyridine, 
thiophene, benzothiophene), but the 3-pyridinyl-methyl side chain sterically 
inhibited all the couplings. We achieved better results by using reactants (i.e., 
benzyl chloride) able to overcome the hindrance of the pyridyl side chain. In 
this way, the final ligand 31 was prepared and tested. 
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3.4. Pharmacological evaluation of compounds 24-31 
 
Compounds 24-31 underwent pharmacological experiments to evaluate 
their affinity at 42 and 7 nicotinic receptor subtypes present in rat cortex 
membranes by binding studies using, as radioligands, [3H]epibatidine (42 
subtype) and [125I]-bungarotoxin (7 subtype) and the results are shown in 
Table 2. Binding affinity studies were performed again by the research group 
coordinated by Dr. Cecilia Gotti. 
Unfortunately, the compounds under study showed Ki values at the 7 
receptor significantly lower than the reference compound 8. The unsubstituted 
compound 24 is the only ligand already known from the literature, and it was 
described as an 42 (Ki = 16 nM) and 62* (Ki = 85 nM) full agonist, with 
some 7 affinity (Ki = 450 nM).
[87] In spite of the differences in the absolute Ki 
values, we observed for compound 24 an 42 vs. 7 selectivity ratio 
comparable to that found in the literature.[87]  
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Compound 
42 
[3H]Epi 
(Ki, nM) 
7 
[125I]-BgTx 
(Ki, nM) 
Selectivity ratio 
42/7 
TC-5619 8 2300
[67]
 1.0
[67]
 2300 
24 114 (12) 3400 (36) 0.03 
25 1200 (12) 763 (23) 1.6 
26 740 (12) 68 (23) 11 
27 1000 (13) 13000 (40) 0.08 
28 291 (11) 21 (20) 14 
29 9000 (17) 21000 (35) 0.4 
30 14000 (13) 11000 (27) 1.3 
31 2400 (12) 11000 (31) 0.2 
 
Table 2. Binding data on the indicated compounds towards the 42 
and 7 nAChR subtypes. 
 
The introduction of biaromatic rings in position 3, such as in compounds 26 
and 28, reverted the selectivity profile of 24 leading to good 7 binding affinity 
values in the high nanomolar range, in line with our purpose when these 
analogues of TC-5619 8 and ABT-107 7 were designed. However, a modest 
7 vs. 42 selectivity (11 and 14, respectively) was detected. These 
observations are also in agreement with the results published by Bunnelle et 
al.[60] and with the binding data obtained for the set of 2,5-
diazabicyle[2.2.2]octane derivatives (Section 3.2). The replacement of the 
aromatic ring in position 6 of the pyridazine nucleus with a chlorine atom 
(compound 25) and the bis-quaternarization of the nitrogen atoms (compound 
27) caused a massive drop of 42 and 7 affinity.  
The very low affinity showed by the spirooxazolidinone derivatives 29-31 at 
the tested nAChRs could be explained by the rigidity of the spirocyclic system, 
which might force the 3-pyridinyl-methyl chain in an unfavourable interaction 
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with the nicotinic channels. This substituent, when inserted in more rigid 
molecular skeleton, might not be able to properly align within the 7 
orthosteric site. In this regard, we recently found out that the Targacept 
researchers published an exhaustive overview on the binding affinity and 
pharmacological profile of TC-5619 8 and its four stereoisomers.[88] In this 
paper, quite surprisingly, the authors reported the trans isomers as the 
eutomers (7 Ki = 1.40 and 4.98 nM, respectively), whereas the cis series 
was described by having only a high nanomolar binding affinity (7 Ki = 0.4 
and 0.8 M). Curiously, the same authors, in the first TC-5619 series paper 
dating back to 2005[67], described the cis configuration as the most favourable 
in the recognition by the 7 nAChR subtype, with an 7 Ki value of 1.0 nM for 
the cis isomers of TC-5619 8 (compounds 8l in that article). Based on this 
amazing report, we certainly chose the wrong structural model to build our 
quinuclidine-containing derivatives and, maybe, the trans isomers would lead 
to a stronger interaction with the target 7 nAChR subtypes. 
 
 
3.5. Synthesis of derivatives structurally related to (S)-nicotine, 
deschloroepibatidine and anabaseine  
 
The synthetic strategy applied to afford the designed novel (–)-nicotine 9 
variants 32 and 33 is shown below in Scheme 12. 
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Scheme 12. Synthesis of (S)–nicotine 9 derivatives 33 and 33. Reagents and 
conditions: (a) Boc2O, TEA, THF, r.t., 20h; (b) 3-Methoxy-bromomethylbenzene, 
60% NaH, THF, reflux, 5h; (c) (–)-Sparteine, s-BuLi, toluene, -78°C, 5h; (d) BBr3, 
DCM, -78°C to r.t., 2h; (e) CH2O, NaBH4, MeOH, 0°C to r.t., 1h; (f) Fumaric acid, 
MeOH, r.t., 5h; (g) Methyl 3-(bromomethyl)benzoate, 60% NaH, THF, reflux, 5h; (h) 
LiBH4, THF, reflux, 30h; (i) TBSCl, imidazole, DMF, 35°C, 8h; (l) TBAF, THF, r.t., 1h; 
(m) 4.0 N HCl in 1,4-dioxane, Et2O, 0°C to r.t., 3h.  
 
Commercially available 3-chloropropylamine hydrochloride 69 was N-Boc-
protected and coupled with two suitably substituted benzyl bromides. Linear 
intermediate 71 underwent an asymmetric cyclization using (–)-sparteine as 
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the chiral enantiopure catalyst. As shown in Scheme 13, two mechanisms 
may account for the role of (–)-sparteine in affecting the enantioselectivity of 
the process.[89] On one hand, (–)-sparteine might co-ordinate the s-BuLi-
mediated lithiation step: an asymmetric deprotonation of the benzyl carbon 
provides the enantio-enriched lithiated intermediate, which then undergoes 
cyclization. On the other hand, the chiral base might operate during the 
cyclization step, promoting an asymmetric ring-closure of the racemic lithiated 
intermediate, thus leading to the same enantio-enriched protected pyrrolidine. 
The cyclic product 72 was obtained with an e.e. of 62%, based on chiral 
HPLC analysis. 
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Scheme 13. Asymmetric cyclization of intermediate 71. 
 
Both methoxy group and protected nitrogen of intermediate 72 were 
liberated by treatment with boron tribromide, and the subsequent reductive 
amination provided the tertiary amine 32, which was crystallized and isolated 
as the corresponding fumarate. Chiral HPLC analysis on the free base of 32 
allowed to detect few traces only of the minor enantiomer (e.e.: 98%). This 
can be explained by the mutual loss of two components in a mixture after 
several reaction/purification/crystallization steps: the ratio between the two 
isomers increases, if the minor component is decreasing. In fact, two 
enantiomers can have different kinetics of reaction (either considering the 
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wanted chemical transformation or an undesired side reaction) or of 
purification/crystallization processes, as known from the theory of the kinetic 
resolution of racemic mixtures. 
Due to the unavailability of commercial benzyl bromides bearing a 
hydroxymethyl group in meta position, we prepared methyl benzoate 74 as 
the precursor of the desired primary alcohol. The altered electronic properties 
of the linear intermediate 74, due to the presence of an electron-withdrawing 
ester group, led to an unsuccessful ring-closure. The ester function was thus 
reduced to the corresponding alcohol, which was protected with tert-
butyldimethylsilyl chloride (TBSCl). Asymmetric cyclization of protected 
alcohol 76 provided the cyclic intermediate 77 in 70% e.e. Deprotection of 
both hydroxyl and amine functions, followed by the usual reductive amination 
step, led to the desired target compound 33 as the pure (S)-enantiomer (e.e.: 
98%). 
A different approach was followed to obtain target compound 34, that can 
be considered a molecular hybrid of both (–)-nicotine 9 and anabaseine 12. In 
fact, it contains the same five-membered basic ring of (–)-nicotine 9 and an 
unsaturation which deletes the stereocenter. The iminocyclic system of 34 can 
be considered as a lower ring-size analogue of anabaseine 12 as well. A 
palladium(0)-catalyzed copper(I)-assisted Liebeskind-Srogl cross-coupling 
between pyrrolidin-thione 80 and the proper boronic acid gave the desired 
cyclic derivative 34 (Scheme 14).[90] 
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34
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Scheme 14. Synthesis of target compound 34. Reagents and conditions: 
(a) 3-(hydroxymethyl)phenylboronic acid, copper(I) thiophene-2-
carboxilate, Pd(PPh3)4, THF, MW irradiation, 100°C, 2h; (b) HCl 2.0N in 
Et2O, r.t., 3h. 
 
The synthesis of the deschloroepibatidine-related molecules 35 and 36 
took advantage of the key intermediate 88, which was prepared using 
literature procedures (Scheme 15).[91] 
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Scheme 15. Synthesis of key intermediate 88. Reagents and conditions: (a) Tosyl 
chloride, AlCl3, DCM, 0°C to r.t., 6h; (b) K2CO3, NaHCO3, DCM/H2O, r.t., 24h; (c) 80°C, 3 
days; (d) NiCl2, NaBH4, HCl 37%, EtOH/THF, r.t., 1h; (e) Tributyltin hydride, AIBN, 
toluene, reflux, 6h; (f) TBAF, THF, reflux, 16h. 
 
One of the two silyl groups of bis(trimethylsilyl)acetylene 81 was replaced 
with a tosyl function. Desilylation in a basic medium afforded alkyne 83, which 
underwent a Diels-Alder reaction with Boc-pyrrole 84 to obtain the protected 
bicyclic intermediate 85. Selective reduction of the less substituted double 
bond was achieved by using nickel boride as the reductive agent (generated 
in situ by addition of sodium borohydride to nickel chloride). Finally, radical 
addition of tributyltin hydride at the residual unsaturated bond and subsequent 
elimination of both tosyl and organostannic functions generated the required 
alkene 88. 
At this stage, alkene 88 was coupled with the properly substituted phenyl 
bromides in a reductive palladium acetate-catalyzed Heck reaction variant 
(Scheme 16).[92] 1H-NMR analysis on products 89 and 90 evidenced a 
racemic mixture of exo epimers, which reflects the active configuration of the 
model compounds epibatidine 10 and deschloroepibatidine 13. The 
preferential syn over anti diastereoselection has been already rationalized in 
the literature.[93,94] Treatment with boron tribromide of 89 allowed deprotection 
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of the phenol oxygen, then the secondary amine functions were generated in 
acidic media, thus providing the target compounds 35 and 36.  
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Scheme 16. Synthesis of deschloroepibatidine-related derivatives 35 and 
36. Reagents and conditions: (a) 3(Methoxy)phenyl bromide, Pd(OAc)2, 
TBAC, KCHO, DMF, 80°C, 5h; (b) (i) BBr3, DCM, -78°C to 0°C, 2h; (ii) 
Boc2O, TEA, DCM, r.t., 2h; (c) 4.0 N HCl in 1,4-dioxane, Et2O, 0°C to r.t., 
4h; (d) 3(Bromophenyl)methanol, Pd(OAc)2, TBAC, KCHO, DMF, 80°C, 
5h. 
 
The preparation of the anabaseine analogues 37-43 required different 
synthetic approaches. In particular, to synthesize compounds 37 and 38, 
commercially available 2-piperidone 91 was used as starting reagent 
(Scheme 18).[95] Protection of the amide nitrogen with Boc and subsequent 
treatment with Grignard reagents led to the isolation of the linear 
intermediates 92 and 94, bearing a methoxy group and an iodine atom in m-
position, respectively. The primary amine function of 92 was obtained after 
acid treatment, then a spontaneous cyclization occurred which provided the 
iminocyclic intermediate 93. Demethylation with 48% hydrobromic acid 
afforded the desired compound 37 (Scheme 17). Since the attempts to 
prepare Grignard reagents in the presence of a hydroxymethyl or a 
carboxylate function were unsuccessful, -valerolactame 91 was treated with 
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3-(iodo)benzyl magnesium bromide. The substituted iodobenzene 95 was 
then submitted to a microwave-assisted carbonylation reaction using 
molybdenum hexacarbonyl as carbon oxide source.[96,97] Application of this 
protocol allowed isolation of the corresponding methyl ester 96, which was 
selectively reduced with sodium bis(2-methoxyethoxy)aluminium hydride 
(Red-Al) to produce the primary alcohol 38.[98] (Scheme 18). 
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Scheme 17. Synthesis of anabaseine-related derivatives 37 and 38. 
Reagents and conditions: (a) (i) n-BuLi, THF, -78°C, 30 min; (ii) Boc2O, 
THF, -78°C, 3h; (iii) 3-(Methoxy)benzylMgBr, THF, -78°C, 3h; (b) (i) TFA, 
r.t., 3h; (ii) NaOH 30%, r.t., 30 min; (c) HBr 48%, reflux, 2h; (d) (i) n-BuLi, 
THF, -78°C, 30 min; (ii) Boc2O, THF, -78°C, 3h; (iii) 3-(Iodo)benzylMgBr, 
THF, -78°C, 3h; (e) Mo(CO)6, Pd/C 10%, DIPEA, DMAP, MeOH, 1,4-
dioxane, MW irradiation, 130°C, 1h; (f) Red-Al, THF, r.t., 1h. 
 
The remaining anabaseine analogues 39-43 were prepared by reacting 5-
bromovaleronitrile 97 and various organolithium and Grignard reagents 
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(Scheme 18).[99] 1,3-Dibromo-5-fluorobenzene 98 was treated with 
butyllithium and the corresponding lithiated intermediate was reacted with 5-
bromovaleronitrile 97 to provide the cyclic dihalogenated derivative 43. In this 
case, the carbonylation-reduction approach illustrated before involved the 
bromine atom of 43, giving the desired compound 39.[96-98] The anabaseine-
related derivatives 40-42 were easily obtained by reacting 5-
bromovaleronitrile 97 with the proper organolithium or Grignard reagent.[99] 
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102
FBr
97, f
N
42
F
 
Scheme 18. Synthesis of anabaseine-related 11 derivatives 39 - 43. Reagents and 
conditions: (a) 1. n-BuLi, Et2O, -78°C, 2h; 2. THF, r.t., 90 min; (b) Mo(CO)6, Pd/C 10%, 
DIPEA, DMAP, MeOH, 1,4-dioxane, MW irradiation, 130°C, 2h; (c) Red-Al, THF, r.t., 24h; (d) 
THF, reflux, 3h; (e) Mg, THF, r.t., 20 min; 2. THF, r.t., 1h; (f) n-BuLi, Et2O, -78°C, 1h; 2. THF, 
r.t., 16h. 
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3.6. Pharmacological evaluation of compounds 32-44 
 
Compounds 32-44 underwent binding experiments to evaluate their affinity 
at 42, 7 and 34* nicotinic receptor subtypes in rat cortex membranes, 
using [3H]epibatidine (42 and 34* subtypes) and [125I]-bungarotoxin (7 
subtype) as radioligands (Table 3). 
 
Compound 
42 
[3H]Epi 
(Ki, nM) 
7 
[125I]-
BgTx 
(Ki, nM) 
34* 
[3H]Epi 
(Ki, nM)
Selectivity ratio 
34*/42
Selectivity 
ratio 34*/7
(S)-Nicotine 
9 
11.1 1600 481 0.02 3.33 
Epibatidine 
10 
0.06 4.2 0.15 0.40 28 
Anabaseine 
11 
32 58 660 0.05 0.09 
32 
703 
(14) 
10000 
(41) 
4900 
(22) 
0.14 14 
33 
6200 
(9) 
15000 
(43) 
4800 
(16) 
1.29 2.41 
34 
2060 
(21) 
590 
(48) 
1550 
(18) 
1.33 0.38 
35 
127 
(11) 
609 
(36) 
80 (13) 1.59 7.61 
36 
429 
(14) 
1800 
(35) 
92 (16) 4.66 20 
37 
32000 
(8) 
9300 
(42) 
680 
(23) 
47 14 
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38 
35000 
(13) 
158 
(35) 
80 (35) 438 2 
39 
744 
(38) 
82 (73) 80 (24) 9.3 10.3 
40 
2080 
(20) 
2400 
(53) 
115 
(18) 
18 21 
41 
1450 
(37) 
384 
(53) 
155 
(20) 
9.4 2 
42 
2040 
(23) 
2370 
(57) 
108 
(20) 
19 2.5 
43 
1770 
(21) 
204 
(44) 
48 (17) 37 4.2 
 
Table 3. Binding data on the indicated compounds towards the 42, 7 and 34 nAChR 
subtypes 
 
Binding affinity studies were performed, as indicated above, at the 
Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, 
University of Milan.  
As discussed in section 1.9, the putative role of the water molecule in the 
binding mode of epibatidine 10 and deschloroepibatidine 13 was investigated 
through molecular dynamics simulations, revealing that a solvated active 
cavity would allow a better allocation of the ligand pyridine ring, particularly if 
the chlorine atom of epibatidine is missing, as it is in 13. In the set of studied 
compounds, the deschloroepibatidine variants 35 and 36 behaved as nicotinic 
ligands characterized by a high nanomolar affinity range at the 42 channel, 
with about a 2000-fold and 7000-fold decrease in affinity compared with the 
super agonist epibatidine 10. Their interaction within the LBD of the 42 
nAChR was analyzed through molecular dynamics. The two compounds were 
docked into the active site of the 42 nAChR subtype homology model using 
the Gold 5.1 program. The docking protocol generated, for compound 35, two 
possible binding modes: in the first cluster the phenol OH group is oriented 
~ 73 ~ 
 
towards the 4 C-loop (Figure 24, left panel) whereas, in the second cluster, 
the OH should be able to displace the putative water molecule, since it directly 
interacts with the 2-Asn108 residue (Figure 24, right panel).  
 
 
Figure 24. The two different binding modes of compound 35 docked within the 42 
homology model: on the left, the OH is oriented towards the C-loop of the 4-chain; 
on the right, it reaches the residue Asn108 on the 2-subunit. 
 
Subsequently, through free energy calculations, we observed that, in the 
most likely binding mode of 35, the aryl moiety is flipped by 180° compared to 
the model ligands, with the OH group towards the C-loop of the major subunit 
(Figure 24, left panel). Therefore, compound 35 seems to adopt a different 
interaction pattern with the receptor compared to that of epibatidine 10 and, in 
this orientation, its OH group is unable to displace the water molecule. The 
distance between the aromatic carbon atom, which has replaced the pyridine 
nitrogen, and the oxygen atom is 1.4 Å, which is too short to mimic the water-
assisted H-bond. As a consequence, compound 35 is not able to reproduce 
the same molecular interactions of the model compound with the target 
receptor and, after the recognition of the basic scaffold by the aromatic box 
(which is the driving force for binding), the aryl moiety shows stabilizing 
interactions with different amino acids compared to epibatidine 10. Indeed, 
this hypothetical difference in the binding mode of 35 with respect to the 
reference agonists could be associated, on one hand and, with a considerable 
loss in binding affinity and, on the other, with the electrophysiological data 
reported in Figure 25, which are indicative also of a variation in the 
pharmacological profile.  
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Figure 25. Functional evaluations of compound 35 at the 42, 7 and 34* 
nAChRs. The electrophysiological experiments were performed by prof. Sergio 
Fucile, Dipartimento di Fisiologia e Farmacologia, Università di Roma La 
Sapienza.
[100]
 Human 42, 7 and 34 nAChRs were expressed by stable 
transfection in the human HEK 293 (42 and 34* subtypes) or rat anterior 
pituitary GH4C1 cell line (7 subtype). Whole-cell current recordings were performed 
and whole-cell capacitance and patch series resistance were estimated from slow 
transient compensations. Then, dose-response relationships were constructed by 
sequentially applying different concentrations of ligands and normalizing the resulting 
current amplitudes to the value obtained by applying 1 mM ACh to the same cell, as 
appropriate. 
 
  
Indeed, epibatidine 10 and deschloroepibatidine 13 are full agonists at the 
42 nAChRs, whereas 35 behaves as an antagonist at the same receptor 
subtype. When considering the other tested nicotinic receptors (7 and 34 
subtypes) 35 shows a partial agonist profile (Figure 25). 
Compound 36, due to the bulkier hydroxymethyl group, shows an 
increased distance between the alcohol OH and the carbon atom replacing 
the pyridine nitrogen up to 2.4 Å. Based on molecular dynamics simulations, 
in the most favourable binding mode the ligand is able to directly create a 
hydrogen bond with 2-Leu119, thus displacing and mimicking the putative 
water molecule (Figure 26). Hence, based on these theoretical results, the 
hydroxymethyl group attached to the phenyl ring is able to displace the 
hypothetical water molecule from the 42 receptor binding site and, 
consequently, the relatively low affinity shown by 36 (with a Ki value about 4-
fold higher than that of its lower homologue 35) could be attributed to the 
reduction of the contribution of the electrostatic terms to the overall value of 
free energy of binding. In fact, through energy calculations on 36, we found 
that the electrostatic contribution to the binding of deschloroepibatidine 13 and 
35 is more relevant than that of 36, and this could suggest that the water 
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molecule, although not directly involved in a hydrogen bond with the pyridine 
nitrogen of epibatidine 10, might influence the weight of the electrostatic terms 
in the free energy of binding. Moreover, taking into account that the 
electrostatic interaction is the first driving force of the ligand-receptor 
recognition process, it is reasonable to assume that the solvent molecules 
direct the correct placement of the pyridine moiety of epibatidine 10 within the 
binding site. 
 
 
Figure 26. Compound 36 docked within the 42 homology model. 
 
As expected, the OH groups of the target compounds have affected the 
binding affinity at the other tested nAChR subtypes as well. The epibatidine-
related compounds 35 and 36 are characterized by a substantial drop of 
affinity at all the tested nicotinic channels compared to the model ligands, with 
a decrease of affinity at the 42 receptor subtype higher than 2000-fold, 
whereas at the 7 and 34* channels the reduction of affinity is less 
pronounced (higher than 200-fold and 500-fold, respectively). The hydroxyl 
groups of compounds 35 and 36, whether mimicking the water bridge or not,  
led to a more relevant perturbation of affinity towards the 42 nAChR 
subtype rather than the other tested nicotinic channels and, indeed, 
compound 35 is still able to partly activate the 7 and 34* nAChR subtypes 
(Figure 25). 
The (–)-nicotine 9 variants 32-34 show a dramatic drop of affinity at all the 
tested receptor subtypes. However, a further analysis reveals that the 
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reduction of binding affinity is again more pronounced for the heteromeric 
42 channel compared to the 7 and 34* subtypes (higher than 100-fold 
vs. 5-fold and 10-fold), the same trend observed for the epibatidine 
analogues. 
On the contrary, the anabaseine derivatives 37-43 are characterized by an 
overall high affinity at the 34* receptors, with some selectivity towards the 
other channels. As a matter of fact, compounds 38-43 modestly increase the 
34* affinity of anabaseine 12 (from 4- to 14-fold), while their affinity is 
substantially reduced at the other nAChR subtypes. In general, the selectivity 
profile of anabaseine 12 has been completely reversed by replacing the 
pyridine nitrogen with the hydroxyl and hydroxymethyl groups. 
The binding affinity at the 42 nAChR subtype was highly affected by the 
absence of the pyridine nitrogen: an average reduction of about 300-fold was 
achieved, even more pronounced for compounds 37 and 38 with a higher 
than 1000-fold decrease. (–)-Nicotine 9 and anabaseine 12 have very similar 
affinity values at the 42 receptor and the reduction in affinity of their 
modified analogues followed a similar trend. Conversely, the binding at the 7 
nAChR subtype was reduced only by 40-fold on average. On the whole, the 
anabaseine-related set of compounds displays a decreased affinity at both 
42 and 7 receptors, more marked again for the heteromeric subtype, while 
possessing a remarkable increase of affinity at the 34* nAChR. 
Compound 38, bearing the hydroxymethyl group in meta position, 
increases the anabaseine 34* vs. 42 selectivity by 8000-fold, while it still 
retains some 7 affinity. We studied the binding mode of 38 within the 34* 
LBD trough a docking analysis into the active site of the homology model of 
this subtype (Figure 27). A hydrogen bond interaction between the 
hydroxymethyl group and 4-Thr107 could suggest the displacing of the water 
molecule and therefore the creation of a less hydrophilic environment of the 
active cavity. A reduced contribution of the electrostatic terms in the free 
energy of binding could be one of the reasons for the decreased binding 
affinity at the 42 and 7 nAChRs subtypes, whereas the same component 
could be less relevant for the 34* orthosteric site. However, a more in depth 
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analysis of the 34* active site properties is still required to support this 
hypothesis. 
 
 
 
Figure 27. Compound 38 docked within the 34 homology model. 
 
Electrophysiological experiments on compound 38 elucidated its 34* 
partial agonist and 7 full agonist profiles (Figure 28). In addition, this 
compound hasn’t been able to evoke any current at the 42 channel.  
 
 
 
Figure 28. Functional evaluations of compound 38 at the 34 and 7 
nAChRs (see legend to Figure 25). 
 
Further comments should be spent on the compounds related to 38. The 
phenol-containing analogue 37 remarkably improved the 34* vs. 7 
selectivity profile compared to 38, although a relevant reduction of 34* 
affinity was observed. On the contrary, the affinity at the 34* nAChR 
subtype is not affected if an extra substituent is inserted in meta position: 
compound 39, which is characterized by a hydroxymethyl group and a fluorine 
on the aromatic ring, displayed the same affinity at the 34* channel 
compared to 38, with an 8-fold decrease of affinity at the homomeric 7 
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receptor and a 40-fold regain at the 42 subtype compared to 38. A broader 
study is required to better clarify the effect of the substitution pattern on the 
affinity/selectivity profile at the 34* subtype for these analogues of 38. 
Interestingly, even compounds bearing only hydrophobic substituents (40-
43) are characterized by a high affinity at the 34* nAChR subtype. In 
general, these novel nicotinic ligands show promising affinity at the 34* 
channel (the best value is displayed by compound 43 with a value of Ki = 48 
nM), with some selectivity towards the other tested nAChRs. These affinity 
data could imply a quite different binding mode with respect to anabaseine 12 
and, as a consequence, a putative change in the pharmacological profile at 
this subtype. The hydrophobic aryl moieties might interact with different amino 
acids within the LBD  and the water molecule might not interfere at all with the 
binding recognition process. As a result of different binding modes, 
electrophysiological data on the most interesting among the anabaseine-
related compounds could point out a progressive modulation of the 
pharmacological behaviour, passing from full agonism, typical of the natural 
model compound, to partial agonism or antagonism of these more 
“hydrophobic” ligands. 
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4. Conclusions 
 
 
Two groups of novel bicycloctane- and quinuclidine-containing derivatives 
14-31 (Figure 29) were initially designed, synthesized, and assayed to study 
and validate a substitution pattern able to direct the selectivity profile towards 
the 42 or 7 nAChR subtypes. 
 
14  R1 = H           R2 = H
15  R1 = (CH3)2   R2 = H
16  R1 = H           R2 = OCH2CH3
17  R1 = H           R2 = OCH2CH2CH3
R1N
N N
R2
18  R1 = H           R2 = Cl
19  R1 = H           R2 = Ph
20  R1 = CH3       R2 = Ph
21  R1 = (CH3)2    R2 = Ph
R1N
N
N
N
R2
22  R1 = H 
23  R1 = CH3
R1N
N
N
N
NH
 
24 25  R1 = H           R2 = Cl
26  R1 = H           R2 = Ph
27  R1 = CH3       R2 = Ph
28  R1 = H           R2 = 5'-Indolyl
N
N
N
N
O
N
N
R2
R1
29  R = H  
30  R = CH3
31  R = Benzyl
N
N
N
O
O
R
 
Figure 29. Bicyclooctane- and quinuclidine-containing derivatives. 
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Some of the investigated compounds 14-23 were characterized as potent and 
selective 42 or 7 nAChR ligands, as a function of the substituents on the 
heteroaromatic moiety as well as the nature of the charged nitrogen atom. 
Conversely, in the set of analogues of quinuclidine (24-31), a drop in affinity 
and selectivity was observed with respect to the reference 7-selective 
ligands. 
Next, a third group of quite novel nicotinic ligands (compound 32-43, Figure 
30) was generated by modifying the structure of selected natural nicotinic 
agonists. Our initial goal was to investigate the putative role of water 
molecules in the LBD of the most studied nAChRs subtypes. 
 
37  R1 = OH           R2 = H
38  R1 = CH2OH    R2 = H
39  R1 = CH2OH    R2 = F
40  R1 = H             R2 = H
41  R1 = CH3         R2 = H
42  R1 = F              R2 = H
43  R1 = F              R2 = Br
32  R = OH  
33  R = CH2OH
N
CH3
34
N
H
N
R
R
35  R = OH  
36  R = CH2OH
N
R1
R2
CH2OH
 
Figure 30. Novel nicotinic ligands based on the structures of natural nicotinic agonists. 
 
We studied this group of new compounds by means of binding affinity 
assays, functional (electrophysiological) experiments, and computational 
analysis (molecular docking, molecular dynamics simulations and free energy 
calculations). Our conclusion is that the molecule of water, rather than being 
directly involved in a hydrogen bond with the ligand participating to the 
stabilization of the ligand-receptor complex, could influence the weight of the 
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electrostatic terms in the free energy of binding. The skeleton of known 
natural nicotinic agonists was modified adding substituents able to mimic or 
disrupt the water molecule in the receptor-ligand interaction, leading to a 
remarkable perturbation of the binding affinity, subtype selectivity and 
pharmacological profile. This last set of compounds represents a new class of 
anabaseine-related analogues characterized as 34*-preferring ligands, in 
which the agonist pharmacological profile of the natural model derivative has 
been shifted towards partial agonism or, maybe, antagonism. In the light of 
these data, the study of the most interesting among the latter compounds will 
be extended, aiming at better defining relevant structural requirements able to 
address nicotinic ligands towards a subtype, the 34* nAChR, which still 
lacks an in depth characterization. 
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5. Experimental 
 
 
5.1. General Procedures 
 
Procedures that resulted in the recovery or decomposition of starting material 
are not described in this section. All reactions that involve air/moisture 
sensitive compounds were performed under an atmosphere of dry argon with 
flame dried glassware. Reactions were stirred using a Teflon® coated 
magnetic stirrer bar and a stirrer hot plate. 
 
NMR Spectroscopy 
Proton and carbon magnetic resonance spectra were recorded at the 
specified field strength and in the solvent indicated using standard pulse 
techniques on Varian Mercury 300 (300 MHz) spectrometer at ambient 
temperatures.  
Chemical shifts (H) are reported in parts per million (ppm) and are referenced 
to TMS or the residual solvent peak. Coupling constants (J) are quoted to the 
nearest 0.1 Hz. 
 
Mass Spectrometry  
Mass spectra were recorded by the University of Milan mass spectrometry 
service using a VG Autospec (EI/CI mode). Only molecular ions (M+), and 
fragments from the molecular ions and other major peaks are reported. 
 
Microwave Reactor 
Where microwave irradiation was used, reactions were carried out in a CEM 
Focused Microwave Synthesis System, Model Discovery. 
 
Chiral HPLC 
Chiral HPLC was performed eluiting with the specified eluent at the specified 
flowrate using a Kromasil Amycoat column (0.46 cm x 25 cm, 5m), using a 
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Jasco PU-980 HPLC pump achieving detection using a Jasco UV-975 
Detector.  
 
Optical Rotation 
Optical rotation measurements were performed using a Jasco P-1010 
Polarimeter. 
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5.2. Experimental Procedures 
 
Diethyl meso-2,5-diazidohexanedioate [45] 
 
EtOOC
COOEt
N3
N3  
 
To a solution of diethyl meso-2,5-dibromoadipate 44 (25 g, 69.43 mmol) in 
absolute EtOH (150 mL), NaN3 was added (12.37 g, 190.25 mmol) and the 
mixture was stirred under reflux for 5 h. The reaction was then diluted with 
water (100 mL) and extracted with Et2O (3 x 50 mL). The organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo to afford 20.25 g of 
clean product (100% yield). 
 
45: yellow oil. 
 
Rf: 0.3 (CyHex/AcOEt 9:1); UV, KMnO4. 
 
1H-NMR (CDCl3):  1.32 (t, J = 7.2 Hz, 6H), 1.80-2.00 (m, 4H), 3.91 (m, 2H), 
4.27 (q, J = 7.2 Hz, 4H). 
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Ethyl 5-amino-6-oxopiperidine-2-carboxylate [46] 
 
N
H
O
H2N
COOEt
 
 
To an ice-cold solution of diethyl meso-2,5-diazidohexanedioate 45 (19.734 g, 
79.5 mmol) in THF (134 mL), PPh3 (43.79 g, 166.9 mmol) was cautiously 
added and the mixture stirred at room temperature for 3 h. Then, water (5.8 
mL) was added and the reaction was stirred overnight at room temperature.  
The solvent was evaporated in vacuo and the crude material purified by flash 
chromatography (DCM/MeOH 95:5  80:20) to give 11.85 g of monocyclic 
amide (80% yield). 
 
46: yellow solid. 
 
Rf: 0.4 (DCM/MeOH 9:1); KMnO4.  
 
1H-NMR (CDCl3):  1.29 (t, J = 7.2 Hz, 3H), 1.59-1.71 (m, 1H), 1.76-1.89 (m, 
1H), 2.01 (bs, 2H), 2.15 (m, 1H), 2.24-2.39 (m, 1H), 3.33 (m, 1H), 4.10 (m, 
1H), 4.20 (q, J = 7.2 Hz, 2H), 6.20 (bs, 1H).   
 
MS (ESI): m/z 187.1 [M+H]+, calc. for C8H14N2O3 186.21.  
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2,5-Diazabicyclo[2.2.2]octane-3,6-dione [47] 
 
HN
NH
O
O  
 
Sodium (1.6 g, 69.344 mmol) was added in an argon atmosphere to dry 
MeOH (250 mL). Once MeONa was completely formed (clean solution), a 
solution of ethyl 5-amino-6-oxopiperidine-2-carboxylate 46 (11.85 g, 63.04 
mmol) in dry MeOH was added (250 mL) and the resulting mixture was 
heated at reflux for 4 h (pH   10). 
The solvent was evaporated in vacuo and the resulting white solid was 
digested with Et2O (two times) and AcOEt (one time) to give 8.84 g of the 
bicyclic amide (100% yield). 
 
47: colourless solid. 
 
m.p.: 245-249° C dec. 
 
Rf: 0.1 (DCM/MeOH 9:1 + 1% TFA). 
 
1H-NMR (CD3OD):  1.89 (m, 2H), 2.06 (m, 2H), 3.90 (m, 2H).  
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2,5-Dibenzyl-2,5-diazabicyclo[2.2.2]octane-3,6-dione [48] 
 
N
N
O
O  
  
To a suspension of  2,5-diazabicyclo[2.2.2]octane-3,6-dione 47 (8.84 g 63.04) 
in dry DMF (200 mL) in an argon atmosphere, 60% NaH was added 
portionwise (5 g, 126 mmol) and the mixture was stirred at room temperature 
for 1 h. 
Once cooled with an ice-bath, benzyl chloride (18.1 mL, 157.6 mmol) was 
added dropwise and the mixture stirred overnight at room temperature. 
The reaction was poured into a mixture of water and ice (300 mL) and 
extracted with CHCl3 (3 x 50 mL).  The organic layers were washed with water 
and brine, then dried over Na2SO4, filtered and concentrated. The crude 
product was treated with Et2O to crash out 13.307 g of protected amide as 
colourless crystals (66% yield). 
 
48: colourless solid. 
 
m.p.:  165-167° C. 
 
Rf: 0.25 (CyHex/AcOEt 5:5); UV, KMnO4. 
 
1H-NMR (CDCl3):  1.69-1.81 (m, 4H), 4.01 (s, 2H), 4.37 (d, J = 14.9 Hz, 2H), 
4.73 (d, J = 14.9 Hz, 2H), 7.24 (m, 4H), 7. 32 (m, 6H).  
 
MS (ESI): m/z 321.1 [M+H]+, calc. for C20H20N2O2 320.39. 
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2,5-Dibenzyl-2,5-diazabicyclo[2.2.2]octane [49] 
 
N
N
 
 
To a solution of 2,5-dibenzyl-2,5-diazabicyclo[2.2.2]octane-3,6-dione 48 
(5.688 g, 17.754 mmol) in dry THF (132 mL) in an argon atmosphere, LiAlH4 
(2.7 g, 71.01 mmol) was added slowly and the mixture stirred under reflux for 
4 h. 
The reaction was ice-cooled, diluted with Et2O (20 mL) and quenched with 
AcOEt (15 mL) and water (10 mL).  The suspension was filtered through a 
celite-septum and the solvent removed in vacuo to provide 4.891 g of 
protected amine (94% yield). 
 
49: yellow oil. 
 
Rf: 0.3 (CyHex/AcOEt 2:8); UV, KMnO4, Dragendorff reagent.  
 
1H-NMR (CDCl3):  1.65 (m, 2H), 1.98 (m, 2H), 2.61 (bs, 2H), 2.74 (d, J = 10.3 
Hz, 2H), 3.08 (d, J = 10.3 Hz, 2H), 3.76 (s, 4H), 7.21-7.40 (m, 10H).  
 
MS (ESI): m/z 293.2 [M+H]+, calc. for C20H24N2 292.42. 
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2,5-Diazabicyclo[2.2.2]octane dihydrochloride [50] 
 
HN
NH
2HCl  
 
A solution of 2,5-dibenzyl-2,5-diazabicyclo[2.2.2]octane 49 (1.546 g, 5.287 
mmol) in MeOH (180 mL) was treated with concentrated HCl (3.8 mL) and 
then Pd/C 10% (0.35 g) was added. The mixture was hydrogenated at room 
temperature for 16 h. 
The resulting suspension was filtered through a celite-septum and the solvent 
evaporated in vacuo to afford 0.937 g of pure crystalline diamine 
dihydrochloride (96% yield). 
 
50: yellow solid. 
 
m.p.: 200°C dec. 
 
Rf: 0.0; KMnO4. 
 
1H-NMR (D2O):  1.83-1.93 (m, 2H), 2.09-2.19 (m, 2H), 3.48 (m, 4H), 3.83 
(bs, 2H).  
 
MS (ESI): m/z 112.9 [M+H]+, calc. for C6H12N2 112.17. 
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tert-Butyl 2,5-diazabicyclo[2.2.2]octane-2-carboxylate [51] 
 
BocN
NH
 
 
To a solution of 2,5-diazabicyclo[2.2.2]octane dihydrochloride 50 (0.937 g, 
5.062 mmol) in i-PrOH/H2O/NaOH 1.0 M  (70 mL/24.3 mL/4.6 mL) at 0° C, a 
solution of Boc2O (0.552 g, 2.531 mmol) in 2-propanol (12 mL) was added 
dropwise and the mixture was stirred at 0° C for 2 h. 
The solvent was removed in vacuo and the crude material was treated with 
brine (30 mL) and 2.0 N NaOH in water (pH = 10), then extracted with AcOEt 
(5 x 20 mL). The pooled organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated to provide 0.535 g of pure mono-Boc-
protected amine (50% yield). 
 
51: yellow oil. 
 
Rf: 0.45 (DCM/MeOH 8:2); KMnO4. 
 
1H-NMR (CDCl3):  1.45 (s, 9H), 1.64-1.84 (m, 2H), 1.86-2.04 (m, 2H), 2.98-
3.10 (m, 2H), 3.20-3.32 (m, 1H), 3.36-3.48 (m, 1H), 3.50-3.62 (m, 1H), 3.90-
4.08 (m, 1H). 
 
MS (ESI): m/z 213.2 [M+H]+, calc. for C11H20N2O2 212.29. 
 
 
 
 
 
 
 
 
~ 91 ~ 
 
tert-Butyl 5-(pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate 
[52] 
 
BocN
N N
 
 
A solution of (±)-BINAP (62 mg, 0.1 mmol) e  Pd2(dba)3 (46 mg, 0.05 mmol) in 
dry toluene (20 mL) was heated at reflux in an argon atmosphere for 10 min. 
Once the solution was cooled to 40°C, a solution of tert-butyl 2,5-
diazabicyclo[2.2.2]octane-2-carboxylate 51 (535 mg, 2.52 mmol) in dry 
toluene (7 mL), t-BuONa (388 g, 4.032 mmol), 3-bromo-pyridine (0.246 mL, 
2.52 mmol) was added and the resulting mixture was stirred at 80°C for 5 h. 
The mixture was cooled to ambient and filtered through a celite-septum. The 
solvent was removed in vacuo and the residue purified by flash 
chromatography (CyHex/AcOEt 20:80  10:90) to obtain 790 mg of pure 
product (67% yield). 
 
52: yellow oil. 
 
Rf: 0.25 (AcOEt); UV, KMnO4, Dragendorff reagent.  
 
1H-NMR (CDCl3): 1.43 (s, 9H), 1.75-1.86 (m, 2H), 2.00-2.08 (m, 2H), 3.32-
3.38 (m, 1H), 3.45-3.53 (m, 1H), 3.60-3.64 (m, 2H), 4.02 (m, 1H), 4.24-4.38 
(m, 1H), 6.86 (m, 1H), 7.09 (m, 1H), 7.92 (m, 1H), 8.04 (m, 1H).  
 
MS (ESI): m/z 290.2 [M+H]+, calc. for C16H23N3O2 289.37. 
 
 
 
 
 
 
~ 92 ~ 
 
2-(Pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane dihydrochloride [14] 
 
HN
N N
2HCl  
 
To a solution of tert-butyl 5-(pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate 52 (139 mg, 0.480 mmol) in Et2O (1 mL) at 0°C, 2.0 M HCl in 
Et2O (1 mL) was added dropwise and the mixture stirred at room temperature 
for 3 h.  
The precipitate was filtered and washed with Et2O to provide 99 mg of the title 
compound (79% yield). 
 
14: dark-yellow solid. 
 
1H-NMR (CD3OD): 1.82-1.91 (m, 2H), 2.03-2.07 (m, 2H), 3.38-3.53 (m, 3H), 
3.68-3.73 (m, 1H), 3.89 (m, 1H), 4.23 (m, 1H), 7.65 (m, 2H), 7.86 (m, 1H), 
7.96 (s, 1H).  
 
MS (ESI): m/z 190.1 [M+H]+, calc. for C11H15N3 289.26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 93 ~ 
 
2,2-Dimethyl-5-(pyridin-3-yl)-5-aza-2-azoniabicyclo[2.2.2]octane iodide 
[15] 
 
N
N N
I
 
 
To a solution of tert-butyl 5-(pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate 52 (420 mg, 1.451 mmol) in formic acid (3.5 mL), 37% 
formaldehyde in water was added (0.622 mL) and the solution was stirred at 
90°C for 1 h. 
The mixture was cooled to ambient and quenched with saturated NaHCO3 
solution (5 mL). The aqueous layer was basified with NaOH 5.0 M (pH > 10) 
and extracted with DCM (6 x 3 mL). The pooled organic layers were dried 
over Na2SO4, filtered and concentrated to afford 292 mg of pure tertiary amine 
(99% yield). 
To a solution of 2-methyl-5-(pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane (182 
mg, 0.895 mmol) in Et2O (4 mL), methyl iodide (0.167 mL 2.69 mmol) was 
added and the mixture stirred at room temperature for 6 h.  
The mixture was filtered and the solid was treated with hot MeOH until a clean 
solution was observed. Once cooled to ambient, the precipitate was filtered 
off, and the clean solution was concentrated in vacuo to obtain 87 mg of the 
title compound (28% yield). 
 
15: yellow solid. 
 
m.p.: 220-222°C dec. 
 
1H-NMR (CD3OD): 2.03-2.12 (m, 3H), 2.47-2.57 (m, 1H), 3.35 (s, 3H), 3.38 
(s, 3H), 3.50-3.54 (m, 1H), 3.70-3.74 (m, 1H), 3.81-3.86 (m, 1H), 3.94 (m, 1H), 
4.2 (dt, J = ? Hz, 1H), 4.39 (m, 1H), 7.30 (m, 1H), 7.96 (m, 1H), 8.12 (d, J = 
2.48 Hz, 1H).  
~ 94 ~ 
 
13C-NMR (CD3OD): 20.31, 21.49, 44.70, 46.56, 53.50, 54.05, 63.28, 68.03, 
120.09, 124.537, 133.88, 138.23, 143.63. 
 
MS (ESI): m/z 218.2 [M+H]+, calc. for C13H20N3 218.32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 95 ~ 
 
3-Bromo-5-ethoxypyridine [55] 
 
Br OCH2CH3
 
 
Sodium (0.146 g, 6.33 mmol) was added in an argon atmosphere to dry EtOH 
(5 mL). Once EtONa was completely formed (clean solution), the solvent was 
removed in vacuo , the residue was taken in dry DMF (6 mL) and 3,5-
dibromopyridine (1 g, 4.22 mmol) was added. The mixture was stirred in an 
argon atmosphere at 70°C for 3 h.  
The reaction was poured into ice/water (25 mL) and extracted with Et2O (3 x 
10 mL). The pooled organic layers were washed with water and brine, dried 
over Na2SO4  and concentrated. The crude product was purified by flash 
chromatography (CyHex/AcOEt 90:10) to afford 690 mg of the desired 
compound (78% yield) 
 
55: yellow oil. 
 
1H-NMR (CDCl3): 1.44 (t, J = 7.15 Hz, 3H), 4.06 (q, J = 7.15 Hz, 2H), 7.34 (t, 
J = 1.92; 2.48 Hz, 1H), 8.22 (d, J = 2.47;  Hz, 1H), 8.26 (d,  J = 1.92 Hz, 1H).  
 
 
 
 
 
 
 
 
 
 
 
 
~ 96 ~ 
 
tert-Butyl 5-(5-ethoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate [53] 
 
BocN
N N
OCH2CH3
 
 
A solution of (±)-BINAP (32 mg, 0.05 mmol) and Pd2(dba)3 (23 mg, 0.03 
mmol) in dry toluene (10 mL) was heated at reflux in an argon atmosphere for 
10 min. Once the solution was cooled to 40°C, a solution of tert-butyl 2,5-
diazabicyclo[2.2.2]octane-2-carboxylate 51 (269 mg, 1.27 mmol) in dry 
toluene (3.6 mL), t-BuONa (195 g, 2.03 mmol), 3-bromo-5-ethoxypyridine 55 
(267 mg, 1.27 mmol) were added and the resulting mixture was stirred at 
80°C for 4 h. 
The mixture was cooled to ambient and filtered through a celite-septum. The 
solvent was removed in vacuo and the residue purified by flash 
chromatography (CyHex/AcOEt 20:80) to obtain 138 mg of pure product (33% 
yield). 
 
53: yellow oil. 
 
Rf: 0.17; UV, KMnO4.  
 
1H-NMR (CDCl3): 1.39-1.44 (m, 3H), 1.47 (s, 9H), 1.80-1.88 (m, 2H), 2.03-
2.09 (m, 2H), 3.33-3.39 (m, 1H), 3.46-3.55 (m, 1H), 3.61-3.67 (m, 2H), 4.02-
4.13 (m, 3H), 4.25-4.40 (m, 1H), 6.41 (m, 1H), 7.67 (m, 1H), 7.73 (m, 1H). 
 
13C-NMR (CDCl3): 14.80, 25.26, 25.92, 28.71, 29.93, 44.22, 50.30, 53.85, 
64.10, 80.03, 104.81, 124.56, 127.06, 145.43, 154.78, 156.23. 
 
MS (ESI): m/z 334.2 [M+H]+, calc. for C18H27N3O3 333.43. 
 
~ 97 ~ 
 
2-(5-Ethoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane dihydrochloride 
[16] 
 
HN
N N
2HCl
OCH2CH3
 
 
To a solution of tert-butyl 5-(5-ethoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane-2-carboxylate 53 (120 mg, 0.232 mmol) in MeOH/Et2O 1:1 (0.8/0.8 
mL) at 0°C, 2.0 M HCl in Et2O (2.14 mL) was added dropwise and the mixture 
stirred at room temperature for 6 h. 
The solvent was removed in vacuo and the residue digested with Et2O to 
obtain 81 mg of  the desired compound (73% yield). 
 
16: colourless solid. 
 
m.p.: 240°C dec. 
 
1H-NMR (CD3OD): t, J = 7.16 Hz, 3H), 2.03-2.07 (m, 2H), 2.11-2.20 (m, 
2H), 3.47-3.67 (m, 3H), 3.85-3.89 (m, 1H), 3.98 (m, 1H), 4.26 (q, J = 7.16 Hz, 
1H), 4.43 (m, 1H), 7.34 (m, 1H), 7.86 (d, J = 1.65 Hz, 1H), 7.94 (d, J = 1.65 
Hz, 1H).  
 
13C-NMR (CD3OD): 13.53, 20.81, 23.20, 43.57, 46.12, 46.27, 65.83, 111.16, 
117.58, 118.40, 147.13, 158.76. 
 
MS (ESI): m/z 234.2 [M+H]+, calc. for C13H19N3O 233.31. 
 
 
 
 
 
~ 98 ~ 
 
3-Bromo-5-propoxypyridine [56] 
 
Br OCH2CH2CH3
 
 
Sodium (0.437 g, 19 mmol) was added in an argon atmosphere to dry 1-
propanol (15 mL). Once n-PrONa was completely formed (clean solution), the 
solvent was removed in vacuo , the residue was taken in dry DMF (18 mL) 
and 3,5-dibromopyridine (3 g, 12.66 mmol) was added. The mixture was 
stirred in an argon atmosphere at 70°C for 4 h.  
The reaction was poured into ice/water (50 mL) and extracted with Et2O (3 x 
20 mL). The pooled organic layers were washed with water and brine, dried 
over Na2SO4  and concentrated. The crude product was purified by flash 
chromatography (CyHex/AcOEt 90:10) to afford 1.817 g of the desired 
compound (66% yield). 
 
56: yellow oil. 
 
1H-NMR (CDCl3): 1.04 (t, J = 7.43 Hz, 3H), 1.82 (sex, J = 6.33; 7.43 Hz, 2H), 
3.95 (t, J = 6.33 Hz, 2H), 7.34 (t, J = 1.65; 2.48 Hz,  1H), 8.22 (d, J = 2.48;  
Hz, 1H), 8.26 (d,  J = 1.65 Hz, 1H).  
 
 
 
 
 
 
 
 
 
 
 
~ 99 ~ 
 
 tert-Butyl 5-(5-propoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate [54] 
 
BocN
N N
OCH2CH2CH3
 
 
A solution of (±)-BINAP (27 mg, 0.04 mmol) and Pd2(dba)3 (20 mg, 0.02 
mmol) in dry toluene (8.5 mL) was heated at reflux in an argon atmosphere for 
10 min. Once the solution was cooled to 40°C, a solution of tert-butyl 2,5-
diazabicyclo[2.2.2]octane-2-carboxylate 51 (227 mg, 1.07 mmol) in dry 
toluene (3 mL), t-BuONa (165 g, 1.71 mmol), 3-bromo-5-propoxypyridine 56 
(231 mg, 1.07 mmol) was added and the resulting mixture was stirred at 80°C 
for 4 hours. 
The mixture was cooled to ambient and filtered through a celite-septum. The 
solvent was removed in vacuo and the residue purified by flash 
chromatography (CyHex/AcOEt 10:90) to obtain 276 mg of pure product (74% 
yield). 
 
54: yellow oil. 
 
Rf: 0.21; UV, KMnO4.  
 
1H-NMR (CDCl3): 1.03 (t, J = 7.42 Hz, 3H), 1.46 (s, 9H), 1.75-1.88 (m, 4H), 
2.05-2.11 (m, 2H), 3.34-3.39 (m, 1H), 3.47-3.55 (m, 1H), 3.61-3.65 (m, 2H), 
3.93-4.04 (m, 3H), 4.25-4.40 (m, 1H), 6.40 (m, 1H), 7.68-7.72 (m, 2H).  
 
13C-NMR (DMSO-d6): 11.08, 22.77, 25.77, 25.09, 25.83, 28.79, 44.36, 
45.14, 45.98, 50.47, 69.77, 79.36, 104.04, 125.68, 127.34, 145.70, 154.38, 
156.27. 
 
MS (ESI): m/z 348.2 [M+H]+, calc. for C19H29N3O3 347.45. 
~ 100 ~ 
 
2-(5-Propoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane dihydrochloride 
[17] 
 
HN
N N
2HCl
OCH2CH2CH3
 
 
To a solution of tert-butyl 5-(5-propoxypyridin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane-2-carboxylate 54 (276 mg, 0.79 mmol) in MeOH/Et2O 1:1 (1.75/1.75 
mL) at 0°C, 2.0 M HCl in Et2O (3.2 mL) was added dropwise and the mixture 
stirred at room temperature for 5 h.  
The solvent was removed in vacuo and the residue digested with Et2O to 
obtain 202 mg of the wanted compound (80% yield). 
 
17: yellow solid. 
 
m.p.: 240-242°C dec. 
 
1H-NMR (CD3OD): 1.07(t, J = 7.43 Hz, 3H), 1.87 (sex, J = 6.32; 7.43 Hz, 
2H), 2.02-2.07 (m, 2H), 2.09-2.26 (m, 2H), 3.52-3.67 (m, 3H), 3.85-3.89 (m, 
1H), 3.98 (m, 1H), 4.16 (t, J = 6.32 Hz, 2H), 4.43 (m, 1H), 7.36 (m, 1H), 7.87 
(d, J = 1.92 Hz, 1H), 7.93 (d, J = 2.2 Hz, 1H).  
 
13C-NMR (CD3OD):  9.45, 20.81, 22.14, 23.20, 43.56, 46.12, 46.28, 71.52, 
111.15, 117.56, 118.40, 147.12, 158.94. 
 
MS (ESI): m/z 248.2 [M+H]+, calc. for C14H21N3O 247.34. 
 
 
 
 
 
~ 101 ~ 
 
tert-Butyl 5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate [57] 
 
BocN
N
N
N
 
 
To a solution of tert-butyl 2,5-diazabicyclo[2.2.2]octane-2-carboxylate 51 (165 
mg, 0.777 mmol) in dry DMSO (0.5 mL) in an argon atmosphere, dry DIPEA 
(0.474 mL, 2.719 mmol) and 3-chloro-6-phenylpyridazine (148 mg, 0.777 
mmol) were added and the mixture was stirred at 105°C for 30 h. 
The mixture was cooled to ambient and quenched with saturated NaHCO3 
solution (5 mL). The aqueous layer was extracted with AcOEt (3 x 3 mL) and 
the resulting organic layers were dried over Na2SO4, filtered and 
concentrated. The residue was purified by flash chromatography 
(CyHex/AcOEt 90:10  70:30) to provide 99 mg of clean product (35% yield). 
 
57: yellow solid. 
 
m.p.: 175-177°C 
 
Rf: 0.10 (CyHex/AcOEt 8:2); UV, KMnO4. 
 
1H-NMR (CDCl3): 1.47 (bs, 9H), 1.86-1.94 (m, 2H), 2.05-2.13 (m, 2H), 3.50-
3.59 (m, 2H), 3.69-3.76 (m, 2H), 4.42 (m, 1H), 5.15 (m, 1H), 6.73 (d, J = 9.35 
Hz, 1H), 7.36-7.47 (m, 3H), 7.67 (d, J = 9.35 Hz, 1H), 7.98-8.00 (m, 2H). 
 
13C-NMR (CDCl3):  25.29, 25.99, 28.71, 29.94, 44.18, 50.46, 52.21, 80.05, 
111.60, 125.62, 125.98, 128.76, 129.03, 137,13, 150.68, 154.92, 157.57. 
 
MS (ESI): m/z 367.2 [M+H]+, calc. for C21H26N4O2 366.46. 
 
~ 102 ~ 
 
2-(6-Phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane dihydrochloride 
[19] 
 
HN
N
N
N
2HCl  
 
To a solution of tert-butyl 5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo 
[2.2.2]octane-2-carboxylate 57 (128 mg, 0.350 mmol) in MeOH/Et2O 2:1 
(1.40/0.78 mL) at 0°C, 2.0 M HCl in Et2O (2.1 mL) was added dropwise and 
the mixture stirred at room temperature for 6 h.  
The solvent was removed in vacuo and the residue digested with Et2O to 
obtain 87 mg of the title compound (73% yield). 
 
17: yellow solid. 
 
m.p.: 224-225°C dec. 
 
1H-NMR (CD3OD): 2.10-2.14 (m, 2H), 2.25-2.29 (m, 2H), 3.57-3.64 (m, 1H), 
3.69-3.73 (m, 1H), 3.92-3.96 (m, 1H), 4.10-4.14 (m, 2H), 4.82 (m, 1H), 7.62-
7.64 (m, 3H), 7.96-7.99 (m, 2H), 8.03 (d, J = 9.9 Hz, 1H), 8.53 (d, J = 9.9 Hz, 
1H).  
 
13C-NMR (CD3OD):  20.50, 22.85, 45.78, 122.95, 127.05, 129.52, 129.56, 
131.81, 132,50. 
 
MS (ESI): m/z 267.2 [M+H]+, calc. for C16H18N4 266.15. 
 
 
 
 
 
~ 103 ~ 
 
2-Methyl-5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane 
fumarate [20] 
 
N
N
N
N
0,5 C4H4O4  
 
To a solution of 2-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane 19 
(34 mg, 0.128 mmol) in MeOH (1.5 mL), 37% formaldehyde in water (0.062 
mL, 0.756 mmol) was added and the mixture was stirred at room temperature 
for 30 min. Then NaBH4 (11 mg, 0.27 mmol) was added at 0°C and the 
mixture stirred at room temperature for further 30 min. 
The mixture was quenched with a saturated NaHCO3 solution (3 mL) and 
extracted with DCM (4 x 2 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated to afford 36 mg of clean tertiary amine (100% yield). 
To a solution of the free tertiary amine (82 mg, 0.292 mmol) in MeOH (2 mL), 
fumaric acid (34 mg, 0.292 mmol) was added and the mixture was stirred at 
room temperature for 2 h. 
The solvent was removed in vacuo and the crude product was crystallized 
from 2-propanol to provide the title compound (94% yield). 
 
20: colourless solid. 
 
1H-NMR (CD3OD): 1.85-2.05 (m, 2H), 2.03-2.18 (m, 1H), 2.22-2.38 (m, 1H), 
2.80 (s, 3H), 3.46-3.53 (m, 1H), 3.64 (dd, J = 2.15; 12.10 Hz, 1H), 4.06 (dt, J = 
2.83; 11.83 Hz, 1H), 4.76-4.83 (m, 1H), 6.66 (s, 1H), 7.18 (d, J = 9.36 Hz, 1H), 
7.39-7.52 (m, 3H), 7.84-7.93 (m, 3H). 
 
13C-NMR (CD3OD): 21.10, 23.41, 24.04, 40.75, 43.12, 45.89, 53.86, 57.39, 
63.57, 113.41, 125.98, 126.70, 128.77, 128.85, 135.16, 136.69, 151,54, 
157.31, 170.65. 
~ 104 ~ 
 
MS (ESI): m/z 267.2 [M+H]+, calc. for C17H20N4 280.37. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 105 ~ 
 
2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-
azoniabicyclo[2.2.2]octane iodide [21] 
 
N
N
N
N
I
 
 
To a solution of 2-methyl-5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane 20 (36 mg, 0.128 mmol) in MeOH/Et2O 1:3 (0.15/0.50 mL), methyl 
iodide (0.25 mL 4 mmol) was added and the mixture stirred at room 
temperature for 2 h.  
The solvent was removed in vacuo and the residue digested with Et2O to 
obtain 42 mg of the title compound (78% yield). 
 
21: yellow solid. 
 
m.p.: 228-230°C dec. 
 
1H-NMR (CD3OD): 2.09-2.15 (m, 3H), 2.54-2.63 (m, 1H), 3.37 (s, 3H), 3.41 
(s, 3H), 3.79-3.86 (m, 3H), 4.01 (m, 1H), 4.37 (dt, J = 3.03; 6.05; 13.48 Hz, 
1H), 5.03 (m, 1H), 7.25 (d, J = 9.63 Hz, 1H), 7.44-7.52 (m, 3H), 7.92-7.98 (m, 
3H).  
 
13C-NMR (CD3OD):  20.26, 21.81, 43.44, 45.36, 53.75, 54.06, 63.43, 68.10, 
113.90, 126.10, 126.89, 128.86, 129.04, 136,53, 152.31, 157.03. 
 
MS (ESI): m/z 295.2 [M+H]+, calc. for C18H23N4 295.40. 
 
 
 
 
~ 106 ~ 
 
tert-Butyl 5-(6-chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-
carboxylate [58] 
 
BocN
N
N
N
Cl
 
 
To a solution of tert-butyl 2,5-diazabicyclo[2.2.2]octane-2-carboxylate 51 (227 
mg, 1.07 mmol) in dry DMSO (0.7 mL) in an argon atmosphere, dry DIPEA 
(0.652 mL, 3.745 mmol) and 3,6-dichloropyridazine (160 mg, 1.07 mmol) were 
added and the mixture was stirred at 105°C for 48. 
The mixture was cooled to ambient and quenched with saturated NaHCO3 
solution (5 mL). The aqueous layer was extracted with AcOEt (4 x 3 mL) and 
then the organic layers were dried over Na2SO4, filtered and concentrated. 
The residue was purified by flash chromatography (CyHex/AcOEt 80:20) to 
provide 193 mg of clean product (55% yield). 
 
58: colourless solid. 
 
m.p.: 152-154°C 
 
Rf: 0.19; UV, KMnO4. 
 
1H-NMR (CDCl3): 1.46 (bs, 9H), 1.79-1.96 (m, 2H), 2.03-2.11 (m, 2H), 3.41-
3.56 (m, 2H), 3.63-3.67 (m, 2H), 4.40 (m, 1H), 5.00 (m, 1H), 6.63 (d, J = 9.62 
Hz, 1H), 7.23 (d, J = 9.62 Hz, 1H). 
 
13C-NMR (CDCl3):  25.15, 25.86, 28.68, 29.93, 44.04, 45.65, 50.27, 52.33, 
80.15, 113.88, 129.17, 146.21, 154.83, 157,69. 
 
MS (ESI): m/z 325.2 [M+H]+, calc. for C15H21Cl N4O2 324.81. 
 
 
~ 107 ~ 
 
2-(6-Chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane dihydrochloride 
[18] 
 
HN
N
N
N
2HCl
Cl
 
 
To a solution of tert-butyl 5-(6-chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane-2-carboxylate 58 (240 mg, 0.739 mmol) in MeOH/Et2O 2:1 (3/1.5 mL) 
at 0°C, 2.0 M HCl in Et2O (4.5 mL) was added dropwise and the mixture 
stirred at room temperature for 7 h.  
The precipitate was collected by filtration and washed with Et2O to get 166 mg 
of clean white solid (75% yield). 
 
18: colourless solid. 
 
m.p.: 187-189°C dec. 
 
1H-NMR (CD3OD): 2.08-2.13 (m, 2H), 2.26-2.28 (m, 2H), 3.57-3.61 (m, 1H), 
3.70-3.75 (m, 1H), 4.11-4.14 (m, 2H), 4.74 (m, 1H), 7.96-7.98 (m, 2H).  
 
13C-NMR (CD3OD):  20.25, 22.61, 45.33, 45.56, 46.28, 123.83, 135.18, 
146.02, 151.85. 
 
MS (ESI): m/z 225.0 [M+H]+, calc. for C10H13 Cl N4 224.69. 
 
 
 
 
 
 
 
 
~ 108 ~ 
 
tert-Butyl 5-(6-(1H-indol-5-yl)pyridazin-3-yl)-2,5-
diazabicyclo[2.2.2]octane-2-carboxylate [59] 
 
BocN
N
N
N
NH
 
 
To a solution of tert-butyl 5-(6-chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane-2-carboxylate 58 (136 mg, 0.42 mmol) in 1,4-dioxane/EtOH 1:1 (6.8 
mL), 5-indolylboronic acid (147 mg, 0.913 mmol), (PPh3)2PdCl (6.5 mg, 0.01 
mmol), triphenylphosphine (8 mg, 0.03 mmol) and Na2CO3 1.0 M (0.25 mL) 
were added, and the mixture was sealed in a tube and heated under MW 
irradiation (250 W) at 150°C for 30 min. 
The mixture was filtered through a celite-septum and the solvent removed in 
vacuo. The residue was taken with water (3 mL) and 2.0 N HCl in water (3 
mL), then the aqueous layer washed with Et2O (3 x 3mL), basified with 
NaHCO3 and extracted with DCM (8 x 3 mL). The pooled organic layers were 
dried over Na2SO4, filtered and concentrated and the crude product was 
finally purified by flash chromatography (CyHex/AcOEt 50:50) to afford 85 mg 
of the title compound (50% yield). 
 
59: yellow solid. 
 
m.p.: 133-135°C. 
 
Rf: 0.15; UV, KMnO4, CAM. 
 
1H-NMR (CDCl3): 1.48 (bs, 9H), 1.83-1.93 (m, 2H), 2.05-2.17 (m, 2H), 3.47-
3.59 (m, 2H), 3.71-3.81 (m, 2H), 4.41 (m, 1H), 5.12 (m, 1H), 6.61 (m, 1H), 
6.70-6.76 (m, 1H), 7.23-7.26 (m, 1H), 7.47 (d, J = 8.52 Hz, 1H), 7.71-7.74 (m, 
1H), 7.93 (d, J = 8.52 Hz, 1H), 8.19 (m, 1H), 8.51 (bs, 1H). 
 
~ 109 ~ 
 
13C-NMR (CDCl3):  25.32, 26.03, 28.74, 43.71, 44.25, 50.51, 52.25, 80.02, 
103.45, 111.72, 118.48, 120.74, 125.25, 125.83, 128.45, 129.25, 136.43, 
152.04, 154.98, 157.28. 
 
MS (ESI): m/z 406.3 [M+H]+, calc. for C23H27N5O2 405.49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 110 ~ 
 
2-(6-(1H-indol-5-yl)pyridazin-3-yl)-2,5-diazabicyclo[2.2.2]octane [22] 
 
HN
N
N
N
NH
 
 
To a solution of tert-butyl 5-(6-(1H-indol-5-yl)pyridazin-3-yl)-2,5-diazabicyclo 
[2.2.2]octane-2-carboxylate 59 (94 mg, 0.232 mmol) in MeOH/Et2O 1:1 
(0.72/0.72 mL) at 0°C, 2.0 M HCl in Et2O (0.93 mL) was added dropwise and 
the mixture stirred at room temperature for 5 h. 
The solvent was removed in vacuo and the residue purified by acid/base 
extraction and digested with Et2O to obtain 34 mg of secondary amine (48% 
yield). 
 
23: colourless solid. 
 
m.p.: 124-125°C dec. 
 
1H-NMR (CDCl3): 1.70-1.90 (m, 2H), 1.97-2.11 (m, 2H), 3.22-3.26 (m, 2H), 
3.39-3.43 (m, 1H), 3.61-3.64 (m, 1H), 3.73-3.77 (m, 1H), 4.84 (m, 1H), 6.62 
(m, 1H), 6.76 (d, J = 9.35 Hz, 1H), 7.24 (m, 1H), 7.48 (d, J = 8.52 Hz, 1H), 
7.72 (d, J = 9.35 Hz, 1H), 7.96 (d, J = 8.52 Hz, 1H), 8.19 (m, 1H), 8.43 (bs, 
1H).  
 
13C-NMR (CDCl3):  25.76, 27.16, 29.94, 43.17, 45.28, 48.83, 103.46, 111.66, 
111.79, 118.37, 120.78, 125.14, 125.62, 128.43, 129.47, 136.36, 151.58, 
157.36. 
 
MS (ESI): m/z 306.2 [M+H]+, calc. for C18H19N5 305.38. 
 
 
 
~ 111 ~ 
 
2-(6-(1H-indol-5-yl)pyridazin-3-yl)-5-metyl-2,5-diazabicyclo[2.2.2]octane 
[23] 
 
N
N
N
N
NH
C4H4O4  
 
To a solution of 2-(6-(1H-indol-5-yl)pyridazin-3-yl)-2,5-diazabicyclo[2.2.2] 
octane 21 (21 mg, 0.069 mmol) in DCM/MeOH 9:1 (2.5 mL), 37% 
formaldehyde in water (0.032 mL, 0.423 mmol) was added and the mixture 
was stirred at room temperature for 30 min. Then NaBH(OAc)3 (30 mg, 0.138 
mmol) was added at 0°C and the mixture stirred at room temperature for 2 h. 
The mixture was quenched with a saturated NaHCO3 solution (3 mL) and 
extracted with DCM (4 x 2 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated to afford 17 mg of clean tertiary amine (77% yield). 
To a solution of the free tertiary amine (17 mg, 0.053 mmol) in MeOH (1.7 
mL), fumaric acid (6 mg, 0.053 mmol) was added and the mixture was stirred 
at room temperature for 2 h. 
The solvent was removed in vacuo and the crude product was crystallized 
from 2-propanol to provide the title compound (97% yield). 
 
23: colourless solid. 
 
m.p.: 124-125°C dec. 
 
1H-NMR (CD3OD): 2.01-2.10 (m, 2H), 2.15-2.19 (m, 1H), 2.30-2.43 (m, 1H), 
3.02 (s, 3H), 3.20-3.26 (m, 2H), 3.61-3.62 (m, 2H), 3.78-3.82 (m, 1H), 4.11-
4.15 (m, 1H), 6.54-6.55 (m, 1H), 6.71 (s, 2H), 7.21 (d, J = 9.35 Hz, 1H), 7.29 
(m, 1H), 7.50 (d, J = 8.53 Hz, 1H), 7.70 (d, J = 8.53 Hz, 1H), 7.97 (d, J = 9.35 
Hz, 1H), 8.09 (bs, 1H).  
 
~ 112 ~ 
 
13C-NMR (CD3OD):  22.94, 40.53, 42.56, 45.24, 54.07, 77.20, 88.14, 101.98, 
111.53, 113.96, 118.41, 119.73, 125.67, 127.43, 128.72, 134.64, 137.11, 
153.70, 156.72, 168.82. 
 
MS (ESI): m/z 320.1 [M+H]+, calc. for C19H21N5 319.40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 113 ~ 
 
2-((Pyridin-3-yl)methylene)quinuclidin-3-one [61] 
 
N
O
N  
 
To a solution of KOH (0.5 g, 8.91 mmol) in methanol (2.8 mL), quinuclidinone 
hydrochloride 60 (5 g, 30.93 mmol) was added and the mixture stirred for 45 
min. Then 3-pyridinecarboxaldehyde (2.9 mL, 30.93 mmol) was added and 
the mixture stirred until complete disappearance of the aldehyde (TLC 
monitoring, 72 h). 
The reaction was diluted with water (45 mL) and the crashed-out solid was 
filtered to afford 4.768 g of pure product as a bright yellow solid (72% yield). 
 
61: yellow solid. 
 
m.p.: 107-108° C. 
 
Rf: 0.17 (CyHex/AcOEt 4:6); UV; Dragendorff reagent. 
 
1H-NMR (CDCl3):  2.00-2.07 (m, 4H), 2.64 (m, 1H), 2.95-2.99 (m, 2H), 3.12-
3.17 (m, 2H), 6.98 (s, 1H), 7.28 (m, 1H), 8.45-8.53 (m, 2H), 9.04 (d, J = 1.93 
Hz, 1H). 
 
13C-NMR (CDCl3):  25.89, 40.34, 47.63, 121.70, 123.59, 130.20, 138.75, 
146.75, 150.13, 153.17, 205.84. 
 
MS (ESI): m/z 215.1 [M+H]+, calc. for C13H14N2O 214.26. 
~ 114 ~ 
 
 2-((Pyridin-3-yl)methyl)quinuclidin-3-one [62] 
 
N
O
N  
 
To a solution of 2-((pyridin-3-yl)methylene)quinuclidin-3-one 61 (2.5 g, 11.668 
mmol) in methanol (26 mL), 6.0 N HCl in water (6.1 mL) and palladium on 
activated charcoal 10% (202 mg) were added and the mixture sealed and 
hydrogenated at room temperature and 25 psi for 16 h. 
The solvent was removed in vacuo, the residue taken with chloroform (20 mL) 
and 2.0 N NaOH in water (20 mL) and the mixture stirred for 1 hour. After 
dilution with brine and DCM, the two layers were separated and the aqueous 
layer extracted with DCM (3 x 30 mL). The organic phase was dried over 
Na2SO4, filtered, concentrated and the crude material crystallized with Et2O to 
provide 1.731 g of clean product (69% yield). 
 
62: yellow solid. 
 
m.p.:  92° C. 
 
Rf: 0.23 (AcOEt/MeOH 9:1); UV; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.94-2.05 (m, 4H), 2.46 (m, 1H), 2.71-2.91 (m, 3H), 3.03-
3.21 (m, 3H), 3.28-3.33 (m, 1H), 7.21 (m, 1H), 7.57-7.59 (m, 1H), 8.43-8.50 
(m, 2H). 
 
13C-NMR (CDCl3):  25.08, 27.14, 30.87, 40.17, 41.23, 49.05, 71.04, 121.70, 
123.54, 134.74, 136.48, 148.07, 150.46, 220.91. 
 
MS (ESI): m/z 217.0 [M+H]+, calc. for C13H16N2O 216.26 
~ 115 ~ 
 
 
[α]20D:  0.9 (c 1, CHCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 116 ~ 
 
2-((Pyridin-3-yl)methyl)quinuclidine dihydrochloride [24] 
 
N
N
2HCl
 
 
To a solution of 2-((pyridin-3-yl)methyl)quinuclidin-3-one 62 (250 mg, 1.156 
mmol) in diethylene glycol (2 mL) in an argon atmosphere, KOH (1.264 g, 
22.542 mmol) and hydrazine hydrate (1.121 mL, 23.12 mmol) were added, 
and the mixture was stirred at 100°C for 2.5 h and at 180 °C for further 2.5 h. 
The reaction was cooled to ambient, diluted with water (12 mL) and conc. HCl 
(pH = 1), washed with Et2O (10 mL), basified with NaOH 20% (pH = 11/12) 
and extracted with DCM (3 x 20 mL). The organic layers were dried over 
Na2SO4, filtered, concentrated in vacuo to obtain 100 mg of the desired 
compound (43% yield). 
The free base (100 mg, 0.495 mmol) was treated with 1.25 M HCl in methanol 
for 1 hour. The solvent was removed in vacuo and the residue crystallized 
with 2-propanol to give 114 mg of the title compound (84% yield). 
 
24: colourless solid. 
 
m.p.:  272-273° C dec. 
 
1H-NMR (CD3OD):  1.67 (m, 1H), 1.91-2.07 (m, 5H), 2.17 (m, 1H), 3.33-3.53 
(m, 5H), 3.59-3.69 (m, 1H), 4.03 (m, 1H), 8.11 (dd, J = 5.77; 8.75 Hz, 1H), 
8.70 (m, 1H), 8.84 (d, J = 5.77 Hz, 1H), 8.98 (m, 1H). 
 
13C-NMR (D2O):  20.04, 21.71, 22.58, 29.44, 34.60, 42.11, 49.07, 57.70, 
127.74, 136.17, 140.62, 141.63, 147.91. 
 
MS (ESI): m/z 203.1 [M+H]+, calc. for C13H18N2 202.30. 
~ 117 ~ 
 
cis-2-((Pyridin-3-yl)methyl)quinuclidin-3-ol [63] 
 
N
OH
N  
 
To a solution of 2-((pyridin-3-yl)methyl)quinuclidin-3-one 62 (200 mg, 0.925 
mmol) in dry 2-propanol (3.8 mL) in an argon atmosphere, aluminium iso-
propoxide (567 mg, 2.774 mmol) was added and the mixture stirred at 72°C 
for 2 h. 
The reaction was cooled to ambient and concentrated in vacuo, the residue 
taken with NaOH 20% (5mL) and extracted with DCM (3 x 3 mL). The organic 
layers were dried over Na2SO4, filtered, concentrated in vacuo to provide 201 
mg of the title compound (99% yield) as a 87/13 mixture of cis/trans isomers 
(1H-NMR analysis). 
 
63: yellow oil. 
 
Rf: 0.08 (DCM/MeOH 9:1); UV; KMnO4; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.25-1.37 (m, 1H), 1.44-1.52 (m, 1H), 1.60-1.66 (m, 1H), 
1.91 (m, 2H), 2.68-2.87 (m, 4H), 3.04-3.20 (m, 3H), 3.90 (m, 1H), 7.20 (dd, J = 
4.68; 7.98 Hz, 1H), 7.62 (m, 1H), 8.42 (m, 1H), 8.55 (m, 1H). 
 
13C-NMR (CDCl3):  19.19, 24.88, 29.52, 31.09, 41.79, 49.04, 62.05, 69.05, 
123.48, 136.47, 136.85, 147.51, 150.80. 
 
MS (ESI): m/z 219.1 [M+H]+, calc. for C13H18N2O 218.29. 
 
 []20D:  0.1 (c 1,1, CHCl3) 
~ 118 ~ 
 
cis-3-(6-Chloropyridazin-3-yloxy)-2-((pyridin-3-yl)methyl)quinuclidine 
[64] 
 
N
O
N
N
N
Cl
 
 
To a solution of cis-2-((pyridin-3-yl)methyl)quinuclidin-3-ol 63 (461 mg, 2.112 
mmol) in dry THF (2.3 mL) at 0°C in an argon atmosphere, NaHDMS 1.5 M in 
THF (1.83 mL, 2.746 mmol) was added and the mixture stirred at 0°C for 1 h. 
Then, 3,6-dichloropyridazine (355 mg, 2.387 mmol) was added and the 
mixture stirred at 0°C for 3 h and at room temperature for further 24 h. 
The reaction was quenched with water (5 mL) and NaOH 2N (5 mL) and 
extracted with AcOEt (6 x 8 mL). The combined organic layers were dried 
over Na2SO4, filtered, concentrated in vacuo, and the residue purified by flash 
chromatography (DCM/MeOH 90:10 → 80:20) to provide 196 mg of a dark-
red oil. Filtration through a short basic aluminium oxide pad afforded 116 mg 
of pure title compound as a racemic mixture of cis isomers (1H-NMR analysis, 
17% yield). 
 
64: yellow oil. 
 
Rf: 0.15 (DCM/MeOH 9:1); UV; KMnO4; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.33-1.43 (m, 1H), 1.62-1.80 (m, 3H), 2.42-2.44 (m, 1H), 
2.78-2.93 (m, 3H), 2.95-3.07 (m, 2H), 3.19-3.29 (m, 1H), 3.37-3.46 (m, 1H), 
5.48 (dd, J = 4.4; 7.7 Hz, 1H), 6.99 (d, J = 9.35 Hz, 1H), 7.14 (dd, J = 4.95; 
7.7 Hz, 1H), 7.37 (d, J = 9.35, 1H), 7.53 (m, 1H), 8.35 (dd, J = 1.37; 4.95 Hz, 
1H), 8.41 (m, 1H). 
 
~ 119 ~ 
 
13C-NMR (CDCl3):  19.51, 24.07, 25.65, 31.02, 41.76, 49.09, 60.92, 74.91, 
120.32, 123.50, 131.40, 135.36, 136.33, 147.65, 150.63, 151.18, 164.24. 
 
MS (ESI): m/z 331.1 [M+H]+, calc. for C17H19ClN4O 330.81. 
 
[]20D:  0.1 (c 0.75, CHCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 120 ~ 
 
cis-3-(6-Chloropyridazin-3-yloxy)-2-((pyridin-3-yl)methyl)quinuclidine 
fumarate [25] 
 
N
O
N
N
N
Cl
C4H4O4
 
 
To a solution of cis-3-(6-chloropyridazin-3-yloxy)-2-((pyridin-3-yl)methyl) 
quinuclidine 64 (20 mg, 0.06 mmol) in methanol (0.2 mL), fumaric acid (7 mg, 
0.06 mmol) in methanol (0.1 mL) was added and the solution was stirred at 
room temperature for 4 h. 
The solvent was removed in vacuo and the solid crystallized from 2-propanol 
to obtain 21 mg of pure product (84% yield). 
 
25: colourless solid. 
 
m.p.:  168-171° C dec. 
 
1H-NMR (CD3OD):  1.78-1.89 (m, 1H), 2.02-2.08 (m, 3H), 2.71 (m, 1H), 3.18-
3.25 (m, 2H), 3.36-3.46 (m, 2H), 3.54 (dd, J = 10.46; 14.31 Hz, 1H), 3.65-3.76 
(m, 1H), 4.31-4.39 (m, 1H), 5.56 (dd, J = 4.95; 7.43 Hz, 1H), 6.68 (s, 1.5H), 
7.31 (dd, J = 4.95; 7.97 Hz, 1H), 7.37 (d, J = 9.08, 1H), 7.71 (d, J = 9.08, 1H), 
7.83 (m, 1H), 8.33 (m, 1H), 8.47 (m, 1H). 
 
13C-NMR (CD3OD):  16.97, 19.81, 24.53, 28.45, 42.12, 61.13, 70.78, 121.07, 
124.17, 132.33, 132.45, 134.87, 137.59, 147.55, 149.67, 151.87, 163.60, 
169.67. 
 
MS (ESI): m/z 331.1 [M+H]+, calc. for C17H19ClN4O 330.81. 
 
~ 121 ~ 
 
cis- 3-(6-(1H-Indol-5-yl)pyridazin-3-yloxy)-2-((pyridin-3-
yl)methyl)quinuclidine fumarate [28] 
 
N
O
N
N
N
C4H4O4
N
H  
 
To a solution of cis-3-(6-chloropyridazin-3-yloxy)-2-((pyridin-3-yl)methyl) 
quinuclidine 64 (97 mg, 0.293 mmol) in 1,4-dioxane/EtOH 1:1 (5 mL), 5-
indolylboronic acid (102 mg, 0.636 mmol), (PPh3)2PdCl (5 mg, 0.0067 mmol), 
triphenylphosphine (5 mg, 0.02 mmol) and Na2CO3 1.0 M (2.3 mL) were 
added, and the mixture was sealed in a tube and heated under MW irradiation 
(250 W) at 150°C for 1 h. 
The mixture was filtered through a celite-septum washing with methanol and 
the solvent was removed in vacuo. The residue was purified by flash 
chromatography (DCM/MeOH 90:10 → 90:10 + NH3 1%) to get 100 mg of 
pure compound (83% yield). 
To a solution of the free base (120 mg, 0.292 mmol) in methanol (0.9 mL), 
fumaric acid (34 mg, 0.292 mmol) in methanol (0.6 mL) was added and the 
solution was stirred at room temperature for 2 h. The solvent was removed in 
vacuo and the solid crystallized from 2-propanol to obtain 117 mg of the title 
compound (73% yield). 
 
28: colourless solid. 
 
m.p.:  230-232° C dec. 
 
1H-NMR (CD3OD):  1.85-1.93 (m, 1H), 2.06-2.16 (m, 3H), 2.81 (m, 1H), 3.20-
3.27 (m, 2H), 3.37-3.51 (m, 2H), 3.62 (dd, J = 10.18; 14.03 Hz, 1H), 3.72-3.81 
(m, 1H), 4.36-4.42 (m, 1H), 5.63 (dd, J = 4.68; 7.7 Hz, 1H), 6.56 (d, J = 3.3 
Hz, 1H), 6.70 (s, 2H), 7.30-7.35 (m, 2H), 7.38 (d, J = 9.35 Hz, 1H), 7.50 (m, 
~ 122 ~ 
 
1H), 7.69 (dd, J = 1.65; 8.52 Hz, 1H), 7.86 (m, 1H), 8.11 (m, 1H), 8.12 (d, J = 
9.35, 1H), 8.32 (m, 1H), 8.52 (m, 1H). 
 
13C-NMR (CD3OD):  16.98, 19.76, 24.06, 24.63, 28.50, 42.30, 61.44, 69.95, 
102.11, 111.65, 118.59, 119.20, 120.03, 124.20, 125.92, 126.77, 128.73, 
129.47, 132.42, 134.83, 137.46, 137.66, 147.57, 149.75, 158.19, 162.73, 
169.52. 
 
MS (ESI): m/z 412.2 [M+H]+, calc. for C25H25N5O 411.50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 123 ~ 
 
cis-3-(6-Phenylpyridazin-3-yloxy)-2-((pyridin-3-yl)methyl)quinuclidine 
fumarate [26] 
 
N
O
N
N
N
C4H4O4
 
 
To a solution of cis-2-((pyridin-3-yl)methyl)quinuclidin-3-ol 63 (300 mg, 1.374 
mmol) in dry THF (1.5 mL) at 0°C in an argon atmosphere, NaHDMS 1.5 M in 
THF (1.5 mL, 2.25 mmol) was added and the mixture stirred at 0°C for 1 hour. 
Then, 3-chloro-6-phenylpyridazine (296 mg, 1.553 mmol) was added and the 
mixture stirred between 0 and 10°C for 5 h. 
The reaction was quenched with water (3 mL) and 2.0 N NaOH in water (3 
mL) and extracted with AcOEt (3 x 5 mL). The organic layers were dried over 
Na2SO4, filtered, concentrated in vacuo, and the residue purified then by flash 
chromatography (DCM/MeOH 90:10 → 80:20) to provide 173 mg of the title 
compound as a racemic mixture of cis isomers (1H-NMR analysis, 34% yield). 
To a solution of the free base (173 mg, 0.464 mmol) in methanol (1.4 mL), 
fumaric acid (54 mg, 0.464 mmol) in methanol (1 mL) was added and the 
solution was stirred at room temperature for 4 h. 
The white precipitate was filtered and washed with Et2O to obtain 185 mg of 
the title compound (93% yield). 
 
26: colourless solid. 
 
m.p.:  219-221° C dec. 
 
1H-NMR (CD3OD):  1.72-1.82 (m, 1H), 1.97-2.06 (m, 3H), 2.70 (m, 1H), 3.18-
3.29 (m, 4H), 3.50-3.66 (m, 2H), 4.18-4.26 (m, 1H), 5.57-5.61 (m, 1H), 6.68 
(s, 1H), 7.29 (dd, J = 5.22; 7.97 Hz, 1H), 7.41 (d, J = 9.08, 1H), 7.49-7.53 (m, 
~ 124 ~ 
 
3H), 7.85 (m, 1H), 7.91-7.94 (m, 2H), 8.09 (d, J = 9.08, 1H), 8.27 (m, 1H), 
8.48 (m, 1H). 
 
13C-NMR (CD3OD):  17.65, 20.89, 24.95, 29.23, 41.93, 60.97, 71.28, 118.68, 
124.06, 126.65, 128.93, 129.13, 129.70, 133.65, 135.10, 135.93, 137.63, 
147.12, 149.70, 156.37, 163.63, 172.43. 
 
MS (ESI): m/z 373.1 [M+H]+, calc. for C23H24N4O 372.46. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 125 ~ 
 
cis-1-Methyl-2-((1-methylpyridinium-3-yl)methyl)-3-(6-phenylpyridazin-3-
yloxy)-1-azoniabicyclo[2.2.2]octane diiodide [27] 
 
N
O
N
N
N
2I-
 
 
To a solution of cis-3-(6-phenylpyridazin-3-yloxy)-2-((pyridin-3-yl)methyl) 
quinuclidine 26 (122 mg, 0.328 mmol) in EtOH (1.3 mL) and MeOH (0.5 mL), 
methyl iodide (0.61 mL, 9.827 mmol) was added and the solution was stirred 
at room temperature for 1 h. 
The solvent was removed in vacuo and the solid digested with Et2O to give 
164 mg of the title compound (76% yield). 
 
27: yellow solid. 
 
m.p.:  176-178° C. 
 
1H-NMR (CD3OD):  2.00-2.07 (m, 1H), 2.18-2.33 (m, 3H), 2.88 (m, 1H), 3.29 
(s, 3H), 3.50-3.58 (m, 1H), 3.72-4.06 (m, 5H), 4.35 (s, 3H), 5.04-5.06 (m, 1H), 
5.71-5.75 (m, 1H), 7.50-7.54 (m, 3H), 7.58 (d, J = 9.36, 1H), 7.85 (m, 1H), 
7.92-7.95 (m, 2H), 8.15 (d, J = 9.36 Hz, 1H), 8.63-8.66 (m, 2H), 9.37 (m, 1H). 
 
13C-NMR (CD3OD):  18.50, 20.22, 24.01, 26.49, 48.91, 53.58, 59.74, 67.70, 
70.34, 118.79, 126.70, 127.47, 129.00, 129.37, 129.92, 135.67, 137.15, 
144.06, 146.08, 146.29, 156.95, 162.80. 
 
MS (ESI): m/z 401.2 [M]+, calc. for C25H30N4O
2+ 402.53. 
 
~ 126 ~ 
 
cis-2'-((Pyridin-3-yl)methyl)-1'-azaspirooxirane-2,3'-bicyclo[2.2.2]octane 
[65] 
 
N
N
O
 
 
To a solution of trimethyl sulfoxide iodide (2.646 g, 12.022 mmol) in dry 
DMSO (10 mL) in an argon atmosphere, 60% NaH (492 mg, 12.3 mmol) was 
added and the mixture was stirred at room temperature for 30 min. Then, 2-
((pyridin-3-yl)methyl)quinuclidin-3-one 62 (2 g, 9.248 mmol) was added 
and the mixture stirred at 70°C for 1.5 h. 
The reaction was cooled to ambient, quenched with water (15 mL) and 
extracted with DCM (6 x 8 mL). The pooled organic layers were washed with 
water (4 x 10 mL), dried over Na2SO4, filtered, concentrated in vacuo to afford 
1.877 g of the title compound as a racemic mixture of cis isomers (based on 
1H-NMR analysis, 68% yield). 
 
65: yellow solid. 
 
m.p.:  104-105° C. 
 
Rf: 0.42 (DCM/MeOH 9:1); UV; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.34-1.38 (m, 1H), 1.48-1.58 (m, 1H), 1.72-1.84 (m, 2H), 
1.93-2.02 (m, 1H), 2.44 (d, J = 4.68 Hz, 1H), 2.63-2.99 (m, 6H), 3.17-3.31 (m, 
2H), 7.18 (dd, J = 4.95: 7.70 Hz, 1H), 7.55 (dt, J = 1.65; 2.20; 7.70 Hz, 1H), 
8.41 (dd, J = 1.65; 4.95 Hz, 1H), 8.46 (d, J = 2.20 Hz, 1H). 
 
~ 127 ~ 
 
13C-NMR (CDCl3):  22.97, 25.22, 30.64, 30.90, 41.25, 49.36, 52.27, 61.75, 
62.26, 123.38, 135.40, 136.82, 147.62, 150.70. 
 
MS (ESI): m/z 231.0 [M+H]+, calc. for C14H18N2O 230.31. 
 
 []20D:  0.27 (c 1.1, CHCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 128 ~ 
 
cis-3-Methyl-2'-((pyridin-3-yl)methyl)-1'-azaspirooxazolidine-5,3'-
bicyclo[2.2.2]octan-2-one hydrochloride [30] 
 
N
N
N
O
O
CH3
HCl
 
 
To a solution of cis-2'-((pyridin-3-yl)methyl)-1'-azaspirooxirane-2,3'-bicyclo 
[2.2.2]octane 65 (200 mg, 0.868 mmol) in MeOH (1.2 mL), excess gaseous 
methylamine was added and the mixture was sealed in a steel-tube and 
stirred at room temperature for 24 h. 
The solvent and the excess of the amine were removed in vacuo, the residue 
was taken with THF (1.5 mL), 1,1'-carbonyldiimidazole (169 mg, 1.042 mmol) 
was added and the mixture stirred under reflux for 3 h. 
The solvent was removed in vacuo, then the residue was treated with 1.25 M 
HCl in MeOH for 1 h. Concentration in vacuo and crystallization with 2-
propanol gave 174 mg of pure title compound (62% yield). 
 
30: colourless solid. 
 
m.p.: 222-224° C dec. 
 
1H-NMR (CD3OD):  1.92-2.07 (m, 3H), 2.28-2.34 (m, 2H), 2.47 (s, 3H), 2.85 
(d, J = 9.9 Hz, 1H), 3.20-3.26 (m, 1H), 3.34-3.57 (m, 5H), 3.63 (d, J = 9.9 Hz, 
1H), 4.25 (m, 1H), 7.45 (dd, J = 5.22; 7.97 Hz, 1H), 7.91-7.94 (m, 1H), 8.49-
8.51 (m, 1H), 8.59 (m, 1H). 
 
13C-NMR (CD3OD):  17.83, 18.03.28, 24.04, 28.39, 29.31, 31.99, 42.08, 
55.02, 65.93, 77.69, 124.28, 131.30, 138.55, 148.23, 150.12, 156.62. 
 
~ 129 ~ 
 
MS (ESI): m/z 288.2 [M+H]+, calc. for C16H21N3O2 287.36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 130 ~ 
 
cis-3-(Azidomethyl)-2-((pyridin-3-yl)methyl)quinuclidin-3-ol [66] 
 
N
N
N3
OH
 
To a solution of cis-2'-((pyridin-3-yl)methyl)-1'-azaspirooxirane-2,3'-
bicyclo[2.2.2]octane 65 (851 mg, 3.695 mmol) in MeOH (30 mL) and water 
(3.4 mL), sodium azide (1.201 g, 18.475 mmol) and ammonium chloride (435 
mg, 8.129 mmol) were added, and the mixture stirred at 80°C for 16 h. 
The reaction was cooled to ambient and concentrated in vacuo, the residue 
was taken with 2.0 N NaOH in water (20mL) and extracted with AcOEt (6 x 8 
mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo to provide 882 mg of -azido alcohol (87% yield). 
 
66: yellow oil. 
 
Rf: 0.16 (DCM/MeOH 9:1); UV; KMnO4; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.27-1.36 (m, 1H), 1.50-1.59 (m, 2H), 1.92-2.04 (m, 2H), 
2.55-2.73 (m, 3H), 2.78-3.02 (m, 3H), 3.11-3.18 (m, 1H), 3.21 (d, J = 12.1 Hz, 
1H), 3.44 (d, J = 12.1 Hz, 1H), 7.19 (m, 1H), 7.60 (m, 1H), 8.42 (m, 1H), 8.50 
(m, 1H). 
 
13C-NMR (CDCl3):  21.48, 24.06, 30.71, 41.10, 49.08, 58.68, 65.80, 73.28, 
123.39, 136.49, 137.20, 147.48, 150.87. 
 
MS (ESI): m/z 274.1 [M+H]+, calc. for C14H19N5O 273.33. 
 
[]20D:  0.1 (c 1, CHCl3) 
 
~ 131 ~ 
 
cis-3-(Aminomethyl)-2-((pyridin-3-yl)methyl)quinuclidin-3-ol [67] 
 
N
N
NH2
OH
 
 
To a suspension of LiAlH4 (496 mg, 13.061 mmol) in dry THF (4.1 mL) at 0°C 
in an argon atmosphere, a solution of cis-3-(azidomethyl)-2-((pyridin-3-
yl)methyl)quinuclidin-3-ol 66 (1.19 g, 4.354 mmol) in dry THF (4.1 mL) was 
added dropwise, and the mixture stirred at room temperature for 3 h. 
The reaction was cooled to 0°C, diluted with Et2O (5 mL), then quenched with 
AcOEt (10 mL) and water (3 mL); the residue was taken with 2.0 N NaOH in 
water (20mL) and extracted with AcOEt (6 x 8 mL). The suspension was 
filtered through a celite-septum and the solvent removed in vacuo to give 885 
mg of  -amino alcohol (77% yield). 
 
67: yellow oil. 
 
Rf: 0.05 (DCM/MeOH 9:1); UV; KMnO4; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.27-1.37 (m, 1H), 1.45-1.74 (m, 4H), 1.99-2.09 (m, 1H), 
2.31 (d, J = 12.65 Hz, 1H), 2.54 (m, 1H), 2.61-2.73 (m, 2H), 2.76-3.00 (m, 
3H), 3.13-3.24 (m, 1H), 3.63 (bs, 1H), 7.18 (dd, J = 4.95; 7.98 Hz, 1H), 7.58 
(m, 1H), 8.39 (dd, J = 1.65; 4.95 Hz, 1H), 8.49 (d, J = 1.65 Hz, 1H). 
 
13C-NMR (CDCl3):  21.46, 24.05, 30.70, 41.10, 49.09, 58.62, 65.79, 73.29, 
123.37, 136.41, 137.16, 147.58, 150.94. 
MS (ESI): m/z 248.2 [M+H]+, calc. for C14H21N3O 247.34. 
 
~ 132 ~ 
 
cis-Benzyl-(3-hydroxy-2-((pyridin-3-yl)methyl)quinuclidin-3-
yl)methylcarbamate [68] 
 
N
N
NHCbz
OH
 
 
To a solution of cis-3-(aminomethyl)-2-((pyridin-3-yl)methyl)quinuclidin-3-ol 67 
(400 mg, 1.617 mmol) in dry DCM (16 mL) at 0°C, DIPEA (0.34 mL, 1.941 
mmol) and benzyl chloroformate (0.28 mL, 1.941 mmol) were added, and the 
mixture stirred at room temperature for 3 h. 
The reaction was quenched with water (10 mL) and 5% H3PO4 (pH < 3), 
washed with DCM (2 x 6 mL), then basified with Na2CO3 (pH > 9) and 
extracted with DCM (5 x 8 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo to provide 291 mg of the protected -amino 
alcohol (47% yield). 
 
68: colourless solid. 
 
m.p.:  110-113° C. 
 
Rf: 0.09 (DCM/MeOH 9:1); UV; CAM; Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.25-1.33 (m, 1H), 1.52-1.63 (m, 2H), 1.82 (m, 1H), 1.96 
(m, 1H), 2.62-2.69 (m, 2H), 2.74-2.88 (m, 3H), 3.10-3.31 (m, 3H), 5.07 (s, 2H), 
5.53 (m, 1H), 7.14 (m, 1H), 7.26-7.36 (m, 5H), 7.53 (m, 1H), 8.36 (m, 1H), 
8.45 (m, 1H). 
 
~ 133 ~ 
 
13C-NMR (CDCl3):  21.40, 24.17, 30.71, 31.11, 41.08, 48.66, 49.09, 66.07, 
67.33, 73.84, 123.49, 128.40, 128.49, 128.79, 136.44, 136.74, 137.17, 
147.26, 150.76, 157.99. 
 
MS (ESI): m/z 382.2 [M+H]+, calc. for C22H27N3O3 381.47. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 134 ~ 
 
cis-2'-((Pyridin-3-yl)methyl)-1'-azaspirooxazolidine-5,3'-
bicyclo[2.2.2]octan-2-one [29] 
 
N
N
NH
O
O
 
 
To a solution of cis-benzyl-(3-hydroxy-2-((pyridin-3-yl)methyl)quinuclidin-3-
yl)methylcarbamate 68 (505 mg, 1.324 mmol) in dry THF (13 mL) at 0°C, 60 
% NaH (64 mg, 1.589 mmol) was added, and the mixture stirred at room 
temperature for 3 h. 
The reaction was quenched with water (8 mL) and H3PO4 5% (pH < 3), 
washed with Et2O (3 x 4 mL), then basified with Na2CO3 (pH > 9) and 
extracted with DCM (8 x 6 mL). The pooled organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo to afford 331 mg of the desired 
compound (91% yield). 
 
29: colourless solid. 
 
m.p.:  254-256° C dec. 
 
Rf: 0.15 (DCM/MeOH 9:1); UV; CAM; Dragendorff reagent. 
 
1H-NMR (CD3OD):  1.48-1.58 (m, 1H), 1.65-1.70 (m, 2H), 2.04 (m, 2H), 2.73-
2.85 (m, 3H), 2.91-2.99 (m, 1H), 3.03-3.25 (m, 4H), 5.58 (d, J = 9.35 Hz, 1H), 
7.35 (m, 1H), 7.79-7.82 (m, 1H), 8.36-8.38 (m, 1H), 8.50 (m, 1H). 
 
13C-NMR (CD3OD):  20.61, 21.28, 30.17, 32.77, 40.95, 49.28, 66.32, 83.94, 
123.90, 135.59, 138.23, 146.72, 149.90, 159.93. 
 
~ 135 ~ 
 
MS (ESI): m/z 274.2 [M+H]+, calc. for C15H19N3O2 273.33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 136 ~ 
 
cis-3-Benzyl-2'-((pyridin-3-yl)methyl)-1'-azaspirooxazolidine-5,3'-
bicyclo[2.2.2]octan-2-one [31] 
 
N
N
N
O
O
C4H4O4
 
 
To a solution of cis-2'-((pyridin-3-yl)methyl)-1'-azaspirooxazolidine-5,3'-
bicyclo[2.2.2]octan-2-one 29 (160 mg, 0.585 mmol) in DMF dry (3 mL) at 0°C, 
60% NaH (71 mg, 1.777 mmol) was added and the mixture stirred at room 
temperature for 30 min. Benzyl chloride (0.074 mL, 0.651 mmol) was then 
added at 0°C and the mixture stirred again at room temperature for 3 h and at 
45°C overnight. 
The reaction was cooled to ambient, quenched with water (5 mL), saturated  
NaHCO3 (5 mL) and extracted with DCM (3 x 6 mL). The organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (DCM →DCM/MeOH 95:05) to obtain 57 mg 
of the desired compound (27% yield). 
To a solution of the free base (57 mg, 0.157 mmol) in MeOH (0.5 mL), fumaric 
acid (23 mg, 0.198 mmol) in methanol (0.4 mL) was added and the solution 
was stirred at room temperature for 4 h. 
The solvent was removed in vacuo and the solid crystallized from 2-propanol 
to obtain 62 mg of the title compound (73% yield). 
 
31: colourless solid. 
 
m.p.:  190-192° C dec. 
 
~ 137 ~ 
 
1H-NMR (CD3OD):  1.80-1.95 (m, 3H), 2.21-2.29 (m, 2H), 2.76 (m, 1H), 3.11-
3.20 (m, 2H), 3.31-3.49 (m, 5H), 3.93-3.96 (m, 1H), 4.06-4.18 (m, 2H), 6.73 
(s, 3H), 7.02-7.04 (m, 2H), 7.29-7.34 (m, 4H), 7.79 (m, 1H), 8.70 (m, 2H). 
 
13C-NMR (CDCl3):  21.21, 22.24, 30.77, 33.36, 41.41, 48.29, 48.55, 53.59, 
67.92, 80.66, 123.47, 128.22, 128.28, 129.13, 135.02, 135.65, 137.29, 
147.84, 150.65, 157.54. 
 
MS (ESI): m/z 364.1 [M+H]+, calc. for C22H25N3O2 363.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 138 ~ 
 
tert-Butyl 3-chloropropylcarbamate [70] 
 
BocHN Cl  
 
To an ice-cold solution of Boc2O (7.78 g, 38.5 mmol) and TEA (5.9  mL, 42.7 
mmol) in THF (70 mL), 3-chloropropylamine hydrochloride 69 (5 g, 38.5 
mmol) was added and the mixture stirred for 20 h. 
The reaction was diluted with a saturated NaHCO3 solution (100 mL) and 
extracted with AcOEt (3 x 60 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo to afford 6.276 g of clean 
product (84% yield). 
 
70: yellow oil. 
 
Rf: 0.32 (CyHex/AcOEt 9:1); PMA. 
 
1H-NMR (CDCl3):  1.42 (s, 9H), 1.91 (m, 2H), 3.25 (m, 2H), 3.59 (t, J = 6.33 
Hz, 2H), 4.70 (m, 1H). 
~ 139 ~ 
 
tert-Butyl 3-chloropropyl(3-methoxybenzyl)carbamate [71] 
 
N
Boc
Cl
OCH3  
 
To a suspension of 60% NaH (558 mg, 13.952 mmol) in dry THF (21 mL) in 
an argon atmosphere, a solution of tert-butyl 3-chloropropylcarbamate 70 
(1.351 g, 6.976 mmol) in dry THF (7 mL) and 3-methoxybromobenzene (1.465 
mL, 10.464 mmol) were added, and the mixture heated at reflux for 5 h.  
The reaction was cooled to 0°C and quenched with water (20 mL), then 
extracted with Et2O (2 x 15 mL).  The organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The crude material  was 
purified by flash chromatography (CyHex  CyHex/AcOEt 95:05) to give 966 
mg of pure product (44% yield). 
 
71: yellow oil. 
 
Rf: 0.36 (CyHex/AcOEt 9:1); UV, PMA. 
 
1H-NMR (CDCl3):  1.47 (bs, 9H), 1.97 (m, 2H), 3.32 (m, 2H), 3.52 (m, 2H), 
3.79 (s, 3H), 4.42 (m, 2H), 6.81 (m, 3H), 7.24 (m, 1H). 
 
 
 
 
 
 
 
 
 
 
~ 140 ~ 
 
(S)-(–)-tert-Butyl 2-(3-methoxyphenyl)pyrrolidine-1-carboxylate [72] 
 
N
Boc
OCH3  
 
To a solution of (–)-sparteine (1.084 g, 4.625 mmol) in dry toluene (10 mL) in 
an argon atmosphere at 78°C, a solution of 1.4 M sec-butyllithium in 
cyclohexane (3.43 mL, 4.81 mmol) was added dropwise. A solution of tert-
butyl 3-chloropropyl(3-methoxybenzyl)carbamate 71 (966 mg, 3.084 mmol) in 
dry toluene (15 mL) was added and the mixture was stirred at 78°C for 5 h.  
The reaction was warmed to ambient and quenched with water (20 mL), then 
extracted with Et2O (3 x 25 mL). The pooled organic layers were washed once 
with H3PO4 5%, twice with water, then dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 95:05  CyHex/AcOEt 90:10) to obtain 611 
mg of clean product (71% yield). 
 
72: yellow oil. 
 
Rf: 0.33 (CyHex/AcOEt 7:3); UV, PMA, KMnO4. 
 
1H-NMR (CDCl3):  1.44 (bs, 9H), 1.84 (m, 3H), 2.27 (m, 1H), 3.59 (m, 2H), 
3.79 (s, 3H), 4.76 (m, 1H), 6.71 (m, 1H), 6.75 (m, 2H), 7.22 (m, 1H). 
 
 []20D:  50.86 (c 1, CHCl3) 
 
E.e.: 62%; Kromasil 5-Amycoat column, eluited with 5% 2-propanol in 
hexane, 1.0 mL/min flow. 
 Rt minor peak = 5.3 min (19%) 
 Rt major peak = 6.3 min (81%) 
 
~ 141 ~ 
 
(S)-(–)-3-(Pyrrolidin-2-yl)phenol [73] 
 
N
H
OH  
 
To a solution of (S)-(–)-tert-butyl 2-(3-methoxyphenyl)pyrrolidine-1-
carboxylate 72 (421 mg, 1.518 mmol) in dry DCM (18 mL) in an argon 
atmosphere at 78°C, a solution of 1.0 M BBr3 in hexane (3.8 mL, 3.415 
mmol) was added dropwise. The solution was stirred at 78°C for 1 h and for 
further 4 h at 10°C.  
The reaction was warmed to ambient and quenched with MeOH (20 mL), then 
concentrated in vacuo. The crude material was purified by acid/base 
extraction. The basic water layer was concentrated under vacuum and the 
resulting mixture was taken with DCM and filtered through a celite-septum. 
The organic layers were dried over Na2SO4, filtered and then concentrated in 
vacuo to afford 133 mg of clean secondary amine (60% yield). 
 
73: yellow oil. 
 
Rf: 0.18 (AcOEt/MeOH 8:2); UV, Dragendorff reagent, KMnO4. 
 
1H-NMR (CDCl3): 1.72 (m, 1H), 1.88 (m, 2H), 2.13 (m, 1H), 2.92 (m, 1H), 
3.15 (m, 1H), 3.95 (dd, J = 7.15; 8.8 Hz, 1H), 6.48 (bs, 2H), 6.7 (m, 3H), 7.1 (t, 
J = 7.98 Hz, 1H). 
 
13C-NMR (CDCl3):  25.47, 33.36, 46.32, 62.92, 114.59, 115.81, 117.70, 
130.03, 142.69, 158.37. 
 
MS (ESI): m/z 164.0 [M+H]+, calc. for C10H13NO 163.22. 
 
 
~ 142 ~ 
 
(S)-(–)-3-(1-Methylpyrrolidin-2-yl)phenol fumarate [32] 
 
N
OH
CH3
C4H4O4  
 
To a solution of (S)-(–)-3-(pyrrolidin-2-yl)phenol 73 (133 mg, 0.815 mmol) in 
MeOH (9 mL), 37% formaldehyde in water (0.39 mL, 4.808 mmol) was added 
and the solution was stirred at room temperature for 30 min. Once cooled to 
0°C, NaBH4 was added and the mixture stirred at room temperature for 30 
min. 
The reaction was quenched with water (10 mL) and extracted with DCM (4 x 8 
mL). The organic layers were dried over Na2SO4, filtered and then 
concentrated in vacuo to get 132 mg of pure tertiary amine (91% yield). 
To a solution of the free base (105 mg, 0.6 mmol) in methanol (1.8 mL), a 
solution of fumaric acid (76 mg, 0.652 mmol) in MeOH (1.2 mL) was added 
and the resulting mixture was stirred at room temperature for 5 h. 
The solvent was removed in vacuo and the residue crystallized from 2-
propanol/Et2O to obtain 94 mg of the title compound (53% yield). 
 
32: colourless solid. 
 
m.p.:  100-101° C. 
 
1H-NMR (D2O): 2.14 (m, 3H), 2.40 (m, 1H), 2.63 (s, 3H), 3.17 (m, 1H), 3.70 
(m, 1H), 4.15 (m, 1H), 6.59 (s, 2H), 6.89 (m, 3H), 7.26 (t, J = 7.97 Hz, 1H). 
 
13C-NMR (D2O):  21.37, 30.72, 37.60, 55.67, 72.54, 115.04, 116.95, 119.07, 
130.53, 134.16, 134.71, 158.53, 169.09. 
 
MS (ESI): m/z 178.1 [M+H]+, calc. for C11H15NO 177.24. 
 
~ 143 ~ 
 
 []20D: 64.20 (c 0.6, MeOH) 
 
E.e.: 98%; Kromasil 5-Amycoat column, elated with 10% 2-propanol in 
hexane, 1.0 mL/min flow. 
 Rt minor peak = 4.9 min (1%) 
 Rt major peak = 5.4 min (99%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 144 ~ 
 
Methyl 3-((tert-butoxycarbonyl(3-chloropropyl)amino)methyl)benzoate 
[74] 
 
N
Boc
Cl
COOCH3  
 
To a suspension of 60% NaH (619 mg, 15.5 mmol) in dry THF (23 mL) in an 
argon atmosphere, a solution of tert-butyl-3-chloropropylcarbamate 70 (1.5 g, 
7.75 mmol) in dry THF (7.8 mL) and methyl-3-bromobenzoate (2.66 g, 11.63 
mmol) were added, and the mixture was heated at reflux for 4 h.  
The reaction was cooled to 0°C and quenched with water (20 mL), then 
extracted with Et2O (3 x 15 mL). The pooled organic phases were dried over 
Na2SO4, filtered and the solvent was removed in vacuo. The crude material  
was purified by flash chromatography (CyHex  CyHex/AcOEt 95:05) to give 
1.277 g of pure product (48% yield). 
 
74: yellow oil. 
 
Rf: 0.25 (CyHex/AcOEt 9:1); UV, PMA. 
 
1H-NMR (CDCl3):  1.46 (s, 9H), 1.96 (m, 2H), 3.33 (m, 2H), 3.51 (m, 2H), 
3.89 (s, 3H), 4.47 (m, 2H), 7.39 (m, 2H); 7.93 (m, 2H). 
 
13C-NMR (CDCl3):  23.57, 28.60, 31.42, 42.66, 52.36, 65.47, 80.48, 128.77, 
128.90, 130.67, 131.96, 132.37, 139.10, 156.30, 167.12. 
 
MS (ESI): m/z 342.0 [M+H]+, calc. for C17H24ClNO4 341.83. 
 
 
 
 
~ 145 ~ 
 
tert-Butyl 3-chloropropyl(3-(hydroxymethyl)benzyl)carbamate [75] 
 
N
Boc
Cl
CH2OH  
 
To a solution of methyl 3-((tert-butoxycarbonyl(3-chloropropyl)amino) 
methyl)benzoate 74 (1.277 g, 3.74 mmol) in dry THF (25 mL), LiBH4 (406 mg, 
18.64 mmol) was added, and the mixture stirred under reflux for 30 h.  
The reaction was quenched with MeOH (3 mL), then concentrated in vacuo. 
The residue was taken with water (50 mL) and extracted with DCM (3 x 35 
mL). The organic layers were dried over Na2SO4, filtered and the solvent 
removed in vacuo. The crude material  was purified by flash chromatography 
(CyHex/AcOEt 85:15) to afford 1.05 g of pure alcohol (90% yield). 
 
74: yellow oil. 
 
Rf: 0.08 (CyHex/AcOEt 8:2); UV, PMA. 
 
1H-NMR (CDCl3):  1.47 (s, 9H), 1.97 (m, 2H), 3.31 (m, 2H), 3.50 (m, 2H), 
4.44 (m, 2H), 4.67 (s, 2H), 7.15 (m, 1H), 7.27 (m, 3H). 
 
13C-NMR (CDCl3):  28.63, 31.37, 42.67, 44.37, 50.39, 65.14, 80.37, 126.07, 
128.81, 128.93, 138.66, 141.54, 141.69, 156.18. 
 
MS (ESI): m/z 336.1 [M+Na]+, calc. for C16H24ClNO3 313.82. 
 
 
 
 
 
~ 146 ~ 
 
tert-Butyl 3-((tert-butyldimethylsilyloxy)methyl)benzyl(3-
chloropropyl)carbamate [76] 
 
N
Boc
Cl
CH2OTBS  
 
To a solution of tert-butyl 3-chloropropyl(3-(hydroxymethyl)benzyl)carbamate 
75 (798 mg, 2.54 mmol) in DMF (1.6 mL), TBSCl (613 mg, 4.07 mmol) and 
imidazole (432 mg, 6.35 mmol) were added, and the mixture stirred at 35°C 
for 8 h.  
The reaction was quenched with water (20 mL), then extracted with Et2O (3 x 
10 mL). The organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 98:02  95:05) to provide 785 mg of 
protected alcohol (76% yield). 
 
76: yellow oil. 
 
Rf: 0.6 (CyHex/AcOEt 9:1); UV, PMA. 
 
1H-NMR (CDCl3): 0.10 (s, 6H), 0.95 (s, 9H), 1.47 (bs, 9H), 1.98 (m, 2H), 
3.32 (m, 2H), 3.51 (m, 2H), 4.45 (m, 2H), 4.73 (s, 2H), 7.12 (m, 1H), 7.26 (m, 
3H). 
 
13C-NMR (CDCl3):  -5,00, 18.65, 26.20, 28.67, 31.41, 42.70, 44.80, 65.12, 
74.96, 80.17, 125.24, 125.51, 126.51, 128.66, 138.32, 142.03, 156.09. 
 
MS (ESI): m/z 450.1 [M+Na]+, calc. for C22H38ClNO3Si 428.08. 
 
 
 
~ 147 ~ 
 
(S)-(–)-tert-Butyl 2-(3-((tert-
butyldimethylsilyloxy)methyl)phenyl)pyrrolidine-1-carboxylate [77] 
 
N
Boc
CH2OTBS  
 
To a solution of (–)-sparteine (679 mg, 2.90 mmol) in dry toluene (4.2 mL) in 
an argon atmosphere at 78°C, a solution of 1.4 M sec-butyllithium in 
cyclohexane (2.72 mL, 3.01 mmol) was added dropwise. A solution of tert-
butyl 3-((tert-butyldimethylsilyloxy)methyl)benzyl(3-chloropropyl)carbamate 76 
(785 mg, 1.93 mmol) in dry toluene (13 mL) was added and the mixture was 
stirred at 78°C for 4 h.  
The reaction was warmed to ambient and quenched with water (20 mL), then 
extracted with Et2O (3 x 10 mL). The combined organic layers were washed 
once with 5% H3PO4 and water, then dried over Na2SO4, filtered and then 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 95:05  CyHex/AcOEt 90:10) to obtain 362 
mg of clean product (48% yield). 
 
77: yellow oil. 
 
Rf: 0.30 (CyHex/AcOEt 9:1); UV, PMA, KMnO4. 
 
1H-NMR (CDCl3):  0.09 (s, 6H), 0.92 (s, 9H), 1.18-1.45 (m, 9H), 1.86 (m, 3H), 
2.30 (m, 1H), 3.62 (m, 2H), 4.72 (s, 2H), 4.76 (m, 1H), 7.04 (m, 1H), 7.15 (m, 
2H), 7.26 (m, 1H). 
 
13C-NMR (CDCl3):  -5,00, 18.61, 23.38, 26.18, 28.40, 36.17, 47.28, 61.53, 
65.19, 79.29, 123.40, 124.35, 124.43, 128.24, 141.55, 145.32, 154.75. 
 
MS (ESI): m/z 414.2 [M+Na]+, calc. for C22H37NO3Si 391.62. 
~ 148 ~ 
 
 []20D:  50.55 (c 1, CHCl3) 
 
E.e.: 70%; Kromasil 5-Amycoat column, eluted with 5% 2-propanol in hexane, 
1.0 mL/min flow. 
 Rt minor peak = 3.2 min (15%) 
Rt major peak = 3.8 min (85%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 149 ~ 
 
(S)-(–)-tert-Butyl 2-(3-(hydroxymethyl)phenyl)pyrrolidine-1-carboxylate 
[78] 
 
N
Boc
CH2OH  
 
To a solution of (S)-(–)-tert-butyl 2-(3-((tert-butyldimethylsilyloxy)methyl) 
phenyl)pyrrolidine-1-carboxylate 77 (313 mg, 0.80 mmol) in dry THF (3.3 mL) 
and in an argon atmosphere at 0°C, TBAF (0.46 mL, 1.6 mmol) was added 
dropwise, and the mixture stirred at 0°C for 5 min and then for 45 min at room 
temperature.  
The reaction was quenched with water (20 mL), then extracted with AcOEt (3 
x 10 mL). The pooled organic layers were dried over Na2SO4, filtered and the 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (DCM  DCM/MeOH 95:05) to give 171 mg of pure alcohol 
(73% yield). 
 
78: yellow oil. 
 
Rf: 0.40 (DCM/MeOH 95:5); UV, PMA, KMnO4. 
 
1H-NMR (CDCl3):  1.2-1.55 (m, 9H), 1.87 (m, 3H), 2.32 (m, 1H), 3.63 (m, 
2H), 4.67 (s, 2H), 4.77-4.94 (m, 1H), 7.10 (m, 1H), 7.20 (m, 2H), 7.28 (m, 1H). 
 
13C-NMR (CDCl3):  23.41, 28.38, 36.16, 47.32, 61.50, 65.20, 79.60, 124.28, 
124.85, 125.29, 128.50, 141.34, 145.51, 154.90. 
 
MS (ESI): m/z 314.1 [M+Cl]+, calc. for C16H23NO3 277.36. 
 
 
 
~ 150 ~ 
 
(S)-(–)-(3-(Pyrrolidin-2-yl)phenyl)methanol [79] 
 
N
H
CH2OH  
 
To a solution of (S)-(–)-tert-butyl-2-(3-(hydroxymethyl)phenyl)pyrrolidine-1-
carboxylate 78 (166 mg, 0.57 mmol) in Et2O (3 mL) at 0°C, 4.0 M HCl in 1,4-
dioxane (1.5 mL) was added dropwise and the mixture stirred at room 
temperature for 3 h.  
The solvent was removed in vacuo and the crude material was purified by 
acid/base extraction. The aqueous phase was concentrated by rotary 
evaporation and the crude material was taken with DCM and filtered through a 
celite-septum. The organic layers were dried over Na2SO4, filtered, then 
concentrated in vacuo to afford 62 mg of clean secondary amine (61% yield). 
 
79: yellow oil. 
 
Rf: 0.1 (DCM); UV, Dragendorff reagent, KMnO4. 
 
1H-NMR (CDCl3):  1.68 (m, 1H), 1.84 (m, 2H), 2.14 (m, 1H), 2.94 (m, 1H), 
3.12 (m, 1H), 3.87 (s, 2H), 4.03 (t,  J = 7.70; 7.98 Hz, 1H), 4.56 (s, 2H), 7.17-
7.29 (m, 4H). 
 
13C-NMR (CDCl3):  25.63, 33.95, 46.77, 62.80, 64.73, 125.41, 125.79, 
125.98, 128.72, 142.17, 143.34. 
 
MS (ESI): m/z 178.1 [M+H]+, calc. for C11H15NO 177.24. 
 
 
 
 
~ 151 ~ 
 
(S)-(–)-(3-(1-Methylpyrrolidin-2-yl)phenyl)methanol [33] 
 
N
CH2OH
CH3
 
 
To a solution of (S)-(–)-(3-(pyrrolidin-2-yl)phenyl)methanol 79 (60 mg, 0.34 
mmol) in MeOH (3.8 mL), 37% formaldehyde in water (0.16 mL, 2.01 mmol) 
was added, and the solution was stirred at room temperature for 30 min. Once 
cooled to 0°C, NaBH4 (28 mg, 0.71 mmol) was added and the mixture stirred 
at room temperature for 1 h. 
The reaction was quenched with water (10 mL) and extracted with AcOEt (3 x 
8 mL). The organic layers were dried over Na2SO4, filtered and then 
concentrated in vacuo. The crude material was purified by acid/base 
extraction to obtain 44 mg of pure tertiary amine (68% yield). 
 
33: yellow oil. 
 
Rf: 0.2 (DCM/MeOH 9:1); UV, Dragendorff reagent, KMnO4. 
 
1H-NMR (CDCl3):  1.79 (m, 2H), 1.94 (m, 1H), 2.13 (m, 4H), 2.27 (m, 1H), 
3.04 (m, 1H), 3.21 (m, 1H), 4.66 (s, 2H), 7.28 (m, 4H). 
 
13C-NMR (CDCl3):  22.64, 35.18, 40.72, 57.27, 65.36, 71.95, 126.05, 126.16, 
127.15, 128.77, 141.62, 143.41. 
 
MS (ESI): m/z 192.1 [M+H]+, calc. for C12H17NO 191.27. 
 
 []20D:  89.64 (c 1.1, CHCl3) 
 
E.e.: 98%; Kromasil 5-Amycoat column, eluted with 10% 2-propanol in 
hexane, 1.0 mL/min flow. 
~ 152 ~ 
 
 Rt minor peak = 8.1 min (1%) 
 Rt major peak = 10.1 min (99%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 153 ~ 
 
(3-(4,5-Dihydro-3H-pyrrol-2-yl)phenyl)methanol [34] 
 
N
CH2OH
HCl
 
 
Pirrolydin-2-thione 80 (168 mg; 1.66 mmol), 3-(hydroxymethyl)phenylboronic 
acid (302.5 mg, 1.99 mmol), Cu(I) thiophen-2-carboxylate (950 mg, 4.98 
mmol) and Pd(Ph3P)4 (78 mg, 0.066 mmol) were dissolved in dry THF (6 mL) 
and sealed in a MW tube in a dry atmosphere. The mixture was heated at 
100°C for 2 h under MW irradiation.  
The solvent was removed in vacuo and the residue taken with DCM  (10 mL). 
The organic layer was then filtered through a celite-septum, washed with 25% 
ammonia (3 x 10 mL), dried over Na2SO4, filtered and then concentrated in 
vacuo. The crude material was purified by flash chromatography (DCM/MeOH 
95:05) to obtain 184 mg of the title compound (63% yield). 
The free imine was treated with 2.0 N HCl in Et2O for 1 hour. The solvent was 
removed in vacuo and the residue crystallized with 2-propanol to give 64 mg 
of the desired derivative (29% yield). 
 
34: colourless solid. 
 
m.p.:  190 °C dec. 
. 
1H-NMR (CD3OD):  2.45 (m, 2H), 3.68 (m, 2H), 4.25 (m, 2H), 4.73 (m, 2H), 
7.66 (m, 1H), 7.83 (m, 1H), 7.97 (m, 1H), 8.05 (m, 1H). 
 
13C-NMR (CD3OD):  19.76, 35.11, 53.77, 62.78, 126.20, 128.14, 129.02, 
129.73, 134.61, 144.17, 186.49.  
 
 
 
~ 154 ~ 
 
Trimethyl(tosylethynyl)silane [82] 
 
S
(H3C)3Si
OO
CH3  
 
To a suspension of AlCl3 (1.722 g, 12.911 mmol) in dry DCM (10 mL) under 
an argon atmosphere, tosyl chloride (2.461 g, 12.911 mmol) was added and 
the mixture stirred at room temperature until complete formation of the 
complex (clear solution, 30 min). 
The solution was added dropwise to an ice-cooled solution of 
bis(trimethylsilyl)acetylene 81 (2 g, 11.737 mmol) in dry DCM (12 mL), and 
the mixture was stirred for 30 min at 0°C and for additional 6h at room 
temperature. 
The reaction was poured in a mixture of 20% HCl (11 mL) and ice (11 g), the 
organic layer was separated and the aqueous layer extracted with DCM (5 
mL). The combined organic phases were washed with water (2 x 7 mL), dried 
over Na2SO4, filtered and concentrated in vacuo. Crystallization from 
cyclohexane afforded 1.749 g of clean product (56% yield). 
 
82: colourless solid. 
 
Rf: 0.20 (CyHex/AcOEt 9:1); UV, KMnO4. 
 
1H-NMR (CDCl3):  0.22 (s, 9H), 2.48 (s, 3H), 7.40 (d,  J = 9.00 Hz, 2H), 7.91 
(d,  J = 9.00 Hz, 2H). 
 
 
 
 
 
 
 
~ 155 ~ 
 
1-(Ethynylsulfonyl)-4-methylbenzene [83] 
 
S
H
OO
CH3  
 
To a solution of trimethyl(tosylethynyl)silane 82 (1.749 g, 6.565 mmol) in 
MeOH (19 mL) under an argon atmosphere, an aqueous solution of 6.2 x 10-3 
M K2CO3 and 6.2 x 10
-3 M NaHCO3 was added to reach pH 9, while 
maintaining the temperature below 30°C with a cold water bath. The mixture 
was stirred overnight at room temperature. 
The reaction was diluted with water (15 mL) and extracted with DCM (3 x 40 
mL). The organic layers were washed twice with water and twice with brine, 
dried over Na2SO4, filtered, and the solvent was removed in vacuo. The crude 
material  was purified by flash chromatography (CyHex/AcOEt 90:10) to give 
1.035 g of the title compound (88% yield). 
 
83: colourless solid. 
 
Rf: 0.2 (CyHex/AcOEt 9:1); UV, KMnO4. 
 
1H-NMR (CDCl3):  2.47 (s, 3H), 3.52 (s, 1H), 7.38 (d,  J = 8.50 Hz, 2H), 7.88 
(d,  J = 8.50 Hz, 2H). 
 
 
 
 
 
 
 
 
 
 
~ 156 ~ 
 
tert-Butyl 2-tosyl-7-azabicyclo[2.2.1]hepta-2,5-diene-7-carboxylate [85] 
 
Boc
N
S
CH3
O
O
 
 
In an argon atmosphere, N-Boc-pyrrole 84 (1.70 mL, 10.22 mmol) and 1-
(ethynylsulfonyl)-4-methylbenzene 83 (1.035 g, 5.742 mmol) were mixed and 
stirred at 80°C for 3 days. The crude reaction mixture was directly purified by 
flash chromatography (CyHex/AcOEt 80:20) to produce 794 mg of clean 
product (40% yield). 
 
85: yellow oil. 
 
Rf: 0.6 (CyHex/AcOEt 7:3); UV, KMnO4. 
 
1H-NMR (CDCl3):  1.27 (s, 9H), 2.45 (s, 3H), 5.18 (m, 1H), 5.39 (m, 1H), 6.88 
(m, 2H), 7.34 (d,  J = 8.2 Hz, 2H), 7.58 (s, 1H), 7.76 (d,  J = 8.2 Hz, 2H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 157 ~ 
 
tert-Butyl 2-tosyl-7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate [86] 
 
Boc
N
S
CH3
O
O
 
 
To a solution of NiCl2 (1.481 g, 6.565 mmol) in dry EtOH (12 mL) under an 
argon atmosphere, a suspension of NaBH4 in dry EtOH (12 mL) was slowly 
added. The mixture was stirred at room temperature for 10 min. Then a 
solution of tert-butyl 2-tosyl-7-azabicyclo[2.2.1]hepta-2,5-diene-7-carboxylate 
85 (794 mg, 2.287 mmol) in dry THF (12 mL) and conc. HCl (2.25 mL, 22.87 
mmol) were added, and the mixture was stirred at room temperature for 1 h. 
The reaction was filtered through a celite-septum and concentrated in vacuo 
and the residue was taken with saturated NaHCO3 (30 mL) and extracted with 
DCM (3 x 10 mL). The organic layers were washed twice with water and twice 
with brine, then dried over Na2SO4, filtered and concentrated in vacuo to 
afford 723 mg of the title compound (91% yield). 
 
86: yellow oil. 
 
Rf: 0.32 (CyHex/AcOEt 8:2); UV, KMnO4. 
 
1H-NMR (CDCl3):  1.21 (s, 9H), 1.27-1.47 (m, 2H), 2.01 (m, 1H), 2.45 (s, 3H), 
4.76 (m, 1H), 4.83 (m, 1H), 7.06 (m, 1H), 7.35 (m, 2H), 7.81 (m, 2H). 
 
 
 
 
 
 
 
~ 158 ~ 
 
tert-Butyl 2-tosyl-3-(tributylstannyl)-7-azabicyclo[2.2.1]heptane-7-
carboxylate [87] 
 
Boc
N
S
CH3
O
O
Sn(C4H9)3  
 
To a solution of tert-butyl 2-tosyl-7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate 
86 (723 mg, 2.071 mmol) in dry degassed toluene (8 mL) under an argon 
atmosphere, AIBN (18 mg, 0.104 mmol) was added and the mixture stirred at 
room temperature for 5 min. Tributyltin hydride (1.148 mL, 4.267 mmol) was 
then added dropwise and the mixture was heated at reflux for 6 h. 
The reaction was quenched with saturated NaHCO3 (15 mL) and extracted 
with AcOEt (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude material  was purified 
by flash chromatography (CyHex → CyHex/AcOEt 97:03) to give 555 mg of 
pure product (33% yield). 
 
87: yellow oil. 
 
Rf: 0.49 (CyHex/AcOEt 9:1); UV, KMnO4. 
 
1H-NMR (CDCl3):  0.79 (m, 4H), 0.85-0.94 (m, 9H), 1.25-1.90 (m, 27H), 2.44 
(s, 3H), 2.57-2.63 (m, 1H), 3.67-3.70 (m, 1H), 4.20-4.26 (m, 2H), 7.34 (m, 2H), 
7.73 (m, 2H). 
 
 
 
 
 
 
 
~ 159 ~ 
 
tert-Butyl 7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate [88] 
 
Boc
N
 
 
To a solution of tert-butyl 2-tosyl-3-(tributylstannyl)-7-azabicyclo[2.2.1] 
heptane-7-carboxylate 87 (555 mg, 0.882 mmol) in dry THF (5 mL) in an 
argon atmosphere, TBAF (1.77 mL, 1.764 mmol) was added and the mixture 
stirred under reflux for 16 h. 
The reaction was quenched with saturated NaHCO3 (15 mL) and extracted 
with AcOEt (3 x 10 mL). The organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 95:05) to give 157 mg of clean alkene (91% 
yield). 
 
88: yellow oil. 
 
Rf: 0.56 (CyHex/AcOEt 9:1); KMnO4. 
 
1H-NMR (CDCl3):  1.10 (m, 2H), 1.41 (s, 9H), 1.85 (m, 2H), 4.65 (m, 2H), 
6.21 (m, 2H). 
 
 
 
 
 
 
 
 
 
 
~ 160 ~ 
 
tert-Butyl 2-exo-(3-methoxyphenyl)-7-azabicyclo[2.2.1]heptane-7-
carboxylate [89] 
 
Boc
N
OCH3  
 
To a solution of tert-butyl 7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate 88 (157 
mg, 0.804 mmol) in dry DMF (3.5 mL) in an argon atmosphere, 
3(methoxy(phenyl)bromide (0.255 mL, 2.01 mmol), Pd(OAc)2 (9 mg, 0.04 
mmol), TBAC (56 mg, 0.201 mmol) and potassium formate (170 mg, 2.01 
mmol) were added, and the mixture stirred at 81°C for 5 h. 
The reaction was cooled to ambient and poured in a mixture of conc. 
ammonia and water 1:1 (10 mL), then extracted with DCM (3 x 10 mL). The 
pooled organic phases were washed with brine (3 times), dried over Na2SO4, 
filtered and concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 98:02) to give 118 mg of pure compound 
(49% yield). 
 
89: yellow oil. 
 
Rf: 0.19 (CyHex/AcOEt 9:1); UV; KMnO4. 
 
1H-NMR (CDCl3):  1.43 (s, 9H), 1.53 (m, 2H), 1.92 (m, 4H), 2.84 (dd, J = 5.5; 
8.8 Hz, 1H), 3.80 (s, 3H), 4.25-4.35 (m, 2H), 6.73 (m, 1H), 6.86 (m, 2H), 7.17 
(m, 1H). 
 
13C-NMR (CDCl3):  28.56, 29.02, 30.22, 40.77, 48.34, 55.30, 55.83, 62.25, 
79.57, 111.83, 112.82, 119.71, 129.51, 147.68, 155.29, 159.89. 
 
MS (ESI): m/z 304.2 [M+H]+, calc. for C18H25NO3 303.40. 
 
 
~ 161 ~ 
 
3-(7-Azabicyclo[2.2.1]heptan-2-exo-yl)phenol hydrochloride [35] 
 
H
N
OH
HCl  
 
To a solution of tert-butyl 2-exo-(3-methoxyphenyl)-7-azabicyclo[2.2.1] 
heptane-7-carboxylate 89 (118 mg, 0.389 mmol) in dry DCM (4.6 mL) in a 
nitrogen atmosphere at 78°C, 1.0 M BBr3 in hexane (0.875 mL, 0.875 mmol) 
was added, and the mixture stirred at 78°C for 1 h and at 0°C for further 2 h. 
The solvent was removed in vacuo and the residue was taken with DCM (4 
mL), then TEA was added until pH reached 9, followed by Boc2O (170 mg, 
0.778 mmol). The mixture was then stirred at room temperature for 2 h. 
The reaction was diluted with saturated NaHCO3 (5 mL), then extracted with 
DCM (3 x 3 mL). The organic layers were washed with 5% H3PO4 (5 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The crude material 
was purified by flash chromatography (CyHex/AcOEt 90:10) to give 95 mg of 
pure N-Boc protected alcohol (85% yield). 
To a solution of this intermediate (82 mg, 0.284 mmol) in Et2O (0.4 mL) at 
0°C, 4.0 M HCl in 1,4-dioxane (0.660 mL, 2.64 mmol) was added and the 
mixture stirred at room temperature for 4 h. 
The solvent was removed in vacuo and the residue digested with Et2O to 
afford 61 mg of the title compound (99% yield). 
 
35: colourless solid. 
 
m.p.: very hygroscopic substance. 
 
1H-NMR (CD3OD):  1.83-2.12 (m, 5H), 2.37 (m, 1H), 3.31 (m, 1H), 4.28 (m, 
1H), 4.44 (m, 1H), 6.70-6.77 (m, 2H), 7.18 (m, 1H). 
 
~ 162 ~ 
 
13C-NMR (CD3OD):  25.73, 27.52, 36.46, 44.74, 59.20, 63.28, 113.59, 
113.77, 117.23, 129.88, 142.98, 157.92. 
 
MS (ESI): m/z 190.1 [M+H]+, calc. for C12H15NO 189.25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 163 ~ 
 
tert-Butyl 2-exo-(3-(hydroxymethyl)phenyl)-7-azabicyclo[2.2.1]heptane-7-
carboxylate [90] 
 
Boc
N
CH2OH  
 
To a solution of tert-butyl 7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate 88 (78 
mg, 0.4 mmol) in dry DMF (1.8 mL) in an argon atmosphere, (3-
bromophenyl)methanol (0.120 mL, 1 mmol), Pd(OAc)2 (5 mg, 0.02 mmol), 
TBAC (28 mg, 0.1 mmol) and potassium formate (84 mg, 1 mmol) were 
added, and the mixture stirred at 81°C for 7 h. 
The reaction was cooled to ambient and poured into a mixture of conc. 
ammonia and water 1:1 (10 mL), then extracted with DCM (3 x 10 mL). The 
organic layers were washed with brine (3 times), dried over Na2SO4, filtered 
and concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 90:10 → 60:40) to obtain 35 mg of pure 
compound (30% yield). 
 
90: yellow oil. 
 
Rf: 0.32 (CyHex/AcOEt 1:1); UV; KMnO4; Ninhydrin. 
 
1H-NMR (CDCl3):  1.43 (s, 9H), 1.50-1-59 (m, 2H), 1.81-1.95 (m, 4H), 2.85 
(dd, J = 5.5; 8.5 Hz, 1H), 4.22 (m, 1H), 4.35 (m, 1H), 4.64 (bs, 2H), 7.20 (m, 
2H), 7.27 (m, 2H). 
 
13C-NMR (CDCl3):  28.58, 29.93, 30.54, 40.75, 48.22, 54.60, 65.56, 79.74, 
125.08, 125.99, 126.50, 128.85, 141.26, 146.30. 
 
MS (ESI): m/z 304.2 [M+H]+, calc. for C18H25NO3 303.40. 
 
 
~ 164 ~ 
 
3-(7-Azabicyclo[2.2.1]heptan-2-exo-yl)phenyl)methanol hydrochloride 
[36] 
 
H
N
CH2OH
HCl  
 
To a solution of tert-butyl 2-exo-(3-(hydroxymethyl)phenyl)-7-azabicyclo[2.2.1] 
heptane-7-carboxylate 90 (30 mg, 0.1 mmol) in Et2O (0.2 mL) at 0°C, 4.0 M 
HCl in 1,4-dioxane (0.5 mL, 2 mmol) was added and the mixture stirred at 
room temperature for 6 h. 
The solvent was removed in vacuo and the residue digested with Et2O to 
afford 19 mg of the title compound (80% yield). 
 
36: colourless solid. 
 
m.p.: very hygroscopic substance. 
 
1H-NMR (CD3OD):  1.88-2.15 (m, 5H), 2-37-2.44 (m, 1H), 3.40 (dd, J = 6.05; 
9.45 Hz, 1H), 4.30 (m, 1H), 4.47 (m, 1H), 4.88 (s, 2H), 7.21-7.38 (m, 4H). 
 
13C-NMR (CD3OD):  25.76, 27.53, 36.44, 44.82, 59.25, 63.35, 63.83, 125.05, 
125.38, 125.56, 128.88, 141.50, 142.28. 
 
MS (ESI): m/z 190.1 [M+H]+, calc. for C13H17NO 203.28. 
 
 
 
 
 
 
 
 
~ 165 ~ 
 
tert-Butyl 5-(3-methoxyphenyl)-5-oxopentylcarbamate [92] 
 
H3CO
O
NHBoc
 
 
To a solution of -valerolactame 91 (1 g, 10.088 mmol) in dry THF (27 mL) in 
an argon atmosphere at 78°C, 2.5 M butyllithium in hexane (4.04 mL, 10.088 
mmol) was added dropwise and the mixture stirred at 78°C for 30 min. 
Subsequently, a solution of Boc2O (2.201 g, 10.088 mmol) in dry THF (3.5 
mL) was added and the reaction stirred at 78°C for 3 h. Then, a solution of 
(3-methoxyphenyl)magnesium bromide (prepared from 2.453 g of 3-methoxy-
bromobenzene and 368 mg of magnesium) in dry THF (13.5 mL) was finally 
added and the mixture stirred at 78°C for additional 3 h. 
The reaction was warmed to ambient and quenched with 2.0 N HCl in water 
(10 mL), then extracted with Et2O (3 x 15 mL). The organic layers were 
washed with 5% NaHCO3 and brine, dried over Na2SO4, filtered and 
concentrated in vacuo to obtain 2.84 g of pure compound (91% yield). 
 
92: yellow oil. 
 
Rf: 0.2 (CyHex/AcOEt 9:1); UV; PMA. 
 
1H-NMR (CDCl3):  1.43 (s, 9H), 1.55 (m, 2H), 1.74 (m, 2H), 2.97 (t, J =  7.15; 
7.42 Hz, 2H), 3.14 (m, 2H), 3.84 (s, 3H), 4.63 (bs, 1H), 7.09 (m, 1H), 7.35 (m, 
1H), 7.46 (m, 1H), 7.52 (m, 1H). 
 
 
 
 
 
 
~ 166 ~ 
 
6-(3-Methoxyphenyl)-2,3,4,5-tetrahydropyridine [93] 
 
N
OCH3  
 
To tert-butyl 5-(3-methoxyphenyl)-5-oxopentylcarbamate 92 (2.74 g, 8.9 
mmol) at 0°C, trifluoroacetic acid (18 mL) was added dropwise and the 
mixture stirred at room temperature for 4 h. 
The reaction was cooled to 0°C and quenched with 30% NaOH dropwise until 
pH reached 10-11. The mixture was extracted with Et2O (5 x 20 mL). The 
organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex →CyHex/AcOEt 90:10) to afford 1.098 g of pure 
compound (65% yield). 
 
93: dark yellow oil. 
 
Rf: 0.2 (CyHex/AcOEt 9:1); UV; PMA. 
 
1H-NMR (CDCl3):  1.68 (m, 2H), 1.83 (m, 2H), 2.62 (m, 2H), 3.84 (m, 5H), 
6.94 (m, 1H), 7.27 (m, 2H), 7.37 (m, 1H). 
 
13C-NMR (CDCl3):  19.93, 22.03, 27.54, 50.00, 55.59, 110.99, 116.24, 
118.74, 129.39, 141.67, 159.85, 166.07. 
 
MS (ESI): m/z 191.1 [M+H]+, calc. for C12H15NO 189.25. 
 
 
 
 
~ 167 ~ 
 
3-(3,4,5,6-Tetrahydropyridin-2-yl)phenol hydrochloride [37] 
 
N
OH
HCl
 
 
A solution of 6-(3-methoxyphenyl)-2,3,4,5-tetrahydropyridine 93 (201 mg, 
1.062 mmol) in 48% HBr (3 mL) was stirred under reflux for 6 h. 
The solvent was removed in vacuo, the residue taken with saturated NaHCO3 
(pH=8) and extracted with AcOEt (5 x 20 mL). The organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated. The yellow 
oil was treated with 1.25 M HCl in methanol for 30 min. Concentration in 
vacuo and crystallization from 2-propanol provided 142 mg of the title 
compound (63% yield). 
 
37: yellow solid. 
 
m.p.:  192-193 °C. 
 
1H-NMR (CD3OD):  2.01 (m, 4H), 3.27 (m, 2H), 3.82 (m, 2H), 7.18 (dd, J = 
2.21; 7.98 Hz, 1H), 7.26 (m, 1H), 7.33 (m, 1H), 7.45 (m, 1H). 
 
13C-NMR (CD3OD):  16.99, 17.09, 19.16, 45.24, 114.21, 118.62, 121.91, 
130.75, 133.13, 158.55, 183.77. 
 
MS (ESI): m/z 177..1 [M+H]+, calc. for C11H13NO 175.23. 
 
 
 
 
 
~ 168 ~ 
 
tert-Butyl 5-(3-iodophenyl)-5-oxopentylcarbamate [94] 
 
I
O
NHBoc
 
 
To a solution of -valerolactame (1 g, 10.088 mmol) in dry THF (27 mL) in an 
argon atmosphere at -78°C, 2.5 M butyllithium in hexane (4.04 mL, 10.088 
mmol) was added dropwise and the mixture stirred at 78°C for 30 min. 
Subsequently, a solution of Boc2O (2.201 g, 10.088 mmol) in dry THF (3.5 
mL) was added and the reaction stirred at 78°C for 3 h. A solution of (3-
iodophenyl)magnesium bromide (prepared from 1.67 mL of 3-iodo-
bromobenzene and 368 mg of magnesium) in dry THF (13.5 mL) was finally 
added and the mixture stirred at 78°C for additional 3 h. 
The reaction was warmed to ambient and quenched with 2.0 N HCl in water 
(10 mL), then extracted with Et2O (3 x 15 mL). The organic layers were 
washed with 5% NaHCO3 and brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 95:05→ 90:10) to give 1.75 g of pure 
compound (41% yield). 
 
94: yellow oil. 
 
Rf: 0.2 (CyHex/AcOEt 9:1); UV; PMA. 
 
1H-NMR (CDCl3):  1.44 (s, 9H), 1.55 (m, 2H), 1.77 (m, 2H), 2.98 (m, 2H), 
3.17 (m, 2H), 4.58 (bs, 1H), 7.37 (m, 1H), 7.53 (m, 1H), 7.75 (m, 1H), 7.81 (m, 
1H). 
 
 
 
 
~ 169 ~ 
 
6-(3-Iodophenyl)-2,3,4,5-tetrahydropyridine [95] 
 
N
I  
 
To tert-butyl 5-(3-iodophenyl)-5-oxopentylcarbamate 94 (5.27 g, 13.07 mmol) 
at 0°C, trifluoroacetic acid (16.3 mL) was added dropwise and the mixture 
stirred at room temperature for 3 h. 
The reaction was cooled to 0°C and quenched with 30% NaOH dropwise until 
pH reached 10-11. The mixture was then extracted with Et2O (5 x 30 mL). The 
organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude material  was purified by flash 
chromatography (CyHex/AcOEt 95:05) to afford 1.683 g of pure compound 
(45% yield). 
 
95: yellow oil. 
 
Rf: 0.40 (CyHex/AcOEt 8:2); UV; PMA. 
 
1H-NMR (CDCl3):  1.68 (m, 2H), 1.84 (m, 2H), 2.59 (m, 2H), 3.84 (m, 2H), 
7.10 (m, 1H), 7.24 (m, 1H), 7.50 (m, 1H), 7.68 (m, 1H). 
 
13C-NMR (CDCl3):  19.84, 21.97, 27.22, 50.19, 122.99, 124.68, 129.36, 
132.63, 138.60, 142.38, 164.20. 
 
MS (ESI): m/z 286.0 [M+H]+, calc. for C11H12IN 285.12. 
 
 
~ 170 ~ 
 
Methyl 3-(3,4,5,6-tetrahydropyridin-2-yl)benzoate [96] 
 
N
COOCH3  
 
To a solution of 6-(3-iodophenyl)-2,3,4,5-tetrahydropyridine 95 (1.2 g, 4.208 
mmol) in 1,4-dioxane (4.5 mL), molybdenum hexacarbonyl (1.664 g,  6.312 
mmol), palladium on activated charcoal 10% (200 mg), DMAP (1.032 g, 8.416 
mmol), DIPEA (1.088 g, 8.416 mmol) and MeOH (1.712 mL, 42.08 mmol) 
were added; the mixture was sealed in a MW tube and heated under MW 
irradiation (250 W) at 130°C for 1 h. 
The reaction was filtered through a celite-septum and concentrated. The 
residue was taken with saturated NaHCO3 (15 mL) and extracted with AcOEt 
(3 x 8 mL). The organic layers were washed with water, dried over Na2SO4, 
filtered and the solvent removed in vacuo. The crude material  was purified by 
flash chromatography (CyHex/AcOEt 90:10 → 80:20) to provide 400 mg of 
pure compound (44% yield). 
 
96: yellow oil. 
 
Rf: 0.30 (CyHex/AcOEt 7:3); UV; PMA. 
 
1H-NMR (CDCl3):  1.68 (m, 2H), 1.83 (m, 2H), 2.65 (m, 2H), 3.84 (m, 2H), 
3.91 (s, 3H), 7.44 (m, 1H), 8.02 (m, 2H), 8.38 (m, 1H). 
 
13C-NMR (CDCl3):  19.85, 21.99, 27.29, 50.16, 52.36, 126.19, 127.28, 
128.58, 130.38, 130.60, 130.78, 140.66, 165.17. 
 
MS (ESI): m/z 218.1 [M+H]+, calc. for C13H15NO2 217.26. 
 
~ 171 ~ 
 
 (3-(3,4,5,6-Tetrahydropyridin-2-yl)phenyl)methanol hydrochloride [38] 
 
N
CH2OH
HCl
 
 
To a solution of methyl 3-(3,4,5,6-tetrahydropyridin-2-yl)benzoate 96 (400 mg, 
1.841 mmol) in dry THF (37 mL) in an argon atmosphere, 65% Red-Al in 
toluene (2.4 mL, 7.733mmol) was added and the mixture stirred at room 
temperature for 1 h. 
The reaction was quenched with saturated NaHCO3 (10 mL) and extracted 
with AcOEt (3 x 8 mL). The organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude material  was purified by flash 
chromatography (AcOEt). The yellow oil was treated with 1.25 M HCl in 
methanol for 30 minutes. Concentration and crystallization with 2-propanol 
provided 106 mg of the title compound (26% yield). 
 
38: yellow solid. 
 
m.p.:  141-142 °C. 
 
1H-NMR (CD3OD):  2.03 (m, 4H), 3.31 (m, 2H), 3.84 (m, 2H), 4.72 (s, 2H), 
7.62 (m, 1H), 7.77 (m, 2H), 7.87 (m, 1H). 
 
13C-NMR (CD3OD):  16.99, 17.10, 19.15, 45.30, 62.94, 125.79, 126.51, 
129.54, 132.03, 133.15, 143.86, 183.98. 
 
MS (ESI): m/z 190.10 [M+H]+, calc. for C12H15NO 189.25. 
 
 
 
~ 172 ~ 
 
2-(3-Bromo-5-fluorophenyl)-3,4,5,6-tetrahydropyridine hydrochloride [43] 
 
N
Br
F
HCl
 
 
To a solution of 1,3-dibromo-5-fluorobenzene 98 (1.47 g, 5.782 mmol) in dry 
Et2O (6 mL) at –78°C, a solution of 1.6 M n-BuLi in hexane (3.48 mL; 5.568 
mmol) was added dropwise and the mixture stirred at 78°C for 1 h. The 
mixture was added dropwise to a solution of 5-bromovaleronitrile 97 (694 mg, 
4.283 mmol) in dry THF (5 mL) and the reaction was stirred at room 
temperature for 2 h. 
The reaction was quenched with a saturated solution of NaHCO3 (20 mL) and 
extracted with DCM (3 x 15 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude material  was purified by flash 
chromatography (DCM/MeOH 100:0 → 96:4). to provide 691 mg of the 
desired compound (63% yield). 
The yellow oil obtained was treated with 4.0 M HCl in 1,4-dioxane for 30 
minutes. Concentration and digestion with Et2O provided 205 mg of the title 
compound (26% yield). 
 
43: dark yellow solid. 
 
1H-NMR (CD3OD):  2.03 (m, 4H), 3.30 (m, 2H), 3.86 (m, 2H), 7.70 (m, 1H), 
7.82 (m, 1H), 7.92 (m, 1H). 
 
13C-NMR (CD3OD):  16.85, 18.91, 45.70, 100.25, 114.20, 123.74, 124.53, 
127.09, 135.34, 161.14, 164.49. 
 
MS (ESI): m/z  256.26 [M+H+]+, calc. for C11H12BrFN
+ 256.01. 
 
~ 173 ~ 
 
Methyl 3-fluoro-5-(3,4,5,6-tetrahydropyridin-2-yl)benzoate [99] 
 
N
COOCH3
F
 
 
To a solution of 2-(3-bromo-5-fluorophenyl)-3,4,5,6-tetrahydropyridine 23 (122 
mg, 0.476 mmol) in 1,4-dioxane (4.5 mL), molybdenum hexacarbonyl (377 
mg,  1.328 mmol), palladium on activated charcoal 10% (30 mg), DMAP (117 
mg, 0.952 mmol), DIPEA (123 mg, 0.952 mmol) and methanol (153 mg, 4.76 
mmol) were added; the mixture was sealed in a MW tube and heated under 
MW irradiation (250 W) at 130°C for 2 h. 
The reaction was filtered through a celite-septum and concentrated. The 
residue was taken with saturated NaHCO3 (20 mL) and extracted with AcOEt 
(4 x 10 mL). The organic layers were washed with water, dried over Na2SO4, 
filtered and the solvent removed in vacuo. The crude material  was purified by 
flash chromatography (CyHex/AcOEt 90:10) to provide 64 mg of pure 
compound (57% yield). 
 
99: yellow oil. 
 
Rf: 0.38 (CyHex/AcOEt 7:3); UV; KMnO4, Dragendorff reagent. 
 
1H-NMR (CDCl3):  1.66 (m, 2H), 1.83 (m, 2H), 2.61 (m, 2H), 3.85 (m, 2H), 
3.93 (s, 3H), 7.74 (m, 2H), 8.18 (m, 1H). 
 
13C-NMR (CDCl3):  19.01, 21.90, 22.30, 48.70, 52.33, 116.82, 117.98, 
125.36, 131.77, 142.11, 164.22, 165.78, 166.21. 
 
~ 174 ~ 
 
3-Fluoro-5-(3,4,5,6-tetrahydropyridin-2-yl)phenyl)methanol hydrochloride 
[39] 
 
N
CH2OH
F
HCl
 
 
To a solution of methyl 3-fluoro-5-(3,4,5,6-tetrahydropyridin-2-yl)benzoate 99 
(35 mg 0.149 mmol) in dry THF (3 mL) in an argon atmosphere, 65% Red-Al 
in toluene (195 mg, 0.626 mmol) was added and the mixture stirred at room 
temperature for 24 h. 
The reaction was quenched with saturated NaHCO3 (20 mL) and extracted 
with AcOEt (4 x 15 mL). The organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude material  was then purified by 
preparative TLC (AcOEt). The yellow oil obtained was treated with 4.0 N HCl 
in 1,4-dioxane for 30 min. Concentration and crystallization from 2-propanol 
provided 6 mg of the title compound (33% yield). 
 
38: dark yellow oil. 
 
1H-NMR (CD3OD):  2.03 (m, 4H), 3.31 (m, 2H), 3.85 (m, 2H), 4.72 (s, 2H), 
7.55 (m, 2H), 7.69 (sa, 1H). 
 
13C-NMR (CD3OD):  21.00, 21.42, 32.85, 43.71, 64.76, 111.99, 114.53, 
122.51, 132.51, 143.17, 162.97, 168.12. 
 
MS (ESI): m/z  207.98 [M+H+]+, calc. for C12H15FNO
+ 208.11. 
 
 
 
~ 175 ~ 
 
2,3,4,5-Tetrahydro-6-phenylpyridine hydrochloride [40] 
 
N
HCl
 
 
To a solution of 5-bromovaleronitrile 97 (236 mg, 1.457 mmol) in dry THF (2.5 
mL), a solution of 1.8 M phenyllithium in cyclohexane/Et2O 70:30 100 (914 μL, 
1.646 mmol) was added dropwise and the resulting mixture was stirred under 
reflux for 3 h. 
The reaction was quenched with 1.0 N HCl in water (20 mL) and extracted 
with DCM (3 x 15 mL). The aqueous layer was basified with a saturated 
solution of NaHCO3 (pH = 8/9) and extracted again with DCM (3 x 15 mL) The 
organic layers were dried over Na2SO4, filtered and concentrated in vacuo to 
provide 151 mg of the desired compound (65% yield). 
The yellow oil obtained was treated with 2.0 M HCl in Et2O for 30 min. 
Concentration and crystallization from EtOH/Et2O provided 46 mg of the title 
compound (25% yield). 
 
43: dark yellow solid. 
 
m.p. = 88-89 °C. 
 
1H-NMR (CD3OD):  2.03 (m, 4H), 3.31 (m, 2H), 3.85 (m, 2H), 7.63 (m, 2H), 
7.76 (m, 1H), 7.91 (m, 2H). 
 
13C-NMR (CD3OD):  17.12, 17.23, 17.33, 19.26, 28.84, 45.50, 128.02, 
129.57, 131.98, 134.98, 183.84. 
 
MS (ESI): m/z  160.92 [M+H+]+, calc. for C11H14N
+ 160.11. 
~ 176 ~ 
 
2,3,4,5-Tetrahydro-6-m-tolylpyridine hydrochloride [41] 
 
N
HCl
CH3  
 
A solution of 3-bromotoluene 101 (586 mg, 3.427 mmol) in dry THF (3 mL) 
was added dropwise in a flame-dried flask containing magnesium powder (82 
mg 3.427 mmol) and the resulting mixture was stirred at room temperature for 
20 min. The resulting solution was added dropwise to a solution of 5-
bromovaleronitrile 97 (555 mg, 3.427 mmol) in dry THF (3 mL) and the 
mixture was stirred at room temperature for 1 h. 
The reaction was quenched with a saturated solution of NaHCO3 (20 mL) and 
extracted with DCM (3 x 15 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude material  was purified by flash 
chromatography (DCM → DCM/MeOH 90:10) to provide 332 mg of pure 
compound (56% yield). 
The yellow oil obtained was treated with 4.0 M HCl in 1,4-dioxane for 30 
minutes. Concentration and digestion with Et2O provided 92 mg of the title 
compound (23% yield). 
 
43: dark yellow oil. 
 
1H-NMR (CD3OD):  2.03 (m, 4H), 2.47 (m, 3H), 3.32 (m, 2H), 3.85 (m, 2H), 
7.52 (m, 1H), 7.60 (m, 1H), 7.73 (m, 2H). 
 
13C-NMR (CD3OD):  17.15, 17.25, 19.21, 20.15, 45.29, 125.11, 128.25, 
129.44, 131.96, 135.68, 139.93. 
 
MS (ESI): m/z  173.88 [M+H+]+, calc. for C12H16N
+ 174.13. 
 
~ 177 ~ 
 
2-(3-Fluorophenyl)-3,4,5,6-tetrahydropyridine hydrochloride [42] 
 
N
HCl
F  
 
To a solution of 1-bromo-3-fluorobenzene 102 (405 mg, 2.317 mmol) in dry 
Et2O (2.5 mL) at 70°C, a solution of 1.6 M n-BuLi in hexane (1.40 mL, 2.231 
mmol) was added dropwise and the resulting mixture was stirred at 70°C for 
1 h. The solution was added dropwise to a solution of 5-bromovaleronitrile 97 
(278 mg, 1.716 mmol) in dry THF (2.5 mL) and the mixture stirred overnight at 
room temperature.  
The reaction was quenched with a saturated solution of NaHCO3 (20 mL) and 
extracted with DCM (3 x 15 mL). The organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude material  was purified by flash 
chromatography (DCM → DCM/MeOH 90:10) to provide 207 mg of pure 
compound (68% yield). 
The yellow oil obtained was treated with 4.0 M HCl in 1,4-dioxane for 30 
minutes. Concentration and digestion with Et2O provided 60 mg of the title 
compound (26% yield). 
 
43: dark yellow solid. 
 
m.p.: 155 °C dec. 
 
1H-NMR (CD3OD):  2.04 (m, 4H), 3.31 (m, 2H), 3.87 (m, 2H), 4.87 (m, 2H), 
7.54 (m, 1H), 7.70 (m, 3H). 
 
13C-NMR (CD3OD):  17.02 (2C), 19.12, 45.65, 114.87, 121.48, 124.14, 
131.69, 133.98, 161.35, 164.64. 
 
~ 178 ~ 
 
MS (ESI): m/z  178.01 [M+H+]+, calc. for C11H13FN
+ 178.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 179 ~ 
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